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Monooxygenase-catalyzed oxidations utilize molecular oxygen as cheap and 
green oxidant to insert oxygen atom under ambient conditions with high 
chemo-, regio- and stereo-selectivity, providing with green and useful methods 
for the syntheses of chiral molecules that are valuable fine chemicals and 
pharmaceutical intermediates. Despite of great achievements in this field, 
some significant challenges remain in developing efficient biooxidation 
processes, including the inhibition and toxicity of substrate and product. This 
thesis aims to engineer biphasic biocatalytic processes to enhance the 
productivity and enantioselectivity of biooxidations via prevention of the 
inhibition and toxicity. 
First, a solid-liquid biphasic system consisting of aqueous phase and resin 
Amberlite
®
 XAD4 was engineered for enhancing biohydroxylation of N-
benzyl-pyrrolidinone with Escherichia coli (E. coli) (P450pyrTM-GDH) 
coexpressing three-component P450pyrTM (triple mutant I83H/M305Q/A77S 
of P450pyr monooxygenase) and glucose dehydrogenase (GDH) for cofactor 
regenerating. In the biphasic system, the inhibition was prevented by 
adsorbing 61.3% of product and 84.7% of substrate on Amberlite
®
 XAD4. The 
biohydroxylation productivity was enhanced by 2.10 folds, giving (S)-4-
hydroxy-N-benzyl-pyrrolidinone in 53.2 mM and 99% ee (enantiomeric 
excess). In the second part, an aqueous (aq.)/ionic liquid (IL) (KP-
buffer/[P6,6,6,14][NTf2]) biphasic system was developed to simultaneously 
enhance enantioselectivity and productivity of sulfoxidation via partially 
dissolving substrate and product in IL for inhibition prevention. E. coli 
X 
 
(P450pyrI83H-GDH) co-expressing P450pyrI83H (single mutant I83H of 
P450pyr) and GDH was engineered for the sulfoxidations. [P6,6,6,14][NTf2] 
showed excellent biocompatibility and high solvation capacity. By using KP 
buffer/[P6,6,6,14][NTf2] system, the product concentrations and 
enantioselectivities were enhanced from 9.4 mM and 85% ee to 20 mM and 99% 
ee for the oxidations of thioanisole to (R)-phenyl methyl sulfoxide, from 1.9 
mM and 80% ee to 9.9 mM and 98% ee for the oxidations of 4-
fluorothioanisole to (R)-4-fluorophenyl methyl sulfoxide, and from 5.4 mM 
and 88% ee to 16 mM and 96% ee for the oxidations of phenylthioethane to 
(R)-ethyl phenyl sulfoxide. In the third part, aq./n-hexadecane biphasic system 
in hollow fiber membrane bioreactor (HFMB) was established for enhancing 
productivity of an oxidative cascade biotransformation in one-pot with whole-
cell tandem biocatalyst. Enantioselective dihydroxylation of styrene to (S)-
vicinal-diol via cascade epoxidation and hydrolysis with E. coli (SSP1) 
coexpressing styrene monooxygenase for epoxidation and epoxide hydrolase 
for hydrolysis was selected as the target oxidative cascade biocatalysis. n-
Hexadecane was used as the cosolvent for the biphasic system, where n-
hexadecane showed good biocompatibility and solvation capacity for toxicity 
prevention. The established aq./n-hexadecane biphasic system was applied in 
HFMB for the dihydroxylation with the cosolvent in shell side and the 
aqueous cell suspension in lumen side of HFMB, giving a final product 
concentration 143 mM, 1.6 folds to that achieved in the traditional dispersive 
partitioning biphase (TDPB).  
In all, we developed useful platforms via bioprocess engineering of 
establishing biphasic system for conducting biooxidation with inhibition and 
XI 
 
toxicity prevented, hence enhancing productivity and sometimes improving 
enantioselectivity. These platforms serve as a simple, green, and potent way 
for improving catalytic performances of biooxidations, which kindles the 
interest in bioprocess engineering as a complementary approach to genetic 
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1.1 Biooxidation: green oxidative biotransformation 
Pharmaceutical industry forms the greatest share of life-science market, where 
the enantiomerically pure compounds, prepared via biotransformations, are 
becoming more and more important and act as the building blocks in the 
pharmaceutical field.
[1 − 4]
 Biotransformations, the chemical alterations or 
modifications catalyzed by enzymes in isolated or whole cell forms for the 
preparations of compounds which used to be synthesized via traditional 
chemical approaches,
[5 − 18]
 are thus highlighted for years. 
As an important type of biotransformation, biooxidations (i.e., the insertion of 
oxygen atoms to substrate molecules catalyzed by enzymes or organisms 
under ambient conditions) can give chiral centers to yield products in high 
chemo-, regio-, and stereoselectivities as the intermediates for many drugs and 
fine chemical compounds.
[1 − 4]
 So far, all the oxidation reactions of 
incorporating exogenous oxygen atoms can be implemented via the oxidative 
biotransformation of biooxidation, including activation of alkanes to alcohols, 
conversion of  olefins to epoxides, oxidation of sulfides to sulfoxides, 
cleavage of aromatic rings, demethylation of O- or N-methyl groups, 
hydroxylation of aromatic and polycyclic substrates and a variety of steroids, 
etc.
[5 − 10] 
Many of these oxidative reactions are challenging to the traditional 
chemical synthetic routes especially in the case of the high selectivity required, 
while biooxidations offer a simple and green approach to selectively perform 
oxidative conversions with satisfactory efficiency and versatility for producing 
valuable and useful compounds.




Nowadays, biooxidation plays an important role in all life-science related 
areas including metabolism (e.g., in vivo detoxification, aromatic-ring 
degradations), preparation of pharmaceutical molecules (e.g., amino acids, 
steroids, alcohols, anticarcinogenic drug of Paclitaxel, anti-malaria drug of 
Artemisinin etc.), clinical diagnostic, biopolymer synthesis, pollution control, 
and oxygenation of hydrocarbons, etc.
[5, 19 − 21]
 Among all various 
biooxidations (Figure 1.1) with practical applications, there are three types of 
biooxidations used frequently: hydroxylation of saturated carbon-hydrogen 
bond, epoxidation of carbon-carbon double bond, oxidation of heteroatom 
(e.g., sulfur or phosphate),
[22]
 which can readily exhibit high selectivity, 
introduce chirality, endow functionality, and confer hydrophilicity and polarity 
to the product molecules.
[23, 24] 
 
Figure 1.1 Several selected biocatalytic oxidation reactions. All the reactions use 
oxygen as substrates. For halogenation, HOCl is formed in the catalytic center of the 
monooxygenase before the inserting the halide ion to the organic compound.
[22]
 
With the progresses in biotechnology, biooxidation is treated as a green 
procedure in the pharmaceutical industry owing to the endorsement in 
environmental credentials, the mild operation conditions, and the highly 
catalytic performance in both the selectivity (i.e. chemo-, regio- and stereo-
selectivity) and the productivity.
[11 − 16, 18]





reactions as the exemplary biooxidations in the industrial practices, where the 




 In comparison with biooxidations, 
oxidation reactions via the traditional chemical routes generally involve using 
the noble metal catalysts for conducting the reactions, where the noble metal 
atoms in the organometallic catalysts are the catalytic centers to perform the 
Table 1.1 Several selected biooxidations in industry.
[24] 
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eletrophilic substitutions for later combining with the oxygen atoms.
[25]
 
Although these traditional chemical ways offer stable catalytic performances, 
they are criticized as environmentally hazardous and sometimes unsustainable 
due to its several drawbacks: high temperature and pressure; low product yield 
and turnover number; severe pollution and waste; soaring prices for the noble 
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metal in global market.
 
For example, the oxidation of benzene calls for the 
catalyst of Pd(OAc)2/1,10-phenanthroline and the presence of carbon 
monoxide and acetic acid, giving 5.6 % product yield and 10 – 15 turnover 




 Besides, these 
chemical routes for oxidative reactions are mostly criticized for the deficiency 
in selectivity. An example is the sulfoxidation with the vanadium complex 
catalyst: given chiral Schiff base ligand used in the catalyst, the vanadium 
complex gives a series of products with ee values ranging from 31% to 87%.
[26]
 
All these drawbacks in chemical routes urge researchers to resort to the 
biooxidations for catalyzing the oxidation reactions.  
1.2 Monooxygenase-catalyzed asymmetric biooxidation 
Monooxygenase-catalyzed biooxidations, by using molecular oxygens as the 
cheap and green oxidants for catalyzing the insertion of oxygen atoms into the 
substrate molecules with electrons donated from the cofactor of NADH or 
NADPH,
[5, 19, 23]
 are intensively studied,  because monooxygenases are often 
more selective than other oxidizing enzymes such as peroxidases.
[23]
 The 
biooxidations catalyzed by monooxygenases cover all the reactions shown in 
Figure 1.1,
[5, 23]
 and we are typically interested in the three key biooxidations 
in this thesis: hydroxylation, sulfoxidation, and epoxidation.  
1.2.1 Biocatalytic asymmetric hydroxylation 
Shown in Scheme 1.1, in biohydroxylation, one of the oxygen atoms in the 
molecular oxygen is inserted into the C-H bond of the non-activated carbon, 
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and the other oxygen atom is reduced into H2O with electron donated from 
cofactor of reduced NADH or NADPH.
[5, 22, 27 − 33]
 The biohydroxylation 
offers the following advantages: high regio- and enantio-selectivities; cheap 
and green molecular oxygen as the oxidant; highly efficient and economically 
competitive.
[13, 27]
 The products of the biohydroxylations could be used for the 
preparations of chiral alcohols which can serve as the synthons or the 
intermediates in pharmaceutics.
[5, 27]
 Comparatively, inserting an oxygen atom 
into the saturated C-H bond still places formidable challenges for traditional 
chemical ways, where the regio- and stereo-selectivities are low.
[5, 11, 13, 22 − 38]
  
 
Scheme 1.1 Monooxygenase-catalyzed biohydroxylation.[23, 27]
 
 
Previously, we reported a novel cytochrome P450pyr monooxygenase derived 
from Sphingomonas sp. HXN-200, which can catalyze various oxidations 
including hydroxylation, sulfoxidation, and epoxidation.
[4, 39 − 51]
 Therefore, in 
the first part of this thesis, hydroxylation of BP with E. coli (P450pyrTM-
GDH)
[51]
 is used as a model biooxidation for producing a drug intermediate, 
where the triple mutant P450pyrTM (I83H/M305Q/A77S) of P450pyr and 
another enzyme GDH for cofactor regenerating are coexpressed in E. coli 









1.2.2 Biocatalytic asymmetric sulfoxidation 
The second experiment topic in this thesis is the asymmetric sulfoxidation. 
Sulfoxidations, i.e. heteroatom sulfur oxidations, can give products of 
nonracemic sulfoxides which are useful chiral auxiliaries for many 
asymmetric reactions.
[52 − 57]
 Nowadays, despite highly efficient procedures for 
asymmetric sulfoxidation of prochiral sulfides are available in chemical ways, 
the enantioselective oxidation of the sulfur atom are still not well achieved,
[52 − 
55]
 while biocatalytic sulfoxidations present good catalytic performances. As 
shown in Scheme 1.3, the sulfoxidation procedure is similar to the 
biohydroxylation reaction, where an oxygen atom is incorporated into the 
sulfur atom, and the other oxygen atom of molecular oxygen is reduced into 




Scheme 1.3 Monooxygenase-catalyzed asymmetric sulfoxidation.[23, 39] 
In the second experiment part of the thesis, biocatalytic asymmetric 
sulfoxidations of several alkyl aryl sulfides with E. coli (P450pyrI83H-
GDH)
[39]
 are used as the model asymmetric sulfoxidations, where the single 
mutant P450pyrI83H (I83H) of P450pyr
[4, 39 − 51]
 and the enzyme of GDH for 
cofactor regenerating are coexpressed in E. coli (P450pyrI83H-GDH) for 
efficient catalytic performance (Scheme 1.4).
[39]
   
 





1.2.3 Biocatalytic asymmetric epoxidation 
Asymmetric epoxidation, oxidization of alkene via bonding both carbons of 
the C-C double bond to a sole oxygen atom for yielding a cyclic ester, is used 
in the third experiment part of this thesis (Scheme 1.5), which could give 
enantiopure epoxides as the useful and valuable intermediates in the chiral 
synthesis for fine chemicals and pharmaceutics.
[4]
 Despite Sharpless and 
Jacobsen’s methods as the classical chemical approaches work well in the 
asymmetric epoxidations, terminal alkene epoxidations are still challenging 
for the chemical ways.
[1, 4]
 Biocatalytic epoxidation catalyzed by 
monooxygenase can selectively insert oxygen atom of molecular oxygen to 
terminal alkene, giving product in high enantioselectivity, and the other 




Scheme 1.5 Monooxygenase-catalyzed asymmetric epoxidation.[1, 4, 23] 
Specifically, in the third experiment part, trans-dihydroxylation of styrene to 
(S)-vicinal diol via the cascade epoxidation and hydrolysis with tandem 
biocatalyst of recombinant E. coli (SSP1) coexpressing styrene 
monooxygenase for the epoxidation and epoxide hydrolase for the sequential 









1.3 Toxicity and inhibition effects in biooxidation 
Many shortcomings of the biooxidations hinder their wider applications, 
especially the ones at the large scale in the industrial. The weaknesses of 
biooxidations include the fragility of the oxidative biocatalyst, toxicity and 
inhibition effects inherent to many substrates and products, slow reaction rates, 
poor production titers, complex separation and purification processes, etc.
[5, 19, 
23, 27, 59 − 70]
 Among all these disadvantages, the toxicity and inhibition effects 
of substrates and products could obviously impair the biocatalysts, reduce the 
productivities, and sometimes affect the selectivities, thus causing great 
fluctuations in biooxidation performances.
[23, 44, 54 − 56, 59 − 66]
 
Even for the whole cell-based biooxidation, negative effects of toxicity and 
inhibition cannot be exempted. Monooxygenase-catalyzed biooxidations are 
carried out in whole cell form (i.e., whole cell containing the target enzyme for 
catalyzing reaction) due to the complex enzyme structures and the intrinsic 
electron transferring mechanism for the monooxygenases.
[19, 23, 27]
 Using 
whole cell can protect monooxygenases from deactivation owing to the 
presence of the cell membrane and can avoid the tedious and expensive 
enzyme purification as well.
[19, 23, 54 − 56, 62 − 66]
 However, given the whole cell 
biocatalyst is used in biooxidations, high concentration of the toxic substrate 
may also damage the membrane integrity, leaving the cell envelops fragile and 
vulnerable during the biooxidations,
[19, 23, 39, 67 − 70]
 which could eventually 
reduce the enzymatic performances of biooxidations.
[39]
 Figure 1.2 shows 
several examples of P450 monooxygenase-catalyzed biohydroxylations in 
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whole cell form at industrial scale, where the low production titers could be 
caused by the toxicity and inhibition effects of the substrates and products.
[59]
 
      
Figure 1.2 Biohydroxylations catalyzed by P450 monooxygenases in whole cells.
[59]
 
As for sulfoxidations, the hydrophobic substrate sulfides impose great 
toxicities to the biocatalysts,
[39, 71 – 73]
 and thus the sulfoxidation reactions 
usually present low production titers.
[74 – 81]
 The toxicities of the hydrophobic 
sulfide substrates are especially conspicuous when the whole cell biocatalysts 
are used, where most of the cells cannot survive through the sulfide-enriched 
environment.
[39, 71]







sulfoxidation reactions, and the final production titers are all unsatisfactory 
due to the toxicity and inhibition effects of the substrates and products.  
Table 1.2 Sulfoxidations catalyzed by different enzymes. 













Low yield corresponds to 
high ee value, vice versa 
Lignin peroxidase
[83]
 <62%  < 1 
Strong electron-donating 
properties of aryl substitutes 
gave high yield and low ee 
value 
Pea cytosolic ascorbate 
peroxidase (rAPX) and the 
single-site mutant (W41A) 
[84]
 
 < 10 
rAPX produce racemic 
mixture while its mutant 

















(R)-10%   
Enantioselectivity increased 
with replacing 30% of 




 (S)-98% 2.5  
Inhibition observed when 
substrate exceed 5 mM 




 < 1  
L29H/H64L double mutant 
enhanced ee from 25% to 
97% 
As for epoxidations of the terminal aryl olefins catalyzed by the two 





of these two exemplary monooxygenases showed vulnerability to the toxicity 
and inhibition inherent to the substrate styrene. Especially for P450 
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monooxygenase-catalyzed epoxidation, the final production titer of no more 
than 2 mM could simply make the reaction much less practical for industrial 
applications.
[4] 
1.4 Motivation and objective 
As stated in section 1.3, the biooxidations of hydroxylation, sulfoxidation and 
epoxidation are hampered by the toxicity and inhibition inherent to the 
substrate and product, giving less desirable enzymatic performances. 
Therefore, the target of this thesis is to overcome the problems of toxicity and 
inhibition and hence to enhance the enzymatic performances (in both 
productivity and selectivity) for monooxygenase-catalyzed biooxidations by 
bioprocess engineering of developing biphasic system to in situ adsorb/desorb 
product/substrate for the prevention of inhibition and toxicity.  
1.4.1 Overall motivation 
Currently, most of the research endeavors are made in protein engineering 
such as the directed evolution and the rational design for enhancing enzymatic 
performances and tolerance to toxicity and inhibition.
[19, 23, 39, 40, 44]
 However, 
protein engineering on molecular level, especially the rational design, requires 
massive information such as enzyme crystal structure to initiate the work. 
Many biooxidations catalyzed by wild-type microorganisms or less-studied 
enzymes will thus be excluded from the rational design. Given all key 
information available, protein engineering is tedious and labor-consuming. 
High throughput methods are used in protein engineering to expedite this 
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procedure, however, until now, it is still reliant on chance discovery that paves 
the way for the success of this work.
[19, 23, 39, 40, 44]
 Hence, a simple and 
universal tool or platform with more practicability and maneuverability for 
quenching the substrate and products’ toxicity and inhibition effects and thus 
enhancing biooxidations’ enzymatic performances is in demand. 
This thesis intends to demonstrate that bioprocess engineering of developing 
biphasic system can enhance the productivity and selectivity for biooxidations 
by preventing the toxicity and inhibition and thus can serve as a 
complementary and convenient approach to the protein engineering. Although 
biphasic systems have been reported for the prevention of toxicity and 
inhibition,
[91– 93]
 only a limited number of biooxidations have been conducted 
in biphasic systems, because many secondary non-aqueous phases (usually 
organic solvents) are toxic, flammable, environmentally hazardous, and lack 
biocompatibility.
[39, 69, 91 – 99]
 This thesis selected three different types of 
representative biooxidations of biohydroxylation, sulfoxidation, and 
epoxidation, and successfully conducted the selected biooxidations in three 
different established biphasic systems respectively, which could rekindle the 
interests in conducting biooxidation with enhanced productivity and selectivity 
by using the green and convenient platform of biphasic systems. 
1.4.2 Specific objective 
In the first part of the thesis, a solid-liquid (aq./Amberlite
®
 XAD4) biphasic 
system was engineered for enhancing the biohydroxylation of BP for 
producing a drug intermediate, as the first solid-liquid biphase for P450-
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catalyzed biohydroxylation with simultaneous biotransformation and in situ 
adsorption in one pot. In the second part, an aq./IL (KP-buffer/[P6,6,6,14][NTf2]) 
biphasic system was developed to simultaneously enhance enantioselectivities 
and productivities of asymmetric sulfoxidations for the production of several 
useful and valuable aryl alkyl sulfoxides, as the first report on engineering of a 
biphasic system with IL to enhance both the enantioselectivity and 
productivity for biooxidation.
[39]
 In the third part, an aq./org. biphasic system 
in HFMB was established for the first time to enhance productivity of the 
trans-dihydroxylation via the cascade epoxidation catalyzed by SMO and 
sequential hydrolysis catalyzed by SpEH hydrolase. 
1.5 Structure of the thesis 
Chapter I of introduction presents the biooxidation concept, shows the 
problems and motivation, and gives the structure of this thesis. Chapter II of 
literature review shows all the necessary background information and current 
research status related to the biooxidation. Chapter III is on establishing a 
solid-liquid biphasic system by using hydrophobic resin for hydroxylation of 
BP with E. coli expressing a triple mutant of P450pyr. Chapter IV focuses on 
conducting asymmetric sulfoxidations of alkyl aryl sulfides with E. coli 
expressing a single mutant of P450pyr in an aq./IL biphasic system.  Chapter 
V is to apply biphasic systems in HFMB to enhance the productivity for trans-
dihydroxylation of styrene with E. coli tandem biocatalyst coexpressing SMO 
for epoxidation and SpEH hydrolase for hydrolysis. Chapter VI concludes the 













2.1 Biotransformation for synthesis of enantiopure chemicals  
Owing to the mushrooming stresses from the environment burden and the 
soaring demand on fossil fuels, green chemistry is one of the most highlighted 
topics in many industrial areas such as pharmaceutical, agricultural, food, etc 
[1, 6 – 13, 100]
. The principle of green chemistry is the using of the biocatalyst 
such as purified enzymes or living microbial organisms to perform the 
biotransformation of organic compounds for producing useful target molecules, 
which also defines the scope and characteristics of biotransformation.
[11, 100 – 
102]
 Since most of the biocatalysts can functionalize under mild conditions 
such as near-neutral pH, ambient temperature, and atmospheric pressure, etc., 
biotransformation is regarded as green and energy efficient.
[1, 18]
  
Aside from the environmental credentials, owing to the innate built-in chirality 
of the biocatalyst, biotransformation is deemed as highly selective, especially 
in regio- and stereo-selectivity, giving nonracemic product,
[54]
 and this is the 
most valued point in the industry applications. Sometimes, biocatalyst can 
endow product with “unexpected” selectivity after random genetic 
modifications.
[19]
 Although in many ways, biotransformation is playing as an 
alternative substitute to chemical route (i.e., not completely replacing chemical 




2.1.1 Chirality and biotransformation 
Chirality bears its importance in pharmaceutical area since it matters greatly to 
the health of human beings. The event of Thalidomide is a good example for 
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world to learn the significance of chirality (Figure 2.1): Thalidomide was first 
developed as racemate to prevent the pregnant women from morning nausea, 
and this drug was banned in 1960 due to the congenital birth defects, which 
was later confirmed that (S)-enantiomer of Thalidomide caused teratogenic 
effects while (R)-enantiomer had sedative effects.
[104]
 Possible reasons for 
different affects caused by the two enantiomers could be the differences in the 
adsorptions, protein bindings, and metabolisms of the two enantiomers, etc., 
which together result in the different therapeutic and toxicological 
performances. Usually, only one enantiomer of the racemate functions 
mainly,
[104, 105]
 and evaluating enantiomers in the racemate before the final 
sanction by FDA as a new drug therefore sounds not only reasonable but also 
indispensible.
[49, 104 – 106]
  
 
Figure 2.1 Structure of the enantiomers of the Thalidomide.
[104]
 
Another example for demonstrating the significance of the chirality could be 
found in Sopromidine (shown in Figure 2.2), whose (R)-enantiomer is the 
agonist at H2-receptors while the (S)-enantiomer of Sopromidine is the 
antagonist. The racemic mixture of Sopromidine shows partial feature of 









Even in the case of similar effects observed in both enantiomers, their 
efficacies may be different.
[57]
 For instances, the R and S enantiomers of 
Omeprazole, the proton-pump inhibitors for blocking the gastric-acid secretion, 
are different in their efficacies given the same dosage used (Figure 2.3).
[57]
 
This implies that the intake dosage of a drug could be greatly reduced by using 
the proper enantiomer, thus decreasing the risk of side effects. Chiral 
molecules are now even extending to the area of agriculture, where the 
enantiopure antiseptic agent could present better efficacy with less amount 





Figure 2.3 Effects of racemic and enantiopure Omeprazole.
[57]
 
The prevailing enantiopure drugs bring the benefits in the following ways:
[105]
 
selective pharmacodynamics; elimination of the potential hazardous impurities; 
enhanced therapeutic efficacies; closer relation between the drug concentration 
in plasma and the final efficacies. Also, driven by the requirement on 
evaluating racemate’s pharmacological effects by FDA, the annual market 
share of enantiopure compounds for drug synthesis increases in response to 






















Recognition on the significance of the chirality highlights the 
biotransformation, which is considered to be a green and efficient way for 
synthesizing nonracemic product owing to the innate build-in chirality of the 
biocatalyst.
[54]
 This advantage is further strengthened and consolidated with 
progresses in biotechnology, and nowadays researchers can even manipulate 




In all, these various factors aforementioned together foretell the prosperity of 
biotransformation in chiral synthesis in the future, not only as a simple 




2.1.2 Preparation of enantiopure compounds 
Arising needs on enantiopure compounds cast spotlight on biotransformation 
due to its innate built-in chirality of the biocatalyst. Comparatively, traditional 
chemical synthesis is depreciated for lacking environment endorsement and 
selectivity, where simple and primitive structure of chemical catalyst can 
hardly discriminate the nuances between different spatial positions and thus 
give racemic mixture of products.
[1, 6 – 10]
 As shown in Figure 2.4 
[47, 105]
, 
traditional chemical synthesis accounts less and less portion in the preparation 
of the chiral molecules, while the biotransformation produces increasingly 
more chiral compounds.  
In chemical approaches, racemic mixture of the target product could be first 
produced, and then the conglomerate crystallization or chromatography by 





Aside from some of the formidable challenges in oxidation reactions such as 
hydroxylation,
[11, 13, 22 – 38]
 chemical synthesis is valued for stability but 
depreciated by energy-consumption and environmental-hazardousness. The 
situation could be further deteriorated by the fluctuations in the availability of  
   
Figure 2.4 World market for chiral molecules.
[47, 105]
 
noble metals, which are critical for preparing the chemical catalysts. 
Biotransformation on the other hand provides a convenient substitute way for 
preparation of the enantiopure compound. In biotransformation, there are 
typically two classes: asymmetric synthesis and kinetic resolution of racemate. 
In kinetic resolution, the enantiomeric enrichment is achieved by one of the 
two enantiomers in the racemic mixture being converted or consumed faster 
than the other enantiomer.
[109 – 112]
 However, kinetic resolution suffers from 
low yield: theoretical maximum yield is 50%.
[105, 109]
 Comparatively, the 
biocatalytic asymmetric synthesis refers to the direct conversion of achiral 
compounds to the chiral compounds with the corresponding enzymes,
[73]
 
where high yields could be achieved with enantioselectivity and economics 
depending on the enzyme chosen. Although these two methods of asymmetric 
synthesis and kinetic resolution complement and compete with each other, 
biocatalytic asymmetric synthesis is preferred as theoretical maximum yield 






World market for chiral molecule in 




World market for chiral molecule in 
year 2009 (Total S14.9bn)
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2.1.3 Biotransformation in pharmaceutics 
On the basis of environmental credential, low operation requirement, high 
yield, good to excellent selectivity, and maneuverability for a wide substrate 
spectrum, biotransformation is now gaining increasingly more attentions.
[6 – 18, 
100 – 102]
 The resulted enantiopure products by biotransformations go to 
different industrial areas such as pharmaceutics, food, cosmetics, polymer, 
agriculture, etc.,
[113 – 118]
 where the pharmaceutical consumes most of the 




 shows several 
biotransformations in pharmaceutical industry,
[1, 54]
 where excellent regio- and 
enantioselectivity are achieved for all the cases.
[1, 6, 7, 11 – 18, 113]
 
 
Figure 2.5 Distribution of enantiopure compounds in industrial sectors.
[113]
 
Also, regulations from FDA require that the compounds with chiral centers 
should be in one isomeric form and without teratogenic effects, and the 
enantiopure level for commercialized product should be no less than 98% in ee 
value.
[49, 104 – 108]
 For simple molecule manufacture that usually has one chiral 
center, the need of using biotransformation for production might not be that 










comes to the complicated molecules, biotransformation is the choice of no 
doubt as it could be impossible for the chemical routes to realize.
[16, 49, 119 – 124]
 
In many cases, biotransformation had been proven to be much more feasible 
and efficient than the chemical route as can be seen in the birth of Penicillium 
in World War II.
[125]
 Nowadays, biotransformation, owing to the unparallel 
selectivity and non-harsh operation requirements, is prevailing through many 
industrial areas.
[16, 119 – 124]
 
Table 2.1 Biotransformations in several pharmaceutical companies.
[113]
 









β-Lactams Glaxo Acylation CALB 45 12 82 98 
Lotrafiban Glaxo Hydrolysis CALB 42 10 25 99 
Paclitaxel BMS Hydrolysis 
Pseudomonas 
lipase AK  
P. cepacia lipase 
PS-30 





P. cepacia lipase 
PS-30 
48 0.1 2 98 
Xemilofiban Monsanto Hydrolysis 
E. coli penicillin 
acylase 
43 1.6 35 98 
Lamivudine Glaxo Hydrolysis 
E. coli cytidine 
deaminase 
50 0.1 1.5 99.5 
AG7088 Pfizer Reduction 
L.mesenteroides 
D-LDH 
C. boidinii FDH 
88 13.2 40 99.9 
LY300164 Eli Lilly Reduction 
Z. rouxii 
dehydrogenase 






91 1.6 41 98 
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2.2 Monooxygenase as selective catalyst in biooxidation 
As natural-existing catalysts, enzymes are proteins in chemical point of view, 
and they are usually exquisitely selective, giving products in unparalleled 
regio- and stereoselectivities.
[1]
 The discovery of enzyme could date back to 
hundreds of years ago, and the name “enzyme” was interpreted as “in yeast” 





 Nowadays, with the tremendous progresses in genomic and 
proteomic technology, many novel and robust enzymes are developed as green, 
maneuverable, and sustainable biocatalysts
[116, 126]
. To date, all discovered 
enzymes are categorized into 6 main classes by the International Union of 
Biochemistry (I.U.B.): oxidoreductases, transferases, hydrolases, lyases, 
isomerases, and ligases (synthetases).
[5, 105, 126, 127]
 
In biotransformation, discovery and engineering potent enzymes is critical. 
For biooxidations, the monooxygenases in oxidoreductase class
[5 – 10, 105, 126, 127]
 
are frequently used for hydroxylation, sulfoxidation, and epoxidation, etc. 
They refer to a large number of the proteins bearing highly active and specific 
catalytic centres for incorporating oxygen atom from molecular oxygen into 
organic compounds while reducing the remaining oxygen atom into water at 
the expense of cofactor NAD(P)H consumed.
[5]
 They are responsible for in 
vivo and in vitro catalyzing alkanes to alcohols, sulfides to sulfoxides, olefins 
to epoxides, cleaving aromatic rings, and hydroxylating aromatic compounds 
and a variety of steroid derivatives.
[1, 4, 5, 22, 23, 27, 39, 58, 128]
 They draw much 
attention due to their capabilities in oxyfunctionalization of non-active organic 




[1, 15, 23, 27, 59 – 66]
 A good example could be the steroid 
productions, where organisms containing monooxygenases catalyzed reactions 
impossible for chemical routes.
[5, 129 – 136]
  
Monooxygenases could be divided into three different groups: heme-, flavin-, 
and multimeric metal-dependent monooxygenases (Figure 2.6).
[23]
 Shown in 
Figure 2.6, dioxygenase, the only sibling to monooxygenase in the oxygenase 
family, is also a large group of enzymes which catalyze dihydroxylations by  
 
Figure 2.6 Classification of the oxidizing enzyme.
[23]
 
incorporating two hydroxyl groups on the substrates simultaneously, at the 
expense of consuming cofactor NAD(P)H as well. Interestingly, dioxygenase, 
which is supposed to incorporate two oxygen atoms of molecular oxygen into 
an organic substrate molecule, sometimes can also catalyze monooxygenation 
reactions including hydroxylation, sulfoxidation, and epoxidation.
























For many years, dioxygenases are considered to be powerful catalyst in 
degrading aromatic compounds, but their slow transformation rates in many 
bioconversion processes prevent their further applications.
[5]
 Another 
drawback to the dioxygenase is that this type of enzyme often generates more 
byproducts, and thus wastes substrates and lowers atom efficiency, which 
could be unwanted especially when the substrate accounts a great portion of 
the total cost.  
2.2.1 P450 monooxygenase of heme-dependent monooxygenase 
Among all the reported monooxygenases, the cytochrome P450 (CYP) 
monooxygenases, the representative of the heme-dependent monooxygenases 
(Figure 2.6), are the most widely studied and used.
[13, 22, 23, 63]
 The word 
“cytochrome” means the cellular (represented by ‘cyto-’) colored (represented 
by ‘-chrome’) protein.[140] P450 monooxygenase, present in nearly all forms of 
life,
[13, 141]
 refers to a large family of cysteinato-heme enzymes, and it plays a 
key role in oxidative transformations in vivo.
[13]
 These enzymes are the heme-
thiolate proteins with their AA sequences highly diverse (as low as 16% 
identical), while their structural fold is identical.
[141]
  
Cytochrome P450 gets its name for the adsorption at 450 nm in the carbon-
monoxide bound form, and each CYP consists of an iron(III) protoporphyrin-
IX catalytic center covalently linked to the protein by the sulfur atom of the 
cysteine ligand (A specific CYP structure was shown in Figure 2.7),
[13, 65, 141, 
142]
 which together with the AA portion around the catalytic center is the most 





              




As can be seen Figure 2.8, in the P450 monooxygenases, the prosthetic group 
is constituted of an ion(III) and protoporphyrin-IX, which is covalently linked 
to the protein via sulfur atom of cysteine on an invariant chain of cysteine 
residue.
[13]
 This invariant cysteine residue connects the heme iron to the 
protein and thus forms the fingerprint (so-called “P450 signature” motif) 









For many years, P450 monooxygenases derived from organisms including 
prokaryotic bacteria and eukaryotic fungi have been tapped for 
biotransformations of natural and non-natural compounds to produce 
molecules of interests. Among them, the commercialized biotransformations 
of steroids (e.g., 11β-hydroxylation of Reichstein to Hydrocortisone with 
Curvularia sp.; hydroxylation of Progesterone; bioconversion of Compactin 
into Pravastatin by the P450 monooxygenase in Streptomyces sp.) could be the 
exemplary industrial applications of P450 monooxygenase.
[59, 65, 143 – 145]
 Also, 
cytochrome P450 monooxygenases are prized for their abilities in synthesizing 
valuable drugs such as anti-cancer drug Paclitaxel and the anti-malaria drug 
Artemisinin 
[19 – 21]
. Besides asymmetric hydroxylation, P450 monooxygenases 
can also catalyze other oxygenations including the asymmetric sulfoxidation, 
epoxidation, dealkylation, oxidation, dehalogenation, and dealkylation (Figure 
1.1).
[19 – 22, 65, 140 – 143]
  
As shown in Figure 2.9, the mechanism of P450 monooxygenase-catalyzed 
oxygenation has been animated
[13, 35, 141]
: substrate first binding to the protein 
with the displacement of the water, and inducing a shift in redox potential (up 
to 300 mv); secondly, one-electron reduction to the ferrous state driven by the 
300 mv in the previous redox potential; thirdly, binding with the molecular 
oxygen to produce a dioxy superoxide complex; fourthly, another electron 
transferring reduction to generate the [A]
2–
 “restless oxygen complex” which 
is transient in living period; the complex of iron-peroxo [B]
–
 produced by 
protonation of the electron reduced dioxygen [A]
2–
; iron-oxo [C] resulted from 
the cleavage of the O-O bond – one oxygen dissociating as water with two 
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electron and two protons; the iron-oxo (the ferryl intermediate) [C], with two 
oxidation state above the resting ferric state, reacting with the substrate to 
form the hydroxylated product; the enzyme returning to the stable ferric state 
after releasing the hydroxylated product and re-equilibrating with the water. 
 
Figure 2.9 Catalytic mechanism of P450 enzymes.
[141]
 
According to Figure 2.9, P450 enzymes are all external monooxygenases, 
which means that every P450 needs an external electron donor to transfer the 
electron necessary for the oxygenation.
[59 – 65]
 The electron donor working for 
P450 monooxygenase is the cofactors of NADH and NADPH, and the P450 
enzyme must cooperate with the redox partner protein of CPR to fetch the 
electron from cofactors of NADH and NADPH to the heme center in P450 
hemeprotein.
[23, 59 – 61, 63 – 65, 141]
 In line with the catalyzing mechanism, P450 
family can be divided into three classes on the basis of the redox partner CPR 
which was involved in the electron transferring (Figure 2.10):
[64]
 The first 
class of P450 enzyme constitutes of P450 hemeprotein, redox iron-sulfur 
ferredoxin protein, and CPR containing FAD or FMN; the second P450 class 
consists of P450 hemeprotein and CPR, and can transfer electron from FAD to 
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FMN within CPR domain; the third group of the P450 enzyme belongs to one 
component protein, where CPR is merged with P450 hemeprotein. 
 
Figure 2.10 Typical P450 monooxygenase classes. (a) Three-component: P450 
hemeprotein, ferredoxin, and reductase (CPR) can be soluble or membrane-integral. 
(b) Two-component: CPR and P450 hemeprotein are membrane-integral. (c) One-




Dependence of P450 enzyme on the cofactor of NADH and NADPH greatly 
limits its wider application especially in industrial areas,
[59, 64, 65, 140]
 and this 
brings many disadvantages, e.g., instability, low activity, complex electron 
transferring, and sensitivity to the organic solvents, etc.
[65]
 In order to expand 
further applications of the P450 monooxygenases, investigations and remedies 
to improve their stability and activity should thus be made.
[23, 59, 61, 63–65, 140]
   
So far, genetic modification of the amino sequences of the enzymes have been 
reported to successfully improve the P450 enzymatic performances for many 
cases.
[19, 23, 39, 61, 63–65, 140]
 Genetic modification of the protein refers to the 
artificial substitutions or changes of several amino acid residues in the enzyme, 
which can bring the enzyme with unexpected functioning.
[11, 15]
 Because the 
enzymes are made of chains of the polypeptides on molecular level, enzyme 




























performances could be changed by genetic modifications, and this genetic 
modification could be classified into two groups of rational design and 
directed evolution.
[64]
 Rational design requires detailed information on protein 
structure to give an insight understanding of the protein characteristics such as 
folding, dynamics, catalytic center, function-structure relations, etc,
[64, 146 – 150]
 
where obtaining the X-ray diffraction of the protein crystal is the key point.
[11, 
15, 64, 146, 149, 150]
 Afterwards, several key AAs (i.e., AAs around the active 
catalytic center) are selected from the polypeptide sequences for the 
mutagenesis, where those selected AAs will be substituted by other AAs with 
manipulating their corresponding gene sequences.
[49, 64, 146, 149 – 151]
 Directed 
evolution actually gets its name from the “natural evolution”, where mutation, 
selection, reproduction, and repetition for many generations have created 
incredible biodiversity and adaptation.
[11, 15, 23, 64, 146 – 149]
 Therefore, directed 
evolution needs no such detailed information on the X-ray diffraction of 
crystal structure, whereas it mainly refers to the random mutagenesis (e.g. 
error-prone PCR, mutagenesis insertion, ethyl methanesulfonate mutagenesis, 
etc.) and recombination of the resulted mutation fragments by approaches such 
as gene reshuffling and homologous recombination. Until now, directed 
evolution has been used for enhance enzymatic performances of selectivity, 
productivity, and tolerance.
[64, 146 – 149, 152]
 Since directed evolution can produce 
a huge mutant gene library due to random mutations, high throughput 
screening methods to select and pinpoint the desired mutant are required.
[11, 15, 
23, 40, 64, 147, 152 – 154]
 Colorimetric high throughput method is frequently used, 
where the adsorption at certain wavelength signals how well the enzyme 
performances.
[40, 153, 154]
 Nowadays, it becomes hard to draw a line between the 
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rational design and directed evolution as these two methods are coming 
closer.
[150]
 The site-saturated mutagenesis is an example of combination of 
rational design and directed evolution: upon obtaining the enzyme structure 
information, each AA of the selected AAs will be substituted by the other 20 
remaining AAs one by one, giving a much smaller mutant library.
[40, 154 – 156]
 
As for many P450 monooxygenases, the availability of the enzyme structures 
enables directed evolution together with the rational design be widely used for 
enhancing the enzyme stability, activity, and selectivity.
[49, 157 – 160]
  
2.2.2 Styrene monooxygenase of flavin-dependent monooxygenase 
Flavin-dependent monooxygenase uses one oxygen atom from molecular 
oxygen to form the flavin-oxygen intermediate complex, producing 
oxygenated product with the other remaining oxygen atom reduced to water at 
the expense of consuming cofactor.
[22, 23, 128]
 This type of monooxygenase 
catalyzes a wide range of biochemical reactions with high regio- and 
enantioselectivity, which are difficult to realize via chemical ways.
 [22]
 Many 
of these enzymes play key roles in metabolism of the natural and non-natural 
compounds, while the other flavin-dependent enzymes are involved in the 
biosynthesis of hormones, vitamins, and antibiotics, etc.
[22, 128]
 Unlike the 
heme-dependent monooxygenases which use the prosthetic group containing 
transient metal of iron to create intermediate for oxygen transferring, flavin-
dependent monooxygenases use the organic prosthetic groups of FAD as the 
catalytic centers to deliver oxygen atoms for the target oxygenation 
reactions.
[22, 23]
 As shown in Figure 2.11, with an electron transferred from 
reduced flavin into oxygen, a transiently stable flavin C4a-oxygen adduct is 
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formed. Upon protonation, the peroxy species of peroxyflavin and 
hydroperoxyflavin react with nucleophilic and electrophilic substates 
respectively, thus splitting the oxygen-oxygen bond and then incorporating 
one oxygen atom from the molecular oxygen into the substrate with the 




Figure 2.11 Oxygenation mechanism catalyzed by flavin monooxygenase.
[22] 
SMO is a good example of flavin-dependent monooxygenase. It can catalyze 
epoxidation reactions with a broad substrate spectrum and thus is well applied 
in industry.
[22, 128, 161 – 165]
 In epoxidation, SMO converts styrene into styrene 
oxide by bonding both carbons of the C-C double bond to a sole oxygen atom 
for producing the cyclic ester.
[1, 4, 22, 128, 161 – 165]
 So far, several types of SMOs 
have been discovered and heterogeneously expressed as the recombinant 
proteins in different forms of organisms, and the bacterial SMOs were studied 
the most. All bacterial SMOs are two-component flavin-dependent 
monooxygenases, consisting of the reductase part (i.e., StyB) and the FAD 
part of monooxygenase (i.e., StyA).
[128]
 In many cases, SMO is written as 
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StyAB, denoting again that this type of enzyme consists of two components. 
Nowadays, SMO is highlighted as it can produce many important building 
blocks such as styrene oxide in pharmaceutical industry, and it also exhibits a 
broad range of substrate spectrum. So far, it has been applied to produce 388 g 
target (S)-styrene oxide at pilot scale of 30 L,
[22, 128]
 and efforts in genetic 
engineering via site-directed evolution and error-prone mutagenesis for further 
improving SMO performances have been implemented already.
[128]
 
2.2.3 Multimeric metal-dependent monooxygenase 
Besides the two important types of heme- and flavin-dependent 
monooxygenases, the remaining monooxygenases are so far all multimeric 
metal-dependent, where the iron-iron, multi-copper or iron-copper metal 
clusters could be found as the catalytic centers in these monooxygenases. For 
example, sMMO has the iron-iron center, which recycles between diferric [i.e., 
Fe(III)Fe(III)] and diferrous [i.e., Fe(II)Fe(II)] states during the reaction with 
electron transferred from NAD(P)H.
[166 – 172] 
 The membrane-bound pMMO 
requires copper and iron to form the copper-iron cluster as the catalytic site.
[170 
– 172] 
 Membrane-integral alkane hydroxylase, known as AlkB, is another good 
example of non-heme iron-iron monooxygenase, which is well characterized 
and is used for alkane degradation for a long time.
[173] 
 Monooxygenases of 
phenol oxidases include two classes: laccase and polyphenol oxidases (also 
known as tyrosinase), and these two types of phenol oxidases both contain 
multimeric copper clusters (laccase contains a tetra-copper center, while 
polyphenol oxidase contains a di-copper center), where these multi-copper 





2.3 Biooxidation reaction catalyzed by monooxygenase 
So far, nearly all types of biooxidations (Figure 1.1) could be catalyzed by the 
so called omnipotent monooxygenases.
[23, 180]
 This could be proven by the 
reactions catalyzed by the first class of monooxygenase (i.e., CYPs) (Figure 
2.6), where the asymmetric hydroxylation (hydrocarbon and aromatic), 
epoxidation (alkene and arene), dealkylation (N-, S-, and O-terminal), 
heteroatom oxidation (N- and S-), oxidative deamination, dehalogenation, 
alcohol oxidation, aldehyde oxidation, and oxidative C-C bond cleavage can 
be catalyzed by CYPs.
[180]
 From a practical point of view, the bacterial P450 
monooxygenases are generally more easier to handle,
[23]
 and they could be in 
one-component form sometimes, with the reductase and hemeprotein being 
merged together. A good example is the widely studied soluble bacterial 
P450BM-3, which is a one-component monooxygenase and shows turnover 
number as high as 280 s
-1
 for producing arachidonic acid.
[164]
   
Oxidation reactions catalyzed by the second class of monooxygenase (i.e., 
flavin-dependent monooxygenase) (Figure 2.6) cover a substrate spectrum as 
wide as P450 monooxygenase does, with SMO (catalyzing epoxidation 
reactions)
[161 – 164] 
and BVMO (producing lactones, sulfoxides, sulfates, etc.)
[23, 
164, 165]
 as the two well-known examples. As the most-intensively studied 
BVMO, CHMO is reported to catalyze Baeyer-Villiger oxidation of (-)-
bicyclo[3.2.0]hept-2-ene-6-one, yielding regioisomeric enantiopure lactone at 
kilogram scale in a 50 L bioreactor.
[164, 181, 182]
 
The third group of monooxygenases comprised of multimeric metal-dependent 
cluster (i.e. iron-iron, multi-copper or iron-copper) could present two well-
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known representative enzymes of MMO and AlkB, which are the two 
celebrities for catalyzing hydroxylation reactions. sMMO and pMMO of 
MMO can hydroxylate the methane, which is a major metabolism pathway 
and plays an important role in the carbon cycling for bacteria.
[166– 172] 
In 
comparison with the membrane-bound pMMO,  sMMO often exhibits quite 
broad substrate spectrum due to the versatile oxidizing performances, where 
the hydroxylation, epoxidation, and oxygenations of the aromatic and cyclic 
alkanes are included.
[5, 61, 170– 172]
 AlkB, due to its capability of hydroxylating 
C4 − C16 alkanes, fatty acids, alkylbenzene, and cycloalkanes, plays the pivot 




2.3.1 Asymmetric biohydroxylation  
Hydroxylation reaction is one of the most recalcitrant to the chemical catalyst, 
especially for regio- and stereo-selectivity, which is the driving force for the 
scientific and industrial to resort to biotransformation.
[5, 11, 13, 22 − 38]
 Given 
massive information and edge-cutting technologies available to build and 
expand the enzyme libraries, the most frequently used monooxygenases for 
catalyzing hydroxylations are still confined to a small scope including the 
P450 monooxygenases, AlkB, and MMOs. Table 2.2
[61] 
gives some examples 
for catalyzing the hydroxylation reactions, and the enzymes shown are all 
multi-component and require cofactor of NAD(P)H for conducting the target 
reactions. Nowadays, intensive progresses are made in identification, 
characterization, and functioning mechanism of the enzymes, and it is thus 
known that these hydroxylases are all ubiquitous in nature and involved in the 





Table 2.2 Monooxygenases capable of catalyzing hydroxylations.
[61]
 
Enzyme Composition and cofactors 
Range of 
substrate 
   Exemplary 
microorganism 
Class I P450 
(CYP153) 
P450 oxygenase: P450 
heme  











Class II P450 
(CYP52) 
Microsomal oxygenase 
P450 heme Reductase 




Candida maltosa,  




P450 heme Reductase 
FAD, FMN, NADPH 





dinuclear iron Reductase 










Membrane hydroxylase  
dinuclear iron Rubredoxin 












dinuclear iron Reductase 




























2.3.2 Asymmetric biocatalytic sulfoxidation  





















 The enzymes best known 
for sulfoxidations are chloroperoxidase, CHMO, and BVMO, etc. Take 
sulfoxidation of thioanisole as an example, CHMO from Acinerobacter could 
produce phenyl methyl sulfoxide as product with ee value up to 99%;
[184]
 other 
BVMO can also give product in good enantioselectivity with production titer 
3.5 mM,
[185]
; tyrosinase could yield product in ee as high as >90%.
[185]
 One 
advantage that makes monooxygenase stand out of the other oxygenases is 
that monooxygenase could use molecular oxygen as the green oxidant. 
Various monooxygenases are found to catalyze sulfoxidations with good 
selectivities, and the future work will concentrate on the modification of the 
discovered monooxygenases by protein engineering.
[54]
  
2.3.3 Asymmetric biocatalytic epoxidation  
As an important type of biooxidation, epoxidation can give enantiopure 
epoxide as useful and valuable pharmaceutical intermediate.
[1, 4, 22, 128, 161 – 165]
 
Enzymes capable of catalyzing this type of reaction include heme 
monooxygenases of CYP and non-heme flavin monooxygenases such as SMO. 
So far, SMO is reported as the most potent enzyme for catalyzing epoxidation 
regarding the specific activity, productivity, and enantioselectivity. As an 
example being applied at pilot scale, SMO can produce the target (S)-epoxide 





The StyB part of SMO is reported to be replaced by organometallic complex 
of pentamethyl-cyclopentadienyl rhodium bipyridine [Cp*Rh(bpy)(H2O)]2
+
, 
which together with the StyA part of SMO forms a chemo-enzymatic system, 
thus giving ~70% of original biocatalytic rate.
[22, 23]
 
2.4 Enzyme and whole cell biocatalyst in biotransformation 
Biocatalyst can be enzyme-based or whole cell-based. Both enzyme and whole 
cell biocatalysts can be used in either unbounded (i.e., free enzyme and cell) or 
bounded (i.e., immobilized enzyme and cell) form. To choose isolated or 
immobilized enzyme as biocatalysts, factors of enzyme stability, reaction rate, 
solubility, and diffusivity, etc., should be evaluated.
[49, 59 – 65, 100, 192]
 For both 
isolated and immobilized biocatalysts, enzyme purification is required, which 
can raise the operation and facility costs.
[54] 
Comparatively, whole cell 
biocatalyst could be criticized for causing bio-fouling.  
2.4.1 Isolated enzyme biocatalyst 
Isolated enzyme has been tapped as biocatalyst for the industrial applications 
for years in food, leather, brewing, and textile industrials, etc.
[5 – 10, 49, 64, 65, 100, 
192]
 It could offer high homogeneity for the reaction, which can reduce 
transport barrier between the biocatalyst and reactants and hence increase the 
overall reaction rate. However, this technology often demands comparatively 
high stability of the enzyme,
[59 – 65, 100, 192]
 not only because the enzyme should 
be first purified before catalyzing reactions, but also because many enzymes 
are required to perform their functioning with the presence of toxic organic 
substrates.




Protein purifications, the first and maybe the most time-consuming step for the 
preparation of isolated enzyme biocatalyst, consist of centrifugation, filtration, 
precipitation, adsorption, chromatography, and crystallization. In the protein 
purification process, the most versatile and important part is the 
chromatography. So far, chromatography could be classified into four 
different types of HIC, AC, IEC, and SEC. The emerging of FPLC has 
dominated the field of the protein purification, where different 
chromatographies could be used sequentially for achieving the highest purity 
in a short period of time. Given all these technologies available, protein 
purification is still labor-intensive and tedious. Biotechnological progresses in 
last century expedited the protein purification significantly, where the target 
protein could be tagged for affinity chromatography. The best example is the 
his-tagged protein with the target protein and a little “tag” of 6 histidine 
residues coexpressed as a fusion protein, where this little “tag” could strongly 
bind with the divalent nickel ion chelated on the affinity chromatography, thus 
enabling the target protein to stand out of the impurities readily.
[49]
  
After enzyme purification, the isolated enzyme is either used directly as one-
time biocatalyst or immobilized for fabricating the recyclable biocatalyst. In 
the past few decades, intensive attentions had been poured into the enzyme 
immobilization because it can ease purification burden and more importantly 
enable the reuse of those very expensive enzymes. Most of the 
immobilizations can cause decrease in enzyme activity, while, in a few rare 
cases, immobilizations do enhance the stability and selectivity of the 
enzymes.
[5]
 So far, the immobilization process could be either chemically or 
physically implemented. In chemical approaches for immobilization, the 
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covalent bond holds the enzyme to the support for immobilization, and this 
method usually includes intermolecular crosslinking between the enzyme and 
other reagent, attachment of the enzyme to polymer beads or particles, and 
incorporation of the enzyme into the long-chain polymer.
[5]
 Whereas, covalent 
bonding is absent when it comes to the physical immobilization, where the 
common approaches refer to entrapment of the enzyme within the matrix, 
containment of the enzyme in the semi-permeable microcapsule, and 
adsorption of the enzyme onto the water immiscible carriers.
[5, 193]
 Beside 
these two methods, nano-particles, which emerge in many fields as the robust 
heterogeneous catalyst and excellent immobilization support, has gain 
extensively interests currently for immobilization of enzyme due to the 
tremendously high ratio of surface area to volume, which endows them with 
the property of homogeneous catalyst and allows them to provide more active 
sites to the reactants.
[194, 195]
 
2.4.2 Whole cell biocatalyst 
Despite their well-documented catalytic potential, only a small portion of 
isolated enzymes are used for producing valuable compounds due to a variety 
of problems such as poor solubility and insufficient activity. On the other hand, 
biotransformation catalyzed by whole cells represents an elegant way of 
producing fine chemical,
[64, 65, 69, 100, 192]
 where the enzyme under the best 
catalytic conditions provided by in vivo natural environment can show higher 
stability and activity in comparison with its isolated form.
[23, 64, 65, 54, 192]
 Using 
whole cell for biotransformation is thus a practical and reasonable choice, 
especially for the enzymes (e.g., monooxygenases) with complex electron 
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transferring mechanism, sub-unit structure and high degree of conformational 
variability.
[5 – 10, 19, 54, 49, 59 – 65, 100, 164, 192]
 
Cells can be used as growing cell biocatalysts for converting substrates to 
products while incubating in the medium, or, alternatively, be harvested first 
and then re-suspended in the buffer solution as resting cell biocatalysts. Using 
growing cells as biocatalysts avoids cell separation from the cell culture broth, 
thus making the biotransformation simpler and more convenient. However, 
growing cells could be catalytically unstable due to the complicated in vivo 
metabolism, and this could be especially true if the cells are active since the 
metabolic activity could be robust enough to complicate the enzymatic 
performances or even consume the key compounds.
[54]
 The resting cell 
biocatalysts imply that the cells did not die and they are just less active in 
metabolism and propagate no more, rendering the cell envelope to be a natural 
protective container for harboring the enzymes. 
Both growing cell and resting cell biocatalysts can provide the in vivo cofactor 
regeneration mechanism, an advantage in the biooxidations. It is important 
because nearly all the monooxygenases are dependent on equimolar amount of 
cofactor NADP(H) for each oxygenation cycling, where the electron is 
transferred to the heme or flavin catalytic center in the monooxygenase 
through a complicated relay mechanism.
[23, 54, 59 – 65, 164]
 With whole cell 
biocatalyst, the cell envelope can provide a tiny and hermetic cubicle for 
electrons to be passed efficiently between the cofactors and the enzymes, 
which enables a highly catalytic efficiency with in vivo cofactor regeneration 
as well. There are papers published with using in vitro cofactor regeneration 
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with the addition of the cofactors exogenously.
[184]
 Obviously, it is costly and 
less efficient. Other ways for cofactor regeneration were also reported, 
however, the performances so far were not good enough to compete with that 
by using the whole cell biocatalyst.
[47, 49]
 For industrial practices at large scale, 
using whole cell biocatalysts is deemed as the only practical way for many 
biooxidations as it was proven many times that using isolated enzymes is not 
feasible.
[23, 59 – 65, 164]
 Regarding the transport barrier brought by cell membrane 
when using whole cell biocatalysts, because almost all biooxidations catalyzed 
by monooxygenases are relatively low in reaction rates, mass transportation 
could be excluded from being the rate controlling step. 
2.5 Cofactor regeneration in biooxidation 
Oxidoreduction reactions are always associated with electron acquiring or 
losing. Therefore, the heme-dependent P450 monooxygenases and the flavin-
dependent monooxygenases consume the cofactor NAD(P)H (Figure 2.12) in 
stoichiometric ratio with the substrate converted at the same time.
[5, 23, 59 – 65, 164]
 
Therefore, cofactor regeneration draws much attention. The chemical, electro-
chemical, photochemical, and enzymatic approaches have hitherto been 









So far, in comparison with the chemical, electrochemical, and photochemical 
regeneration approaches which are generally incompatible with the biocatalyst 
and usually offer low in selectivity and turnover number, enzymatic approach 
is the most widely used method for cofactor regeneration.
[47, 49, 196]
 There are 
two different enzymatic cofactor regenerations: enzyme coupled regeneration 
(i.e., hiring anther enzyme and another substrate) and substrate coupled 
regeneration (i.e., using one enzyme to convert two substrates).
[47, 49, 51, 196, 197]
 
To date, many enzymes have been tapped for the cofactor NAD(P)H 
regenerations, such as the glucose dehydrogenase with the glucose as the 
reducing reagent. Table 2.3 shows several enzymes used for regenerating the 
cofactors of NAD(P)H, where the glucose dehydrogenase shows the highest 
activity among all other dehydrogenases.  
Table 2.3 Enzyme used for recycling reduced NAD(P)H.
[47, 49, 196]
 

















4 – 6 
4 – 6 
4 – 6 
4 – 6 
7.6 
Glycerol dehydrogenase Escherichia coli 1.5  
Phosphite dehydrogenase Pseudomonas stutzeri 16 
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2.5.1 Enzyme-coupled approach 
In enzyme-coupled way, two enzymes work complementarily with each other 
in consuming reduced/oxidized cofactors and producing oxidized/reduced 
cofactors respectively, which brings a recycle to the cofactors of NAD(P)H 
(Figure 2.13).
[47, 49, 51, 196]
 This approach offers flexibility in the biooxidation 
process since a second enzyme with high stability and activity can be chosen 
for regeneration without the main enzyme being diverged from catalyzing the 
target oxidation.
[47, 49]
  This approach had been used for both the whole cell (in 
vivo) and isolated enzyme (in vitro) biooxidation. Furthermore, the second 
enzyme and its corresponding reaction can be purposely chosen to facilitate 
the downstream separation process. For instance, enzymes which can produce 
volatile products should be considered preferentially.  
 
Figure 2.13 Enzyme-coupled approach for cofactor regeneration.
[47, 49, 196]
 
2.5.2 Substrate-coupled approach 
The substrate-coupled approach use one enzyme to catalyze two reactions at 
the same time with one reaction consuming NAD(P)H while the other reaction 
converting NAD(P)
+
 to NAD(P)H (Figure 2.14).
 [47, 49, 196, 197]
 Shown in Figure 
2.14, there are one enzyme and two substrates in one system, where the 
cofactor regeneration could be accomplished with one substrate reduced 







(oxidized cofactor required) while the other substrate oxidized (reduced 
cofactor required).
[47, 196, 197]
 Despite the separation process being simplified 
due to only one enzyme employed, this approach aggravates the competition 
and inhibition because of the coexistence of two substrates and two 
products.
[47, 49, 196, 197]
 To direct the reaction onto the target track, researchers 
can either add one substrate excessively or use ISPR technology, which brings 
the problem of the enzyme deactivation or cost arising due to the extra 




Figure 2.14 Substrate-coupled approach for cofactor regeneration.
[47, 49, 196]
 
2.6 Approach to reduce toxicity and inhibition 
Bioprocess engineering via establishing different biphasic systems for carrying 
out biooxidations is a good way to reduce the effects of toxicity and inhibition 
from substrates and products. The mechanism for this approach is to harbor 
the toxic and inhibitive substrate and product in the reservoir of another phase, 
where these substrate and product could preferentially dissolve, thus reducing 
their hazardous effects to the biocatalysts. So far, the biphasic system used for 
biotransformation mainly refers to the solid-liquid biphasic system (i.e., by 
using the solid adsorbents such as resin) and the liquid-liquid biphasic system 
(i.e., by using a second water-immiscible liquid such as organic solvent, ionic 






liquid, and supercritical liquid, etc.). As long as the second phase is water 
immiscible and could be used as the shelter for harboring the toxic substrate 
and product preferentially, the system could be treated as biphasic system. 
Traditionally, biphasic systems are used in tank reactor such as CSTR. 
Nowadays, with the progresses achieved in the biotechnology, biphasic system 
had been used in other reactors such as HFMB and air-lift reactor.
[198 – 201]
 
Although their operations are different, the mechanisms are similar. 
2.6.1 Solid-liquid biphasic system 
In solid-liquid biphasic system, the solid phase of adsorbent is usually resin 
beads. Resins are polymers made of common monomers such as 
divinylbenzene, styrene, and methacrylate, etc.
[202 – 209]
 Commercial resins are 
sphere-shaped with diameter ca., 0.3 mm, mostly. There are three types of 
resins: cation exchange resin, anion exchange resin, and hydrophobic resin. 
Cation and anion exchange resins are the polymers with functionalized cation 
and anion immobilized on the matrix, respectively, while the hydrophobic 
resins have nothing functionalized on their polymer macromolecules.
[202]
 The 
adsorption capacity for the hydrophobic resin depends on the hydrophobic 
interaction between the adsorbate molecules and the resin mainly, while the 
ion (i.e., cation and anion) exchange resins exhibit their adsorption capacities 
by bonding between the ionized functional groups and the ionized target 
molecules.
[202 – 209]
 Hence, cation exchange resin is only used for adsorption of 
the molecules with positive charge, while anion exchange resin only for the 
negatively charged molecules. In a typical solid-liquid biphasic system by 
using resins for biotransformation, substrate and product are adsorbed in the 
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resins, hence preventing their inhibition and toxicity effects. Also, the product 
could be concentrated in the resins, which could be later eluted out for further 
purification. Most of the resin beads could be recycled after elution process, 
thus lowering the cost. Until now, the solid-liquid biphasic system has been 
used for many biotransformation and fermentation processes (Table 2.4).  
Table 2.4 Biotransformations in solid-liquid biphasic systems by using resins. 














For production of benzophenanthridine 
alkaloids: 20-fold increase in sanguinarine 























Production titer for epothilone D was 







Various resins with 
chemical structure of 
styrene/butadiene 
copolymer 
4.2-4.6 fold higher in carveol and carvone 









Production titer was 7.56 g/L for 
biotransformation of isoeugenol to vanillin 
with addition of macroreticular resin HD-
8, much higher than the 1.42 g/L in the 









Volumetric and specific productivity for 
conversion of (R,S)-mandelonitrile to (R)-
(−)-mandelic acid increased from 0.083 
mmol/L/min and 55.1 mmol/g to 0.281 






2.6.2 Liquid-liquid biphasic system 
The liquid-liquid biphasic system is comprised of the aqueous phase and the 
water-immiscible liquid phase, where the toxic and inhibitory substrate and 
product could preferentially stay in the water-immiscible phase and the 
biotransformation is carried out in the aqueous phase.
[73, 94 – 99]
 Thus, the 
biocatalyst of enzyme or whole cell in the aqueous phase could be prevented 
from toxicities of substrate and product at high concentrations. During the 
biotransformation, the aqueous phase and the water-immiscible phase are 
mixed thoroughly,
[73, 94 – 98, 198 – 200]
 and the substrate and product can travel 
from one phase into another through the interface. 
Traditionally, the water-immiscible phase is organic solvent. However, using 
the organic solvent could be depreciated because most of the organic solvents 
are toxic, flammable, and environmental harmful, and they often show 
unsatisfactory biocompatibility to many biocatalysts in both enzyme and 
whole cell forms.
[69, 210]
 This imposes great risk to biooxidation reactions, 
because many monooxygenases require higher biocompatibility for the water-
immiscible phase due to their multi-component structures and complicated 
electron-transferring mechanism.
[69, 210]
 As evidenced in Table 2.5, the 
productivities of the P450-catalyzed oxygenations are low for nearly all the 
liquid-liquid biphasic systems by using organic solvents.  
The drawbacks of the aqueous-organic biphasic system are overcome by using 
ILs as the water-immiscible phase. ILs are actually molten salts, and owing to 
the mismatching in size of cation and anion which prevents them from 
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 Their constituent 
cation and anion could be changed or modified to attune to the needs, which 
brings them the advantages such as near-zero vapor pressure, thermal stability,  
























Hydroxylation rate decreased 
around 70%, giving final 







O-demethylation retained 76% 
activity and 30% production titer, 
giving product 10 μM; the 
biphasic system allowed an N-
deethylation which never 
happened in absence of organic 




















P4503A4 tolerates small amount 
of organic solvents or ionic 
liquids, and [BMIM][PF6] was the 










Production titer 4.6 g/L after 75 
hours biotransformation 
 
environmental-credentials, and turnable properties in miscibility and 
hydrophobicity.
[67 – 69, 211 – 214]
 Above all, ILs could be made with desired 
biocompatibility, which is one of the most important points in the case of 
using ILs as the cosolvents for biooxidations.
[211 – 214]
 Table 2.6 shows a few 
examples of using ILs as cosolvents in the liquid-liquid biphasic systems for 
the biooxidations such as hydroxylation and sulfoxidation. 
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A series of 
organic solvents 
and ionic liquids 
P4503A4 tolerates small 
amount of organic solvents 
or ionic liquids, and 
[BMIM][PF6] was the lest 
detrimental. Production 






[P6, 6, 6, 14] 
[NTf2]/3.35:1 









Production titer 20.8 mM 
with ee (R)-73%, lower 
than the 22.1 mM and ee 
(R)-85% of the control. 





 (4-MBP)BF4/3: 1 









Reaction rate with ionic 
liquid was comparable to 
that observed in the 
presence of an organic 
solvent acetonitrile, but 





A series of 
organic solvents 
and ionic liquids 
Some of the ILs help to 
increase the conversion 
ratio while others not. 
Conversion ratio decreases 
when the content of the IL 
in the biphasic system 
increases. As for the ee 
value, some of the ILs help 
to increase the ee values a 
little (~1%) while other 
have no effect or decrease 




A series of 
organic solvents 
and ionic liquids 
a. Unless state otherwise, all the phase ratios mentioned were aqueous to IL; b. unless 
stated otherwise, all the controls mentioned referred to the reactions conducted in the 
aqueous phase; c. unless stated otherwise, all the production titers were given on the 
basis of the volume of the aqueous phase. 
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2.6.3 Biphasic system in hollow fiber membrane bioreactor 
Although traditional biphasic systems by using organic solvents or solid beads 
of resin could be used to tackle the problems of toxicity and inhibition caused 
by substrate and product, there are practical problems associated with the 
applications of the two approaches: phase dispersion such as foaming and 
emulsification which cause great burden to the downstream processing; 
production of emulsion-promoting bio-surfactant by cells; limited capacity in 
preventing the toxicity and inhibition, extra cost due to the uncompleted 
recycling of the solvents or beads; low adsorption/desorption rate and 
diffusivity of the adsorbents, etc.
[198 – 200]
 
All these problems mentioned above for the biphasic system could be handled 
by applying the liquid-liquid biphasic system in a hollow fibre membrane 
bioreactor, where the aqueous and organic phases could be separated 
physically by using the hollow fibre membranes and the aqueous-organic 
interface can be immobilized into the membrane pores.
[198 – 200]
 The setup 
could be advantageous in the following ways: independent phase flow rate; 
compact design and high specific interfacial area;
[198, 199]
 non-dispersive 
operation could prevent foaming and emulsification, thus lowering down the 
downstream processing burden during product separation and enabling 
complete reuse of the solvents;
[199, 200]
 the physical separation of the aqueous 
phase from the organic phase could also be protective to the cells, which will 
in return strengthen the capability in reducing the toxicity and inhibition; 
compact design of the setup enables modeling, easy scaling up, and 
continuous operation, where the mass transportation barrier due to the 
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membrane could be easily negated by increasing the member of fibre and 
membrane module.
[198]
 Until now, biphasic systems used in hollow fiber 
membrane bioreactor had been reported for several biooxidation processes 
(Table 2.7). 
Table 2.7 Biooxidations conducted in HFMB-based biphasic systems. 
Reaction Biocatalyst Note 
Dihydroxylation of 







Production titer of ca., 8 g/L was reached with 
automatic control of aqueous phase toluene 
concentration, and it dropped to ca., 2 g/L if 
toluene concentration was controlled manually; 








Octane was selected as the best organic solvent; 
Volumetric production rates increased 40% as 
compared to two-phase with direct phase 









A new solid ceramic membrane aerated biofilm 
reactor was designed for growing a biofilm as 











Liquid-liquid extractive process was continuous 
mode, and isooctane was used as the organic 
phase; High conversions (72-90%) and overall 







CHAPTER III.  
ENHANCING PRODUCTIVITY OF P450 
MONOOXYGENASE-CATALYZED 
BIOHYDROXYLATION BY USING SOLID-LIQUID 
BIPHASIC SYSTEM FOR SIMULTANEOUS 
BIOTRANSFORMATION AND in situ 





Biotransformations for the preparation of enantiomerically pure compounds as 
chemical building blocks are becoming more and more important in 
pharmaceutical manufacture,
[1, 6]
 among which, regio- and stereoselective 
biohydroxylation catalyzed by monooxygenase is a very useful reaction for 
preparation of chiral alcohol, steroid, and natural-identical aroma product.
[13, 19, 
27 223]
 Enzymes capable of catalyzing the biohydroxylation include a variety of 
oxygenases.
[22, 23, 64]
 As an example, cofactor-dependent cytochrome P450 
monooxygenases, which covers a broad range of enzymes with cysteinato-
heme structure, are widely studied for catalyzing biohydroxylation.
[13, 22, 27, 64, 
176, 178, 179, 224]
 So far, P450 enzymes, in the form of whole cell, have been 
successfully used to produce intermediate and the drug molecules in 
pharmaceutical industry, where natural intracellular microenvironment could 
give cofactor regeneration for electron transferring and reduce the deactivation 
of P450 enzymes.
[19, 54, 59, 63, 64, 69, 100]
 However, the biohydroxylation usually 
exhibits low productivity, and one of the reasons is that the biocatalyst of P450 
monooxygenase is vulnerable to the inhibition and toxicity effects inherent to 
many substrates and products. Traditional way to prevent the inhibition effects 
is to use a liquid-liquid biphasic system, where the organic solvents or ionic 
liquids serve as the cosolvent to harbor the substrate and product for inhibition 
prevention.
[73, 91 – 93, 210]
 However, these liquid-liquid biphasic system could be 
environmental harmful and costly as many organic solvents are toxic and 
explosive.
[39, 69]
 Sometimes, the cosolvent of organic solvent could impair 
membrane integrity,
[39, 69]
 causing hazardous effects to the biocatalyst. In 
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addition, emulsion-promoting surfactant produced by the microbial biocatalyst 
could incur extra burden in solvent reuse and product purification.
[198]
 
Therefore, only a limited number of P450 monooxygenase-catalyzed 
biohydroxylations was hitherto carried out in aqueous-organic system. As the 
few examples, diisononyl phthalate was used as the organic phase for α-
Pinene hydroxylation with total production titer no more than 1 g/L;
[94]
 
isooctane as cosolvent even decreased the biohydroxylation rate and gave final 
product in less than 0.6 mM;
[95]
 α-pinene hydroxylation with substrate as the 
cosolvent give production titer ca., 20 mg/L.
[97]
 In another two examples of 
using liquid-liquid biphasic system with organic solvent as the secondary 
phase, productivity of the reactions were enhanced noticeably, giving final 
production titers of 35 mM for testosterone 6β-hydroxylation[225] and 4.6 g/L 
for L-limonene biohydroxylation
[99]
, however, the former reaction requires 
hard-to-remove surfactant and later one requires plasticizer of bis(2-
ethylhexyl)phthalate which is under restrict regulation. In the only one 
example with ionic liquid as cosolvent in liquid-liquid biphasic system for 
enhancing productivity of testosterone 6β-hydroxylation catalyzed by P450 
monooxygenase, the final production titer was no more than 1 mM.
[98]
  
We noticed that the solid-liquid biphasic system successfully enhanced the 
productivities for other types of biotransformations.
[206, 208, 209, 226 – 230]
 So far, 
to our best knowledge, P450 monooxygenase-catalyzed biohydroxylations are 
seldom enhanced by using solid-liquid biphasic with resin as the adsorbent for 
shielding the inhibition effects and hence enhancing productivity. In this 
chapter, we report using a hydrophobic resin to establish a solid-liquid 
biphasic system for simultaneous biotransformation and in situ adsorption in 
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one pot, and the established system successfully prevented inhibition effects of 
the substrate and product and hence enhanced the productivity of the model 
biohydroxylation of BP catalyzed by a P450 monooxygenase for producing a 
useful drug intermediate, giving highest production titer among all hitherto 
reported biohydroxylations.  
3.2 Materials and methods 
3.2.1 Chemicals and resins 
Ampicillin sodium salt (98%), kanamycin disulfate salt (>99%), and δ-
aminolevulinic acid hydrochloride (ALA, >98%) were obtained from Sigma-
Aldrich. IPTG (>99%) was obtained from Calbiochem, Germany. Medium 
components LB premix, tryptone, and yeast extract were purchased from 
Biomed Diagnostics, USA. N-benzyl-pyrrolidinone (BP, >99%) was 
purchased from Sigma-Aldrich. Unless stated otherwise, all the inorganic salts 
for the medium preparations were purchased from Sigma-Aldrich.  
Hydrophobic resins of Amberlite
®
 XAD4, XAD16, and XAD7HP were 
purchased from Sigma. Cation exchange resins Amberlite
®
 IRC748 was 
obtained from Dow Co., USA. Anion exchange resin Amberlite
®
 IRA-400 
was purchased from Sigma.  
3.2.2 Strain and medium compositions 
Recombinant E. coli (P450pyrTM-GDH) preserved in the − 80○C deep freezer 
was published previously by our group
[51]
, and this strain is used as the 
biocatalyst in this work.  
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LB medium followed the receipt published previously.
[231]
 YTG medium was 
composed of yeast extract (24 g/L), trypton (12 g/L), glucose (5 g/L), KH2PO4 
(2.31 g/L), and K2HPO4 (12.54 g/L). EFM was composed of yeast extract (96 
g/L), trypton (48 g/L), glucose (100 g/L), MgSO4 (0.24 g/L), and trace element 
[1 mL stock trace solution (1000 ×) per 1 L medium]. Stock trace solution 
(1000 ×) was composed of FeSO4·7H2O (4.78 g/L), MnCl2·4H2O (1.50 g/L), 
ZnSO4 (1.05 g/L), CuCl2·2H2O (0.15 g/L), H2BO3 (0.30 g/L), Na2MoO4·2H2O 
(0.25 g/L), and disodium EDTA·2H2O (0.84 g/L).  
3.2.3 Analytical methods 
The concentrations of substrate BP and product (S)-N-benzyl-4-
hydroxypyrrolidinone [(S)-BPOH] were analyzed by a Shimadzu Prominence 
HPLC on an Agilent Eclipse C18 plus column (150 mm × 4.6 mm; 5 µm). UV 
detection: 210 nm; flow rate: 0.5 mL/min; eluent: acetonitrile/water (50: 50, 
v/v); retention time: 3.97 min for (S)-BPOH and 5.58 min for substrate BP.  
The enantiomeric excess (ee) of biotransformation product (S)-BPOH was 
analyzed by using a Shimadzu Prominence HPLC on Chiralcel OB-H column 
(250 mm × 4.6 mm, 5 µm). UV detection: 210 nm; flow rate: 1.0 mL/min; 
eluent: n-hexane/isopropanol (92: 8, v/v); retention time: 18.3 min for (R)-
BPOH and 22.8 min for (S)-BPOH. The peak areas of the two enantiomers 
from the chromatograms were used for calculating the ee value for the desired 
product { ([ ] [ ]) / ([ ] [ ]) 100%ee R S R S    }. 
The optical density of the cells was determined at 600 nm (OD600) by using a 
HITACHI U-1900 spectrophotometer. 
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3.2.4 Determination of the adsorption capacity for the resins 
KP buffer (10 mL, 100 mM, pH 8) contained either 80 mM substrate BP or 80 











IRA-400) for form different solid-liquid biphasic 
systems. Then, these solid-liquid systems were shaken at 30
○
C and 250 rpm 
for 3 h. The aqueous phase of the liquid-solid biphasic systems were 
withdrawn and analyzed by HPLC to quantify the amount of BP or (S)-BPOH. 
Analytical samples were prepared as follows: aqueous phase of the KP buffer 
(0.1 mL) was combined with 0.4 mL water and mixed thoroughly with 0.5 mL 
ethanol containing 2 mM acetophenone as internal standard; after 
centrifugation of the mixture at 13000 g for 5 min, supernatant was analyzed 
by HPLC. 
Adsorption capacity (g adsorbate/g resin) is defined as the amount of the 
adsorbate captured (in gram) per gram of resin in the solid-liquid system. 
3.2.5 Cell growth and specific biohydroxylation activity of E. coli 
(P450pyrTM-GDH) in a 2 L fermentor 
Cryogenic cell stock of E. coli (P450pyrTM-GDH) at -80°C was picked up 
and inoculated to LB medium (50 mL) with ampicillin (100 µg/mL) and 
kanamycin (50 µg/mL) in a baffled flask (250 mL). Cells were incubated at 
30°C and 250 rpm for 12 hours for the seed preparation. The seed was then 
introduced in to a 2 L Biostat
®
 B plus Sartorius bioreactor with YTG medium 
(1 L) containing ampicillin (100 µg/mL) and kanamycin (50 µg/mL). Cell 
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cultivation was conducted at 30°C, 0.3 VVM, and 300 rpm, respectively. At 4 
h, OD600 reached 2.8, IPTG and ALA were added to the final level of 0.25 
mM and 0.5 mM for induction, respectively, and temperature was changed to 
25°C thereafter. At different time points, samples were taken for monitoring 
cell growth and specific activity for biohydroxylation of BP. For 
biotransformation with resting cells, E. coli (P450pyrTM-GDH) were 
harvested at 10 h with cell density of 3.4 – 4.4 g CDW (Cell dry weight)/L and 
used freshly as the biocatalyst. 
The specific activity for biohydroxylation of BP was tested with the cell 
density 1.5 g CDW/L in 10 mL KP buffer (50 mM, pH 8.0) containing 2 mM 
substrate and 2% (w/v) glucose at 30°C and 250 rpm for the initial 30 min. 
Product formed was determined by HPLC, and the analytical samples were 
prepared by procedures as described above. The specific activity was then 
calculated in U/g CDW, and one U is defined as one micromole product 
formed per minute. 
3.2.6 Effect of substrate inhibition on biohydroxylation of BP with resting 
cells of E. coli (P450pyrTM-GDH). 
Biohydroxylation of BP was carried out at 30°C and 250 rpm with resting E. 
coli (P450pyrTM-GDH) cells (1.5 g CDW/L) in 10 mL KP buffer (100 mM; 
pH 8.0) containing 2% (w/v) glucose at substrate concentrations ranging from 
0.5 to 40 mM for 15 min. Product formation was determined by HPLC, and 
sample was prepared as described above.  
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3.2.7 Apparent kinetics of biohydroxylation of BP with resting cells of E. 
coli (P450pyrTM-GDH). 
E. coli (P450pyrTM-GDH)-catalyzed biohydroxylation of BP was carried out 
at 30°C and 250 rpm with cell suspension (1.5 g CDW/L) in 0.5 mL KP buffer 
(50 mM; pH 8.0) containing 2% (w/v) glucose at substrate concentrations 
ranging from 0.5 to 5 mM for 15 min. Product formation was determined by 
HPLC, and sample preparation was the same as described as above. The initial 
rates were measured, and Vmax and Km were calculated from the Lineweaver-
Burk plot. To determine dissociate constant Ki, product (S)-BPOH as the 
inhibitor were added to the final concentration of 2 mM and 3 mM, 
respectively, and reactions were conducted at the same substrate 
concentrations and conditions as aforementioned. Ki was calculated 
accordingly. 
3.2.8 Biohydroxylation of BP in aqueous monophase with growing cells of 
E. coli (P450pyrTM-GDH) in fermentor 
Mode 1: Seed (50 mL) preparation was the same as described in section 3.2.5. 
The seed was then introduced in to a 2 L Biostat
®
 B plus Sartorius bioreactor 
with YTG medium (1 L) containing ampicillin (100 µg/mL) and kanamycin 
(50 µg/mL). Cell cultivation was conducted at 30°C, 0.3 VVM, and 300 rpm, 
respectively. At 4 h, OD600 was within 2.3 to 2.5, IPTG and ALA were added 
to the final concentrations of 0.25 mM and 0.5 mM for induction, respectively, 
and temperature was changed to 25°C. Substrate BP [80 mM in total: 20 mM 
(i.e., 3.2 mL) BP added at 6 h, 16 h, 29 h, and 39 h, respectively, concentration 
normalized on the basis of initial medium volume] and glucose [glucose (1%, 
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w/v) was added at 6 h, 12 h, 18 h, and 30 h, concentration normalized on the 
basis of initial medium volume] were directly added into the fermentor to start 
biohydroxylation. The fresh feeding YTG medium (100 mL) containing 
ampicillin (100 µg/mL), kanamycin (50 µg/mL), IPTG (0.25 mM), and ALA 
(0.5 mM) was added at 12 h and 32 h into the fermentor via peristaltic pump, 
respectively. The aeration rate and stirring speed were gradually raised up 
until 1.2 VVM and 800 rpm, respectively. At different time points, samples 
were taken to determine cell density, specific activity, and product formation. 
Specific activity was determined by the procedures as described above. 
Product formation was measured by HPLC, and analytical samples were 
prepared by procedures as described above. 
Mode 2: Seed preparation, initial medium, cell induction, and cultivation 
conditions were the same as described in Mode 1 in section 3.2.8. Substrate 
BP [80 mM in total: 30 mM (i. e., 4.8 mL) BP added at 14 h and 20 h, 
respectively; 20 mM (i. e., 3.2 mL) BP added at 39 h; concentration 
normalized on the basis of volume of the initial YTG medium] and glucose 
[glucose (1%, w/v) was added at 14 h and 23 h, respectively, concentration 
normalized on the basis of initial medium volume] were directly added into 
the fermentor to start biohydroxylation. Fresh EFM medium (500 mL) 
containing ampicillin (100 µg/mL), kanamycin (50 µg/mL), IPTG (0.25 mM), 
and ALA (0.5 mM) was gradually introduced to the fermentor at a flow rate of 
55.6 mL/h via peristaltic pump from 5 h to 14 h. The aeration rate and stirring 
speed were gradually increased to 2.0 VVM and 1200 rpm, respectively. At 
different time points, samples were taken to determine cell density, specific 
activity, and product formation by procedures described above.  
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3.2.9 Biohydroxylation of BP in aqueous/Amberlite
®
 XAD4 biphasic 
system with growing cells of E. coli (P450pyrTM-GDH) in fermentor  
Mode 3: Seed preparation, initial medium, cell induction, cultivation 
conditions, glucose addition, and feeding of fresh YTG medium were 
described in Mode 1 in section 3.2.8. Hydrophobic resin Amberlite
®
 XAD4 
100 g (10% w/v, on the basis of initial medium volume) together with the 12.8 
mL substrate BP (i.e., 80 mM, concentration normalized on the basis of initial 
medium volume) was directly added into the fermentor at 6 h to form the 
solid-liquid biphasic system and start the reaction. The aeration rate and 
stirring speed were gradually raised up until 1.2 VVM and 500 rpm, 
respectively. At different time points, samples were taken to determine cell 
density, specific activity, and product formation by the procedures described 
above. For the determination of product formation, product in aqueous phase 
was assayed by procedures as described above, and product in resin 
Amberlite
®
 XAD4 was determined as follows: one gram of the resin was taken 
for washing with ethanol (10 mL × 3) containing 1 mM acetophenone as 
internal standard, and after the centrifugation of the eluent at 13000 g for 5 
min, supernatant was analyzed by HPLC. 
Mode 4: Seed preparation, initial medium, cell induction, cultivation 
conditions, glucose addition, and feeding of fresh EFM medium were 
described in Mode 2 in section 3.2.8. Hydrophobic resin Amberlite
®
 XAD4 
100 g (10% w/v, on the basis of initial medium volume) together with the 12.8 
mL substrate BP (i.e., 80 mM, concentration normalized on the basis of initial 
medium volume) was directly added into the fermentor at 14 h to form the 
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solid-liquid biphasic system and start the reaction. The aeration rate and 
stirring speed were gradually raised up until 2.0 VVM and 1000 rpm, 
respectively. At different time points, samples were taken to determine cell 
density, specific activity, and product formation by the procedures as 
described in Mode 3 in section 3.2.9.  
3.2.10 Biohydroxylation of BP with resting cells of E. coli (P450pyrTM-
GDH) in flask 
Freshly prepared biocatalyst of resting cells of E. coli (P450pyrTM-GDH) 
harvested from late exponential phase at 10 h by centrifugation of 5000 g for 
10 min was resuspended in KP buffer (10 mL, 100 mM; pH 8) to form the cell 
suspension with density of 10 g CDW/L. For biohydroxylation in the aqueous 
monophase, substrate BP [80 mM in total: 30 mM (i. e., 48 µL) substrate 
added at 0 h and 6 h, respectively; 20 mM (i. e., 32 µL) substrate added at 20 h; 
concentration normalized on the basis of KP buffer] and glucose [glucose (1%, 
w/v) was added at 0 h, 6 h, and 24 h, respectively; concentration normalized 
on the basis of KP buffer] were added directly into the cell suspension to start 
the reaction at 30°C and 250 rpm, and product formation was analyzed by 
HPLC.  
For hydroxylation in the aq./Amberlite
®
 XAD4 biphasic system, one gram of 
resin Amberlite
®
 XAD4 (10% w/v, on the basis of 10 mL KP buffer) together 
with 128 µL substrate BP (i. e., 80 mM, concentration normalized on the basis 
of 10 mL KP buffer) and glucose [glucose (1%, w/v) added at 0 h, 6 h, and 24 
h, respectively] were directly introduced to the cell suspension to form the 
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solid-liquid biphasic system and start the reaction at 30°C and 250 rpm. The 
biotransformation was conducted in multiple flasks. Samples were taken at 
different time points for monitoring the product formation by using the 
procedures as described in section 3.2.9. For each sampling, a flask 
(containing 10 mL cell suspension and 1 g Amberlite
®
 XAD4) was withdrawn 
for analysis. 
3.2.11 Resin regeneration and recovery of product (S)-BPOH from 
Amberlite
®
 XAD4 by eluting with ethanol 
Amberlite
®
 XAD4 resin (20 g), used for the biotransformation in fermentor as 
the adsorbent, was taken from the liquid-solid biphasic system. The resin was 
then trapped within a column [Ø 1.5 cm × 32 cm (Ø signifies the diameter)]. 
The elution began with running ethanol from the top to bottom at a rate of 4.8 
mL/min. When effluent was tested without product and substrate, the resin 
was deemed as well regenerated and the product was regarded as fully 
recovered by elution from the resin. For quantifying the product and substrate 
in the eluent, HPLC was used, and the analytical samples were prepared by the 
procedures as stated above. 
3.2.12 Preparation of (S)-BPOH with E. coli (P450pyrTM-GDH) by using 
aq./Amberlite
®
 XAD4 biphasic system  
Biohydroxylation of 12.8 mL BP (i.e., 80 mM; concentration normalized on 
the basis of initial medium volume) in aq./Amberlite
®
 XAD4 biphasic system 
by using growing cells of E. coli (P450pyrTM-GDH) in fermentor (procedures 
as described in Mode 4 in section 3.2.9). After separation from solid resin by 
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filtration, the aqueous solution was centrifuged at 5000 g for 10 min to remove 
the cell pellets, and the supernatant (1.5 L) was extracted with ethyl acetate 
(1.5 L × 1). Product in resin Amberlite
®
 XAD4 was first eluted by ethanol (0.5 
L), and then the ethanol was evaporated under reduced pressure and high 
temperature. Afterwards, the eluent (containing the product and substrate) was 
dissolved in ethyl acetate (0.2 L). The ethyl acetate was combined and dried 
over Na2SO4, and then evaporated under reduced pressure. The crude product 
of (S)-BPOH were purified by flash chromatography on a silica gel with ethyl 
acetate/ethanol (100: 1) as eluent (Rf ≈ 0.3). Flow rate was 3-5 mL/min. (S)-
BPOH: 6.05 g, colorless liquid, >99% ee and 39.6% isolated yield. 
3.3 Results and discussion 
3.3.1 Cells growth and specific biohydroxylation activity for E. coli 
(P450pyrTM-GDH) 
Recently, a novel P450pyr monooxygenase derived from Sphingomonas 
HXN-200 is reported by our group, which requires Fdx and FdR to transfer 
electron donated from cofactors of NAD(P)H for catalyzing biooxidations of 
hydroxylation, epoxidation, and sulfoxidation.
[4, 39, 41 – 43, 45, 232, 233]
 Several 
mutants of this P450pyr monooxygenase were engineered as well, with triple 
mutant I83H/M305Q/A77S (P450pyrTM) demonstrating the highest activity 
and selectivity in catalyzing the model biohydroxylation of BP to give (S)-
BPOH as an intermediate for synthesizing drugs of carbapenem antibiotic CS-
834 and nootropic drug (S)-Oxiracetame.
[50, 51]
 In this work, whole cell 
biocatalyst was used for the model biohydroxylation, where the genes of 
66 
 
P450pyrTM, Fdx, and FdR are coexpressed in Escherichia. coli (P450pyrTM-
GDH) together with cofactor regenerator GDH which oxidized glucose to 
gluconolactone (Figure 3.1). The cell growth and specific hydroxylation 
activity of E. coli (P450pyrTM-GDH) are given in Figure 3.2. Cells 
cultivation was conducted in YTG medium in a 2 L fermentor at 30°C and 300 
rpm with initial airflow rate of 0.2 mL/min, and induction was triggered at 4 h 
by adding IPTG and ALA, followed by incubation at lower temperature of 
25°C, which is to avoid the formation of inclusion body and possible improper 
folding of enzymes due to the fast cell growth at higher temperature. 
 
Figure 3.1 Regio- and stereoselective biohydroxylation of BP to produce (S)-BPOH 
with E. coli (P450pyrTM-GDH) coexpressing P450pyrTM monooxygenase complex 
(P450pyrTM, FdR, and Fdx) and GDH in a solid-liquid biphasic system containing 
resin as the solid adsorbent (Scale not proportional to the real size; figure only for 
visual aid). 
The specific hydroxylation activity at 6 – 12 h reached 8.57 – 13.5 U/g CDW 
at late exponential and the early stationary phases. The highest specific 
activity for biohydroxylation of BP was 13.5 U/g CDW at 10 h for E. coli 





















Figure 3.2 Cell growth and specific activity curves for biohydroxylation of BP with 
E. coli (P450pyrTM-GDH) in a 2 L fermentor. ◆: cell density; ■: specific activity; 
arrow indicating induction by adding IPTG and ALA (arrow) to the concentrations of 
0.25 mM and 0.5 mM at 4 h, respectively; data are the mean values with standard 
deviations of three replicates.  
could be made for preparation of the resting cells as the highly active the 
whole cell biocatalyst for the target biohydroxylation reaction. 
3.3.2 Inhibitions of substrate and product to biohydroxylation of BP with 
resting cells of E. coli (P450pyrTM-GDH) 
Substrate inhibition was first examined by adding to E. coli (P450pyrTM-
GDH) cell suspension (1.5 g CDW/L) in KP buffer with substrate at different 
concentrations ranging from 0.5 mM to 40 mM, respectively. The reaction was 
then carried out at 30°C and 250 rpm for 15 min. The velocities of the reaction 
at different substrate concentrations were calculated on the basis of the 
production formation. The results clearly showed the substrate inhibition 
effect as the velocity first increased and then decreased with substrate 
concentration’s rise (Figure 3.3). The declining of the velocity was even more 
obvious when the substrate concentration exceeding 30 mM, and the 
concentration corresponded to the highest velocity was 10 mM. The possible 






















































reasons for the substrate inhibition could be impairment to the membrane 
integrity at high substrate concentration,
[39]
 causing potential leakage of 
enzyme subunits and hence lower catalytic performance.  
 
Figure 3.3 Reaction velocities for biohydroxylation of substrate BP with E. coli 
(P450pyrTM-GDH) at different concentrations of BP: substrate inhibition. Data are 
the mean values with standard deviations of three replicates.  
Product inhibition was investigated by examining the apparent kinetics of the 
whole cell-catalyzed biohydroxylation reaction. Product was added as the 
inhibitor to the biotransformation solution prior to the reaction, and substrate 
concentration was within 0.5–5 mM, which was to avoid possible substrate 
inhibition to E. coli (P450pyrTM-GDH). Shown in Figure 3.4, the product 
 
Figure 3.4 Lineweaver-Burk plot for biohydroxylation of BP catalyzed by E. coli 
(P450pyrTM-GDH) with 0 mM (◇), 1 mM (○), and 2 mM (Δ) of product (S)-BPOH 








































was evidenced to show competitive inhibition to the biohydroxylation reaction 
as the apparent Vmax of 24.4 µmole/min/g CDW remained unchanged while 
apparent Km climbed from 0.43 to 0.96 to 1.34 mM with 0, 1, and 2 mM 
product added as inhibitor, respectively. Apparent dissociate constant Ki was 
determined to be 0.88 mM. 
3.3.3 Determination of adsorption capacity of resin to establish solid-
liquid biphasic system for biohydroxylation of BP with E. coli 
(P450pyrTM-GDH) 
For establishing the solid-liquid biphasic system, the adsorption capacity of 
the adsorbent is a key criterion for resin selection,
[206, 208, 209, 226 – 230]
 where 
higher adsorption capacity is desired for better inhibition prevention. In this 
work, several resins were screened by examining the adsorption capacity for 
the substrate of BP and the product of (S)-BPOH. To perform this experiment, 
five different resins (as mentioned in section 3.2.1) including hydrophobic, 
cation exchange, anion exchange resins were introduced to the KP buffer (100 
mM, pH 8.0) containing BP or (S)-BPOH as adsorbate with preset 
concentration for adsorption, respectively. After adsorption equilibrium was 
reached, the quantitative analysis of the residual adsorbate in aqueous phase 
was carried out, according to which the adsorption capacity was determined. 
Figure 3.5 showed the adsorption capacities for the selected resins, and 
hydrophobic resins of Amberlite
®
 XAD4, XAD16, and XAD 7HP exhibited 
higher adsorption capacity for the adsorbates of both substrate and product. 
Comparatively, the cation and anion exchange resins of Amberlite
®
 IRC748 
and IRA 400Cl showed limited capacities for adsorption of the substrate and 
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product (Figure 3.5). Therefore, it is concluded that hydrophobicity owing to 
the matrix of the resins affected the adsorption capacity mostly, while the  
                     
Figure 3.5 Adsorption capacities (g adsorbate/g resin) of different resins for 
adsorbing substrate BP (white) or product (S)-BPOH (grey) from the aqueous phase 
of different solid-liquid biphasic systems. Data are the mean values with standard 
deviations of three replicates. 
functional groups on the ion exchange resins barely influenced the adsorption. 
Amberlite
®
 XAD4 gave the highest adsorption capacities of 0.131 and 0.126 g 
adsorbate/g resin for adsorbing the BP and (S)-BPOH (Figure 3.5), 
respectively, appearing to be the desired resin for establishing the solid-liquid 
system in this work. Shown in Table 3.1, as a test, we performed 
biohydroxylation of BP with resting cells of E. coli (P450pyrTM-GDH) in 





 XAD16, and aq./Amberlite
®
 XAD7HP), and results showed 
that the biphasic system by using Amberlite
®
 XAD4 gave the highest 
production titer. As shown in Table 3.1, all these three biphasic systems 



































role in adsorption and the substrate is more hydrophobic than the 
corresponding hydroxylated product. Nevertheless, because the inhibitions 
from substrate and product were both decreased by the resin Amberlite
®
 
XAD4, all these three established solid-liquid systems could enhance the 
production titer greatly in comparison to the control of aqueous monophase 
(Table 3.1). Here again, because of the highest adsorption capacity of resin 
Table 3.1 Biohydroxylation of BP (80 mM) with resting cells of E. coli (P450pyrTM-































27.8 0.4 21.2 1.2 49.1 1.5 19.2 0.7 11.3 0.3 30.5 1.0 
Aqueous
b
 55.2 0.9     N.A.
c
 55.2 0.9 24.7 1.6     N.A.
c
 24.7 1.6 
a
Solid-liquid systems consisted of aqueous phase (KP buffer: 10 mL; 100 mM; pH 
8.0) and corresponding resins (1 g) were used for biohydroxylation of BP (80 mM) 
catalyzed by resting cells of E. coli (P450pyrTM-GDH) at 30
○
C and 250 rpm for 24 h, 
with glucose addition (1%, w/v) at 0 h and 6 h, respectively; cell density and all 
concentrations of the product (S)-BPOH and substrate BP were normalized on the 
basis of the volume of aqueous phase; data are the mean values with standard 
deviations of three replicates. 
b
Aqueous monophase (KP buffer: 10 mL; 100 mM; pH 






 XAD4 (Figure 3.5), aq./Amberlite
®
 XAD4 biphasic system 
presented the least amount of substrate (5.01 mM) and product (14.7 mM) in 
aqueous phase, while the remaining 85.0% of substrate and 64.3% of product 
were adsorbed by the resin, which reduced the inhibitions of substrate and 
product the most significantly, hence showing the highest production titer of 
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41.2 mM among all the three solid-liquid biphasic systems tested, much higher 
than 24.7 mM achieved in the control of aqueous monophase (Table 3.1). 
According to Table 3.1, during the biohydroxylation with E. coli 
(P450pyrTM-GDH), resin Amberlite
®
 XAD4 exhibited adsorption capacity of 
0.115 g adsorbate/g resin, where one gram of resin simultaneously adsorbed 
0.051 gram of the product and 0.064 gram of the substrate. In comparison with 
the adsorption capacity of 0.131 or 0.126 g adsorbate/g resin in adsorption test 
(Figure 3.5), this adsorption capacity of 0.115 g adsorbate/g resin was low 
when Amberlite
®
 XAD4 was used in biphasic system for the real 
biotransformation, and it was probably because the macromolecules coming 
from the microbial biocatalyst could take over some adsorption sites on the 
resin, hence decreasing the adsorption capacity for the substrate and product 
during the biotransformation.  
In addition, other advantages of using hydrophobic resin were the simple 
pretreatment and regeneration: the pretreatment procedure could be carried out 
by washing resin with water; resin regeneration could be implemented by 
washing with ethanol. Comparatively, base and acid were used for 
pretreatment and regeneration of the ion exchange resins,
[229]
 where merits of 
using solid-liquid biphasic system could be tarnished by the environmental 
burden and the tricky neutralization procedure afterwards.  
On the basis of results and discussion above, Amberlite
®
 XAD4 was chosen as 
the desired resin to establish solid-liquid biphasic system of aq./Amberlite
®
 
XAD4 for preventing inhibition and hence enhancing productivity of 
biohydroxylation of BP with E. coli (P450pyrTM-GDH). 
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3.3.4 Biohydroxylation of BP with growing E. coli (P450pyrTM-GDH) 
To perform biohydroxylation of BP with growing cells of E. coli 
(P450pyrTM-GDH) in aq./Amberlite
®
 XAD4 biphasic system, E. coli 
(P450pyrTM-GDH) cells were first grown in the fermentor. After stationary 
phase, the E. coli cells enter into the early exponential phase at 4 h, at which 
time E. coli (P450pyrTM-GDH) cells were induced by IPTG and ALA (Figure 
3.6). P450pyrTM monooxygenase was expressed and specific activity for 
biohydroxylation of BP quickly increased to 14.6 – 14.4 U/g CDW at 8 – 10 h 
(Figure 3.6). Just before approaching the highest specific activity at 8 h, resin 
Amberlite
®
 XAD4 together with the substrate BP was introduced to the cell 
culture at 6 h to form a solid-liquid biphasic system and the biohydroxylation 
 
Figure 3.6 Biohydroxylation of substrate BP (80 mM) with growing cells of E. coli 
(P450pyrTM-GDH) in a 2 L fermentor. Amberlite
®
 XAD4 (100 g; 10%, w/v) and BP 
(80 mM) were added into the medium at 6 h to form solid-liquid system. ◆: cell 
density; ■: specific biohydroxylation activity; ▲: concentration of product (S)-BPOH 
in medium; ●: total (S)-BPOH concentration. Arrow indicates induction by adding 
IPTG and ALA to the concentrations of 0.25 mM and 0.5 mM at 4 h, respectively. 
Glucose 1% (w/v) was added at 6 h, 12 h, 18 h, and 30 h, respectively. Fresh feeding 
medium of YTG (100 mL) was added at 12 h and 32 h, respectively. All 
concentrations and cell density were normalized on the basis of the initial medium 
volume; data are the mean values with standard deviations of three replicates. 
reaction was started at the same time (Figure 3.6). In the established biphasic 
system, Amberlite
®
 XAD4 adsorbed 58.2% – 62.8% of the product and 79.9% 
























































































































































































































































































































































































































– 83.3% of the substrate, thus greatly preventing the inhibition of substrate and 
product via in situ adsorption and hence enhancing the production titer greatly 
in comparison with control conducted in aqueous monophase (Figure 3.7). In 
the solid-liquid biphasic system, the hydrophobic substrate could be adsorbed 
on the solid resin and then be released mildly via desorption into the aqueous 
phase, and this could leave increasingly more adsorption sites on the resin for 
adsorbing product (Figure 3.1). In this solid-liquid biphasic system, the resin 
acted as the reservoir for the substrate, mitigating the inhibition greatly, and it 
could also protect cell membrane from being damaged by high concentrations  
 
Figure 3.7 Biohydroxylation of substrate BP (80 mM) with growing cells of E. coli 
(P450pyrTM-GDH) in a 2 L fermentor. BP was added directly to the medium at 6 h 
for the biohydroxylation. ◆: cell density; ■: specific biohydroxylation activity; ▲: 
concentration of product (S)-BPOH in medium; --: cumulative BP concentration. 
Arrow indicates induction by adding IPTG and ALA to the concentrations of 0.25 
mM and 0.5 mM at 4 h, respectively. Glucose 1% (w/v) was added at 6 h, 12 h, 18 h, 
and 30 h, respectively. Fresh feeding medium of YTG (100 mL) was added at 12 h 
and 32 h, respectively. All concentrations and cell density were normalized on the 
basis of the initial medium volume; data are the mean values with standard deviations 
of three replicates.  
of substrate and product (Figure 3.1). Shown in Figure 3.6, production 
formation was fast at the beginning and turned slower with time: product 
accumulated fast (from 0 mM at 6 h to 17.3 mM at 25 h) with the drastic 
increasing in cell density and specific activity, while product formation was 
























































































































































































































































































































































































































slowed down after 25 h and was hardly observed from 34 h to 56 h, during 
which period the cell growth was attenuated as well (Figure 3.6). This could 
be caused by a combination of factors, e.g., decaying of specific activity due 
to biocatalyst’s deactivation, fatigue cell growth due to the accumulation of 
toxicity and the depletion of necessary nutrients, and inhibition effects 
deriving from the remaining product in aqueous phase (Figure 3.6). Here again, 
despite most of inhibition alleviated by Amberlite
®
 XAD4 in the solid-liquid 
system, there were still 8.09 mM product in the aqueous phase at 56 h, which 
was much higher than dissociate constant Ki of 0.88 mM for product, 
signifying an inhibition due to the remaining product in aqueous phase (Figure 
3.6). Whereas, in comparison with the control which suffered from much more 
severe inhibition (Figure 3.7), aq./Amberlite
®
 XAD4 system was still useful in 
enhancing productivity owing to the alleviation of the inhibition: Amberlite
®
 
XAD4 still adsorbed 60.1% of the product and 82.4% of the substrate at 56 h, 
and the mere 10.1 mM of substrate remaining in the aqueous phase was below 
the substrate inhibition threshold. The biphasic system hence gave a final 
production titer of 20.3 mM, 2.4 fold higher than the 8.43 mM of the control 
in aqueous monophase (Figure 3.6 & 3.7). 
In Figure 3.6 & 3.7, specific biohydroxylation activity reduced quickly after 
the substrate was introduced to E. coli (P450pyrTM-GDH) for the conversion. 
Although the E. coli cells showed decrease in specific activity as well despite 
no substrate added in Figure 3.2, this reduction in specific biohydroxylation 
activity (Figure 3.2) appeared to be much slower and milder than the activity 
reduction in Figure 3.6 & 3.7. Therefore, it is concluded that the substrate and 
product affected the specific activity negatively. Solid-liquid system in Figure 
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3.6 could somewhat mitigate this deterioration in specific activity, because 
Amberlite
®
 XAD4 in the biphasic system could adsorb the majority of the 
substrate and the product. Comparatively, despite almost the same highest 
activity of 14 U/g CDW at 8 h observed in Figure 3.7, the control in the 
aqueous monophase aggravated the reduction in specific activity due to severe 
inhibition, hence presenting a sharp decrease in specific activity (Figure 3.7). 
Therefore, we decided to first induce and grow the E. coli (P450pyrTM-GDH) 
to a much higher cell density without addition of any substrate, at which point 
the substrate was added to start the reaction. The rationale is obvious: given 
similar specific hydroxylation activity observed, the production titer could be 
positively proportional to the absolute amount of biocatalyst E. coli 
(P450pyrTM-GDH). As shown in Figure 3.8, E. coli (P450pyrTM-GDH) was  
 
Figure 3.8 Biohydroxylation of substrate BP (80 mM) with growing cells of E. coli 
(P450pyrTM-GDH) in a 2 L fermentor. Amberlite
®
 XAD4 (100 g; 10%, w/v) and BP 
(80 mM) were added into the medium at 14 h to form solid-liquid system for the 
biohydroxylation. ◆: cell density; ■: specific biohydroxylation activity; ▲: product 
(S)-BPOH concentration in medium; ●: total (S)-BPOH concentration. Arrow 
indicates induction by adding IPTG and ALA to the concentrations of 0.25 mM and 
0.5 mM at 4 h, respectively. Glucose 1% (w/v) was added at 14 h and 23 h, 
respectively. Fresh feeding medium of EFM (500 mL) was added from 5 h to 14 h at 
the flow rate of 55.6 mL/h. All concentrations and cell density were normalized on 
the basis of the initial medium volume; data are the mean values with standard 
deviations of three replicates.  
























































































































































































































































































































































































































induced at 4 h with IPTG and ALA, and the E. coli cells were grown well to a 
high density of 38 g CDW/L at 14 h, at which time resin Amberlite
®
 XAD4 
together with substrate BP was introduced to the cell culture to form the solid-
liquid biphasic system and hence start the reaction. With active biocatalyst of 
E. coli (P450pyrTM-GDH) at high density, the product was produced at 
volumetric productivity of 0.72 g/L/h to reach product concentration of 45.3 
mM at 26 h (Figure 3.8), which represents the highest record of this type of 
reaction by our knowledge so far. Afterward, the product formation was rather 
slow owing to the reasons as described above, and the final production titer 
was 48.0 mM, 2.18 fold higher than the 22.0 mM of the control in aqueous 
monophase (Figure 3.9). Comparatively, although the control showed a similar 
 
Figure 3.9 Biohydroxylation of substrate BP (80 mM) with growing cells of E. coli 
(P450pyrTM-GDH) in a 2 L fermentor. BP was added directly to the medium at 14 h 
for the biohydroxylation. ◆: cell density; ■: specific biohydroxylation activity; ▲: 
product (S)-BPOH concentration in medium; --: cumulative BP concentration. Arrow 
indicates induction by adding IPTG and ALA to the concentrations of 0.25 mM and 
0.5 mM at 4 h, respectively. Glucose 1% (w/v) was added at 14 h and 23 h, 
respectively. Fresh feeding medium of EFM (500 mL) was added from 5 h to 14 h at 
the flow rate of 55.6 mL/h. All concentrations and cell density were normalized on 
the basis of the initial medium volume; data are the mean values with standard 
deviations of three replicates. 
specific activity profile and even slightly higher density (Figure 3.9), its 
production titer was much lower due to the inhibition effects of substrate and 
























































































































































































































































































































































































































product. Here again, advantage of using solid-liquid biphasic system was 
obvious: Amberlite
®
 XAD4 adsorbed 55.3% – 58.8% of the product and 77.9% 
– 79.3% of substrate, greatly reducing the inhibitions of substrate and product 
via in situ adsorption and hence enhancing the production titer (Figure 3.8). 
Due to the higher hydrophobicity as described above, more substrate was 
adsorbed by the resin than product, and remaining substrate in aqueous phase 
at 50 h was 7.33 mM, lower than the threshold of substrate inhibition (Figure 
3.3). However, shown in Figure 3.8, product inhibition at 50 h could be even 
severer as the 44.2% of the product remaining in aqueous phase amounted to 
20.9 mM, much higher than Ki of 0.88 mM for product.  
We also noticed several papers were published on establishing solid-liquid 
system with external extractive column containing the adsorbent for in situ 
removal of the toxic and inhibitory substrate and product.
[227, 230, 234]
 This 
technology is especially useful if the process is fermentation with product as a 
metabolite and the resin could selectively adsorb product. For the 
biohydroxylation in this work, this design might not be that efficient because 
substrate BP cannot be metabolized as a nutrient to yield product and the 
hydrophobic resin always adsorb more substrate than product. For validation, 
we used this kind of external extractive system for biohydroxylation of BP 
with E. coli (P450pyrTM-GDH), and the final production titer 34.6 mM, 
where the cells were first grown to high density of 41.4 g CDW/L and then the 
biohydroxylation reaction was started via passing the cell culture though the 
external extractive column packed with substrate-containing Amberlite
®
 





 XAD4 in the external packed column lacks locomotion, which 
might incur cell adhering on the resin surface, hence deterring the adsorption. 
Comparatively, using this biotransformation and in situ adsorption in one-pot 
could give better mass transferring including the oxygen transferring.  
3.3.5 Biohydroxylation of BP with resting E. coli (P450pyrTM-GDH)  
In the solid-liquid system and its control (Figure 3.6 – 3.9), growing whole 
cells were used as the biocatalyst to avoid tedious purification and enzyme 
deactivation, which is useful and practical for biotransformations with the 
multi-component and cofactor-dependent P450 enzymes.
[64]
 However, 
growing cells might be haunted by the unstable catalytic performances due to 
the complicated in vivo metabolism.
[54]
 Therefore, many cases report using the 
resting cell for biotransformation,
[45, 73, 192, 223]
 where the cell could be first 
grown to the highest specific activity and then harvested as the biocatalyst for 
the biotransformations. 
Here again, to perform biohydroxylation of BP with resting cells of E. coli 
(P450pyrTM-GDH), freshly prepared E. coli suspension (10 g CDW/L) in KP 
buffer (100 mM, pH 8.0) was introduced with substrate-containing resin 
Amberlite
®
 XAD4 to form a solid-liquid biphasic system for triggering the 
biohydroxylation. As shown in Figure 3.10, 63.7% – 67.3% of the product was 
in situ adsorbed by resin Amberlite
®
 XAD4, and the 83.1% – 89.5% of the 
substrate was adsorbed on the resin, simultaneously. With the inhibition 
effects of the substrate and product being reduced greatly, final production 
titer of 53.2 mM at 65 h was achieved, 2.02 fold higher than the 26.4 mM of 
the control in aqueous monophase (Figure 3.10). As shown in Figure 3.10, the 
80 
 
product concentration ceased to increase after 10 h for the control of aqueous 
mono-phase, while the product in aq./Amberlite
®
 XAD4 biphasic system 
continued to increase until 52 h. 
 
Figure 3.10. Time course for biohydroxylation of BP (80 mM) with resting cells of E. 
coli (P450pyrTM-GDH) (10 g CDW/L) in mono- and bi-phasic systems at 30°C and 
250 rpm, with addition of glucose (1%, w/v) at 0 h, 6 h, and 24 h, respectively. ▲: 
Product (S)-BPOH in aqueous phase of KP buffer (10 mL; 100 mM; pH 
8.0)/Amberlite
®
 XAD4 (1 g) biphasic system; ●: total (S)-BPOH in the biphasic 
system; ▼: (S)-BPOH in the control using monophase (KP buffer: 10 mL; 100 mM; 
pH 8.0). All concentrations and cell density were normalized by volume of the KP 
buffer; data are the mean values with standard deviations of three replicates.  
The biohydroxylation rate paced down after 24 h, and increased slightly from 
49.9 mM at 38 h to 53.2 mM at 65 h, which could be caused by enzyme 
deactivation and accumulation of the product in aqueous phase of KP buffer. 
Despite 17.7 mM product was still in aqueous phase, 66.7% of the product 
was adsorbed by Amberlite
®
 XAD4 of solid-liquid system, which decreased 
the inhibition and thus give higher production titer (Figure 3.10). Although the 
using resting cells of E. coli (P450pyrTM-GDH) exhibited a slightly higher 
production titer for the biohydroxylation reaction than using growing E. coli 
cells (Figure 3.6–3.10), biotransformation with growing cells could be more 
practical for applications at large scale, because cell separation at large scale 
could raise and the cost. 






































 XAD4 in our solid-liquid biphasic system was 
fulfilled by eluting the product and substrate out of the resin with ethanol, 
which was also a procedure for product recovery. To perform the product 
recovery and resin regeneration, Amberlite
®
 XAD4 after biotransformation 
(containing both the product and the substrate) was trapped in a column, and 
the elution began with running ethanol at a flow rate of 4.8 mL/min from the 
top to the bottom of the column. Samples of eluent were collected and 
prepared by procedures as described above for HPLC analysis. When eluent 
was tested without product and substrate, the resin was deemed as fully 
regenerated and could be dried later for next run. Shown in Figure 3.11, the 
 
Figure 3.11. Elution of BP (□) and (S)-BPOH (○) from resin Amberlite® XAD4 by 
ethanol. C/C0 is the ratio of the adsorbate concentration in the eluent to the initial 
adsorbate concentration (at 0 min) in the eluent. Data are the mean values with 
standard deviations of three replicates.  
samples were taken every two minutes to monitor the elution process, and 
nearly all product and substrate were purged out of the resin-packed column 
within 30 min, signifying the resin being well regenerated. As also can be seen 













in Figure 3.11, 50% of the product could be eluted out within 5 min, while the 
substrate, due to the higher hydrophobicity, tended to have stronger binding 
with the resin and exhibited longer retention time, as evidenced by the fact that 
50% of the substrate was eluted out after 14 min. 
3.3.7 Preparation of (S)-BPOH with E. coli (P450pyrTM-GDH) by using 
solid-liquid biphasic system of aq./Amberlite
®
 XAD4  
The potential of using aq./Amberlite
®
 XAD4 biphasic system for 
biohydroxylation of BP to prepare chiral (S)-BPOH in high enantioselectivity 
was explored. Oxidation of BP was conducted with growing cells of E. coli 
(P450pyrTM-GDH) in a 2 L fermentor. After separation of the resin from 
liquid phase via filtration, product in aqueous phase was extracted by ethyl 
acetate, while product in resin was first eluted out by ethanol and then 
dissolved in ethyl acetate. After combining product from aqueous phase and 
solid resin, the solvent of ethyl acetate was dried over Na2SO4 and then 
removed at reduced pressure. The crude product was purified to >98% purity 
(examined by HPLC) by flash chromatography on a silica gel column. The 
valuable and useful drug intermediate (e.g., carbapenem antibiotic CS-834 and 
nootropic drug (S)-Oxiracetame
[50, 51]
) of (S)-BPOH was obtained: 6.05 g, 
colorless liquid, >99% ee, and 39.6% isolated yield. Because high substrate 
concentration was used, isolated yield appeared to be lower, however, 124 mg 
of the product was produced by one gram of dry cell. This production titer 
represents hitherto the highest recorded for all the P450-catalyzed 




Three-component triple mutant P450pyrTM monooxygenase and GDH was 
coexpressed in E. coli to fabricate the whole cell biocatalyst of E. coli 
(P450pyrTM-GDH) for catalyzing the biohydroxylation of BP at high 
productivity by using solid-liquid biphasic system of aq./Amberlite
®
 XAD4, 
with intracellular cofactor regeneration, which gave the product (S)-BPOH as 
a drug intermediate with the highest production titer among all known P450 
monooxygenases for biohydroxylation to our best knowledge. In the solid-
liquid biphasic system, resin Amberlite
®
 XAD4 showed high adsorption 
capacity to the adsorbates of both substrate and product in comparison with 
other four tested resins, hence preventing greatly the inhibition effects of 
substrate and product. During the biohydroxylation with growing E. coli 
(P450pyrTM-GDH) in the fermentor, as the solid phase in the aq./Amberlite
®
 
XAD4 biphasic system, resin Amberlite
®
 XAD4 successfully in situ adsorbed 
the majority of both the substrate (79.9% – 83.3%) and product (55.3% – 
62.8%) from the aqueous phase, hence giving the final production titer of 48.0 
mM, 2.18 fold higher than the control in aqueous monophase. Although a 
portion of the product and substrate still remained in aqueous phase of the 
aq./Amberlite
®
 XAD4 system, Amberlite
®
 XAD4 took the majority and hence 
decreased the inhibition greatly. To address the adverse effects of substrate on 
cell growth and specific activity, for the first time, a general procedure was 
demonstrated: for biotransformation with growing recombinant cells, we 
should first cultivate the cell to high density and then conduct the 
biotransformation, where longer time elapsed between the induction and the 
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adding substrate could allow more cells and higher productivity. We believe 
our work shows good maneuverability and practicability and could hence be 
useful for the whole cell biotransformations at large scale. Biohydroxylation 
of BP with resting cells of E. coli (P450pyrTM-GDH) in flask by using 
aq./Amberlite
®
 XAD4 system showed even better performance with the final 
product amounted up to 53.2 mM,  2.02 fold higher than the 26.4 mM of 
control in aqueous monophase. The higher production titer was caused by 
stronger adsorption capacity to the substrate (83.1% – 89.5% adsorbed by 
resin) and the product (63.7% – 67.3% adsorbed by resin). The hydrophobic 
resin Amberlite
®
 XAD4 in our established solid-liquid biphasic system 
demonstrated convenient and green procedures of pretreatment and 
regeneration without using any base or acid. Preparative biohydroxylation of 
BP in out biphasic system gave a green method to produce useful and valuable 
(S)-BPOH. To our knowledge, it is the first report of using non-charged 
hydrophobic resin to establish solid-liquid biphasic system for P450 
monooxygenase-catalyzed biohydroxylation in whole cell form, as an 
exemplary procedure of simultaneous biohydroxylation and in situ adsorption 
in one pot for industrial applications. As more intention has been converged 
on the wider application of P450 monooxygenase in synthetic application, the 
success of this work demonstrates bioprocess engineering as a complementary 
approach to genetic engineering for enhancing the catalytic performance of 
P450 monooxygenase-catalyzed biooxidation in whole cell form, which 
provides a green and convenient reaction platform to biohydroxylation with 






CHAPTER IV.  
ENHANCING ENANTIOSELECTIVITY AND 
PRODUCTIVITY OF P450-CATALYZED 
ASYMMETRIC SULFOXIDATION WITH AN 






Biocatalysis is a useful and green tool to produce enantiopure compounds for 
pharmaceutical manufacture.
[1 – 9, 39, 59 – 66, 69]
 Despite of the great achievements 
in biocatalysis, many biotransformations such as some asymmetric oxidations 
suffer from unsatisfied enantioselectivity and/or low productivity due to the 
inhibition of substrate and/or product.
[39]
 Directed evolution has been proven 
as a useful method
[235 – 240]







 However, such an 
approach is still labor-intensive, time-consuming, and costly. On the other 
hand, solvent engineering using a two-liquid phase system represents a simple 
way to enhance the productivity by dissolving substrate and/or product in an 
organic solvent and thus reducing the inhibition on enzyme in aqueous 
phase.
[73, 210] 
Several organic solvents with high log P values showing less 
toxicity to the biocatalysts are widely used in the two-liquid phase system. 
However,
 
they also suffer from low solubility of many types of substrates and 
products, and they are not environmentally benign. Recently, ionic liquids 
(ILs) have received increasing attention as greener and promising solvents for 
multi-phase biocatalysis,
[67, 69, 210 –215]
 providing with less toxicity to the 
biocatalysts and high solubility. Thus far, ILs have been used as co-solvents 
for several types of reactions
 
to enhance the productivity.
[67, 69, 210 – 218]
 It is our 
great interest to explore aqueous/IL biphasic systems, as the first example, for 




Biocatalytic asymmetric sulfoxidation was selected for such investigation, 
since it could produce chiral sulfoxides that are important auxiliaries or 
synthetic intermediates
[75]
 and it often suffers from unsatisfactory 
enantioselectivity and low productivity. Several sulfoxidation reactions and 
chiral sulfoxides were chosen as the target reactions and products, respectively 
(Scheme 4.1). (R)-phenyl methyl sulfoxide 2 is an intermediate for the 
synthesis of anti-obesity drug Tetrahydrolipstatin;
[2]
 (R)-ethyl phenyl sulfoxide 
6 is useful for preparing luminescent materials;
[39]
 (R)-methyl p-tolyl sulfoxide 
8 is used for synthesizing glucocorticoid receptor ligands
[243]
 and the drugs 
such as Compactin, Mevinolin und Provastatin;
[39, 244, 245]
 and (R)-methyl p-
methoxyphenyl sulfoxide 10 is an intermediate to produce antihypertensive 




Scheme 4.1 Asymmetric sulfoxidations with E. coli (P450pyrI83H-GDH) in a KP 
buffer/IL biphasic system. 
Cyclohexanone monooxygenase (CHMO) was reported to catalyze the 
sulfoxidation of thioanisole 1 to give (R)-2 in 99% ee by using an in vitro 
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oxidation system with two coupled enzymes,
[75]
 however, no product 
concentration was mentioned and the number of NADPH recycling was low. 





produced (R)-2 in 92% ee and 17.8 mM and in 99% ee and 9.3 mM, 
respectively. Sulfoxidation of other substrates 4-fluorothioanisole 3, 
phenylthioethane 5, p-methylthioanisole 7, and 4-methoxythioanisole 9 with 
CHMO gave unsatisfied product ee [(R)-4-fluorophenyl methyl sulfoxide 4: 
92%; (R)-6: 47%; (R)-8: 37%; and (R)-10: 51%].
[75]
 P450 monooxygenases 
were known for the sulfoxidations of 1, 3, 5, 7, and 9, giving either (S)-
enantiomers in low concentrations (≤1 mM) or (R)-enantiomers in low ee (11-
56%).
[77, 186, 248 – 250]
 Herein, we report a novel P450 monooxygenase-catalyzed 
R-enantioselective sulfoxidations of 1, 3, 5, 7, and 9 by using an aqueous/IL 
biphasic system to enhance both enantioselectivity and productivity to produce 
the corresponding products (R)-2, 4, 6, 8, and 10, with better performance than 
other known biosystems for the same reactions.  
4.2 Materials and methods 
4.2.1 Chemicals and resins 
Ionic liquids (Table 4.1): 1-butyl-3-methylimidazolium hexafluorophosphate 
(>99%), 1-butyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide 
(>99%), methyltrioctylammonium bis(trifluoromethylsulfonyl)imide (>99%), 
and trihexyltetradecylphosphonium bis(trifluoromethylsulfonyl)imide (>98%) 




Table 4.1 Hydrophobic ionic liquids used in this chapter. 


















[P6,6,6,14] [NTf2] 1.10 
Other chemicals: ampicillin sodium salt (98%), kanamycin disulfate salt 
(>99%), δ-aminolevulinic acid hydrochloride (>98%), thioanisole 1 (>99%), 
4-fluorothioanisole 3 (>97%), phenylthioethane 5, (>97%), p-
methylthioanisole 7 (>99%), 4-methoxythioanisole 9 (>97%), and phenyl 
methyl sulfoxide 2 (≥97%) were bought from Sigma-Aldrich. Isopropyl β-D-
1-thiogalactopyranoside (>99%) was purchased from Calbiochem, Germany. 
Medium components LB premix, tryptone, and yeast extract were purchased 
from Biomed Diagnostics, USA. Unless stated otherwise, all the inorganic 
salts for the medium preparations were purchased from Sigma-Aldrich.   
p-Fluorophenyl methyl sulfoxide 4 (>97%), phenyl ethyl sulfoxide 6 (>97%), 
methyl p-tolyl sulfoxide 8 (>97%), and p-methoxyphenyl methyl sulfoxide 10 
(>97%) were prepared according to the reference.[251] 
Strains and biochemicals: competent cell E. coli BL21 (DE3) and plasmid 
pETDuet-1 were purchased from Novagen, Germany. Competent cell E. coli 
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DH5α was purchased from Invitrogen, USA. Quick ligation kit and restriction 
enzymes (NcoI, NdeI, EcoRV, and PstI) were purchased from New England 
Biolabs, USA. Phusion DNA polymerase was purchased from Thermo Fisher 
Scientific, USA. Miniprep kit, PCR purification kit, and gel extraction kit 
were purchased from Qiagen, Germany.  
4.2.2 Analytical methods 
The concentrations of substrates (1, 3, 5, 7, and 9) and products (2, 4, 6, 8, and 
10) were analyzed by using a Shimadzu Prominence HPLC on an Agilent 
Poroshell 120 EC-C18 column (150 mm × 4.6 mm; 2.7 µm). UV detection: 
210 nm; flow rate: 0.4 mL/min; eluent: acetonitrile/water (50: 50, v/v); 
retention time: 4.68 min for 2, 12.8 min for 1, 4.99 min for 4, 13.4 min for 3, 
5.19 min for 6, 17.9 min for 5, 5.17 min for 8, 18.0 min for 7, 4.87 min for 10, 
and 12.4 min for 9.   
The ee values of biotransformation products 2, 4, 6, 8, and 10 were analyzed 
by using a Shimadzu Prominence HPLC on Chiralcel OB-H column (250 mm 
× 4.6 mm, 5 µm). UV detection: 210 nm; flow rate: 1.0 mL/min; eluent: n-
hexane/isopropanol (80: 20, v/v); retention time: 11.1 min for (S)-2, 18.9 min 
for (R)-2, 10.5 min for (S)-4, 15.1 min for (R)-4, 9.6 min for (S)-6, 18.9 min 
for (R)-6, 9.4 min for (S)-8, 20.2 min for (R)-8, 14.1 min for (S)-10, and 32.2 
min for (R)-10. The peak areas of the two enantiomers from the 
chromatograms were used for calculating the ee values 
{ ([ ] [ ]) / ([ ] [ ]) 100%ee R S R S    }. 
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The optical density of the cells was determined at 600 nm (OD600) by using a 
HITACHI U-1900 spectrophotometer.  
The 
1
H-NMR spectrum was recorded in CDCl3 with TMS as internal standard 
at 400 MHz on a Bruker machine.  
The specific optical rotation was measured on a Jasco-Spectropolarimeter 
(DIP-1000). 
4.2.3 Engineering E. coli (P450pyrI83H-GDH), E. coli (P450pyrM305Q-
GDH), E. coli (P450pyrA77S-GDH), and E. coli (P450pyr-GDH) 
coexpressing the corresponding P450 monooxygenase and GDH.  
The four target P450 genes
[50]
 (i.e., P450pyrI83H, P450pyrM305Q, 






as the templates, respectively. 
Ferredoxin reductase gene was amplified with plasmid pETDuet-P450pyrTM-
FdR
[51] 
as template. The forward and reverse primers for the P450 genes were 
5’-GAATTCCCATGGAACATACAGGACAAAGCG-3’ (underlined is the 
NcoI restriction site) and 5’-
GAATTCCTGCAGCTACGCGTGGACGCGAACC-3’ (underlined is the PstI 
restriction site), respectively. The forward and reverse primers for ferredoxin 
reductase gene were 5’-GGATTCCATATGATCCACACCGGCGTGACCG-
3’ (underlined is the NdeI restriction site) and 5’- 
GAATTCGATATCTTAGAGGGAGGTTGGGGACG-3’ (underlined is the 
EcoRV restriction site), respectively. The digested ferredoxin reductase gene 
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fragment was ligated into the multiple cloning site 2 of the pETDuet-1 vector 
digested by restriction enzymes NdeI and EcoRV, which gave plasmid 
pETDuet-1-R. The fragment of the digested P450 gene was ligated into the 
multiple cloning site 1 of pETDuet-1-R (digested by restriction enzymes of 
NcoI and PstI), giving the plasmid pETDuet-1-PI83HR, pETDuet-1-PM305QR, 
pETDuet-1-PA77SR, and pETDuet-1-PR, respectively. Each of these plasmids 
was co-transformed together with Plasmid pRSFDuet1-GDH-Fdx
[51]
 into 
competent cell E. coli BL21(DE3) to give E. coli (P450pyrI83H-GDH), E. coli 
(P450pyrM305Q-GDH), E. coli (P450pyrA77S-GDH), and E. coli (P450pyr-
GDH), respectively.   
4.2.4 Strain screening for catalyzing the asymmetric sulfoxidation 
E. coli (P450pyrI83H-GDH), E. coli (P450pyrM305Q-GDH), E. coli 
(P450pyrA77S-GDH), E. coli (P450pyrTM-GDH),[51] and E. coli (P450pyr-
GDH) (all the strains preserved at − 80°C) were inoculated into 3 mL LB 
medium containing 50 µg/mL kanamycin and 100 µg/mL ampicillin, 
respectively, and incubated at 37°C and 250 rpm for 12 h. The seeds (3-5%, 
v/v) were introduced to 50 mL TB
S3
 medium containing 100 µg/mL ampicillin 
and 50 µg/mL kanamycin, respectively. Incubations were conducted at 37°C 
and 250 rpm for 2 h to reach an OD600 of 0.6 to 0.8, respectively. IPTG and 
ALA were added to the final concentration of 0.25 mM and 0.5 mM for 
induction, respectively, followed by incubation at 25°C. At 8 h, the cells 
reached a density of 2.6 to 2.8 g CDW/L, respectively. The cells were 
harvested by centrifugation at 5000 g for 10 min and were used freshly as the 
biocatalysts, respectively.    
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The freshly prepared E. coli (P450pyrI83H-GDH), E. coli (P450pyrM305Q-
GDH), E. coli (P450pyrA77S-GDH), E. coli (P450pyrTM-GDH),[51] and E. 
coli (P450pyr-GDH) were then suspended to a density of 10 g CDW/L in 10 
mL KP buffer (100 mM; pH 8) containing 2% (w/v) glucose, respectively. 
Sulfide 1 (12 µL) was added to each cell suspension. All the mixtures were 
shaken at 30°C and 250 rpm for 24 h. Samples (1 mL) were taken at 24 h to 
determine the ee values of product (R)-2 by chiral HPLC analysis. The 
analytical samples were prepared as follows: biotransformation solution (1 mL) 
was subjected to centrifugation at 13000 g for 5 min to remove the cell pellets; 
supernatant (600 µL) was extracted by ethyl acetate (600 µL); the aqueous 
phase was separated from ethyl acetate phase by centrifugation at 10000 g for 
1 min; ethyl acetate phase was dried over Na2SO4, and the solvent was 
removed by evaporation at reduced pressure; n-hexane (60-100 µL) was added 
to dissolve the extractives by vortexing; after centrifugation at 13000 g for 5 
min, the supernatant of n-hexane (containing the product) was subjected to 
chiral HPLC analysis. The results were used to calculate the ee value. 
4.2.5 Cell growth and specific activity for asymmetric sulfoxidation of E. 
coli (P450pyrI83H-GDH).  
E. coli (P450pyrI83H-GDH) cells (preserved at − 80°C) were inoculated into 
3 mL LB medium containing 50 µg/mL kanamycin and 100 µg/mL ampicillin. 
Incubation was conducted at 37°C and 250 rpm for 12 h. The seeds (3 − 5%, 
v/v) were then introduced to 50 mL TB medium containing 100 µg/mL 
ampicillin and 50 µg/mL kanamycin. Incubation was conducted at 37°C and 
250 rpm for 2 h to reach an OD600 of 0.6 to 0.8. IPTG and ALA were added to 
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a final concentration of 0.25 mM and 0.5 mM for induction, respectively, 
followed by incubation at 25°C. Samples at different time points were taken 
for the analysis of the cell density and the specific activity for sulfoxidations 
of 1, 3, 5, 7, and 9, respectively. For biotransformation with resting cells, the 
E. coli cells were harvested at late exponential phase at 10 h with a cell density 
of 3.6 CDW/L and used as the fresh biocatalyst.  
Activity test: Cell pellets were suspended to a cell density of 1.5 g CDW/L in 
0.5 mL KP buffer (50 mM; pH 8.0) containing 2% (w/v) glucose and 2 mM 
substrates of 1, 3, 5, 7, or 9. The reactions were carried out at 30°C and 1000 
rpm for 30 min. Aliquots (0.3 mL) were taken and mixed thoroughly with 0.3 
mL ethanol containing 2 mM benzylacetone as internal standard. After 
centrifugation of the mixture at 13000 g for 5 min, the supernatant was 
separated and analyzed by HPLC to quantify the product concentration. The 
specific activity was then calculated in U/g CDW. 1 U is defined as 1 µmol 
product formed per minute. 
4.2.6 Toxicity of the sulfides 1, 3, 5, 7, and 9 and sulfoxides 2, 4, 6, 8, and 
10 on the cells of E. coli (P450pyrI83H-GDH).  
Freshly prepared E. coli (P450pyrI83H-GDH) cells were re-suspended to a 
cell density of 10 g CDW/L in 15 mL KP buffer (50 mM; pH 8.0). The 
suspension was divided equally into 15 tubes, and each tube contains 1 mL 
cell suspension. Sulfides (1, 3, 5, 7, and 9) and sulfoxides (2, 4, 6, 8, and 10) 
were added into 10 tubes to a final concentration of 20 mM, respectively. The 
rest 5 tubes served as the control without the addition of sulfide or sulfoxide. 
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The mixtures in the 15 tubes were shaken at 30°C and 1000 rpm for 6 h, 
followed by washing with KP buffer (50 mM; pH 8.0) for 8 times to totally 
remove the sulfide and sulfoxide.  
The cells pretreated with the sulfide and corresponding sulfoxide (i.e., 1 and 2; 
3 and 4; 5 and 6; 7 and 8; 9 and 10) were examined for sulfoxidation activities 
of the corresponding sulfides 1, 3, 5, 7, and 9, respectively, by using the 
procedures described above. The control cells in the 5 tubes were also tested 
for sulfoxidation activities of the sulfides 1, 3, 5, 7, and 9, respectively. The 
residual activity was defined as the ratio of the specific activity of pretreated 
cells to that of the control cells.  
The viability of the pretreated cells was checked via inoculation of diluted 
cells onto the LB agar plate at 37°C for 12 h, followed by counting the number 
of the colonies.  
4.2.7 Apparent kinetics of asymmetric sulfoxidations of sulfides 1, 3, 5, 7, 
and 9 with the resting cells of E. coli (P450pyrI83H-GDH).  
E. coli (P450pyrI83H-GDH)-catalyzed asymmetric sulfoxidations of 1, 3, 5, 7, 
and 9 were carried out at 30°C and 250 rpm with cell suspension (1.5 g 
CDW/L) in 0.5 mL KP buffer (50 mM; pH 8.0) containing 2% (w/v) glucose 
at substrate concentrations ranging from 0.5 to 5 mM for 15 min. Product 
formation was determined by HPLC. The initial rates were measured, and the 
apparent Vmax and Km were calculated from the Lineweaver-Burk plot.
[39]
 To 
determine the apparent dissociate constant Ki, sulfoxides (R)-2, 4, 6, 8, and 10 
were added to a final concentration of 2 mM, respectively, and reactions were 
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carried out at the same range of substrate concentrations under the same 
conditions as described above. Ki was then calculated accordingly.
[39]
  
4.2.8 Examination of the effects of ILs and sulfide on the cell growth of E. 
coli (P450pyrI83H-GDH).  
Seeds (3 – 5%, v/v) of the E. coli cells were introduced to 50 mL LB medium 
containing 50 µg/mL kanamycin and 100 µg/mL ampicillin, and the 
cultivation was carried out at 37°C and 250 rpm for 2 h to reach an OD600 of 
1.5. Cell culture broth (10 mL) was then aliquot equally into 10 sterile tubes 
with each tube containing 1 mL cell culture broth. 100 µL IL [P6,6,6,14][NTf2], 
[BMIM][NTf2], [BMIM][Pf6], or [NMeOct3][NTf2] was added into 4 tubes, 
respectively. A mixture of IL [P6,6,6,14][NTf2], [BMIM][NTf2], [BMIM][Pf6], 
or [NMeOct3][NTf2] (100 µL) and sulfide 1 (1.2 µL) was added into another 4 
tubes, respectively. The last two tubes without adding any IL served as the 
controls, one containing 1.2 µL sulfide 1 and the other containing no sulfide. 
E. coli cells in the 10 tubes were then grown at 37°C and 1000 rpm and the 
cell densities were recorded. 
4.2.9 Asymmetric sulfoxidations of 1, 3, 5, 7, or 9 with resting cells of E. 
coli (P450pyrI83H-GDH) in mono-phasic KP buffer 
Freshly prepared cell pellets of E. coli (P450pyrI83H-GDH) were suspended 
to a density of 10 g CDW/L in 10 mL KP buffer (100 mM; pH 8) containing 2% 
(w/v) glucose. Sulfides 1 (12 µL), 3 (12 µL), 5 (14 µL), 7 (13 µL), and 9 (14 
µL) were added into 10 mL cell suspension, respectively, to give a final 
concentration of 10 mM. The asymmetric sulfoxidation was carried out at 
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30°C and 250 rpm. During the biotransformation, samples were taken at 1, 3, 
6, 9, 12, and 24 h for monitoring sulfoxidation of 1; samples were taken at 3, 5, 
9, 12, and 24 h for analyzing sulfoxidation of 3; samples were taken at 3, 6, 12, 
and 24 h for assaying asymmetric sulfoxidation of 5; and samples were taken 
at 24 h for measuring sulfoxidations of 7 and 9, respectively. 
The concentrations of products 2, 4, 6, 8, and 10 were analyzed by HPLC. 
Analytical samples were prepared as follows: biotransformation solution (0.05 
mL) was mixed thoroughly with ethanol (0.05 mL) containing 2 mM internal 
standard benzylacetone; the mixture was centrifuged at 13000 g for 5 min to 
remove the cell pellets; and the supernatant was used for HPLC analysis.  
The ee values of products (R)-2, 4, 6, 8, and 10 at 24 h were determined by 
chiral HPLC. The analytical samples were prepared as follows: 
biotransformation solution (1 mL) was subjected to centrifugation at 13000 g 
for 5 min to remove the cell pellets; supernatant (600 µL) was extracted by 
ethyl acetate (600 µL); after separation from the aqueous phase by 
centrifugation at 10000 g for 1 min, ethyl acetate phase was dried over Na2SO4 
and organic solvent was then removed by evaporation at reduced pressure; n-
hexane (60-100 µL) was added to dissolve the extractives by vortexing; after 
centrifugation at 13000 g for 5 min, the supernatant of n-hexane (containing 
the product) was subjected to chiral HPLC analysis. 
4.2.10 Sulfoxidations of sulfides 1, 3, 5, 7, and 9 with resting cells of E. coli 
(P450pyrI83H-GDH) in KP buffer/[P6,6,6,14][NTf2] biphasic system.  
[P6,6,6,14][NTf2] (3.3 mL) containing sulfide 1 (71 µL), 3 (37 µL), 5 (54 µL), 7 
(54 µL), or 9 (56 µL) was added to the freshly prepared 10 mL cell suspension 
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(10 g CDW/L) in KP buffer (100 mM; pH 8.0) containing 2% (w/v) glucose to 
give an initial substrate concentration of 60, 30, 40, 40, or 40 mM 
(concentrations were based on the volume of aqueous phase), respectively. 
The biotransformations were carried out at 30°C and 250 rpm in multiple 
flasks. Samples were taken at different time points. For each sampling, a 
whole flask (containing 3.3 mL [P6,6,6,14][NTf2] and 10 mL cell suspension) 
was withdrawn for analysis. For assaying asymmetric sulfoxidation of 1, 
samples were taken at 3, 9, 12, and 24 h; for determining asymmetric 
sulfoxidation of 3, samples were taken at 3, 6, 9, 12, 18, and 24 h; for 
monitoring asymmetric sulfoxidation of 5, samples was taken at 3, 6, 9, 18, 
and 24 h; for measuring asymmetric sulfoxidation of 7 and 9, samples were 
taken at 24 h. 
The concentrations of products 2, 4, 6, 8, and 10 in both aqueous and IL 
phases were analyzed by HPLC. Analytical samples of aqueous phase were 
prepared as follows: after separating from IL phase by centrifugation at 1000 g 
for 1 min, aqueous phase of cell suspension (0.1 mL) was added with 0.4 mL 
water and mixed thoroughly with 0.5 mL ethanol containing 2 mM 
benzylacetone as internal standard; after centrifugation of the mixture at 13000 
g for 5 min, the supernatant was analyzed by HPLC. Analytical samples of IL 
phase were prepared as follows: after separating from aqueous phase by 
centrifugation at 1000 g for 1 min, [P6,6,6,14][NTf2] (20 µL) was dissolved in 
the 1 mL ethanol containing 1 mM benzylacetone as internal standard; after 
centrifugation of the mixture at 13000 g for 5 min, the supernatant was 
analyzed by HPLC.  
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The ee values of products (R)-2, 4, 6, 8, and 10 at 24 h were determined by 
chiral HPLC.  The analytical samples were prepared as follows: the aqueous 
phase was first separated from the IL phase by centrifugation at 1000 g for 1 
min; aqueous phase (1 mL) was subjected to centrifugation at 13000 g for 5 
min to remove the cell pellets; supernatant (600 µL) was extracted by ethyl 
acetate (600 µL); after separation from the aqueous phase by centrifugation at 
10000 g for 1 min, ethyl acetate phase was dried over Na2SO4, and the solvent 
was then removed by evaporation at reduced pressure; n-hexane (60-100 µL) 
was added to dissolve the extractives by vortexing; after centrifugation at 
13000 g for 5 min, the supernatant of n-hexane (containing the product) was 
subjected to chiral HPLC analysis 
4.2.11 Recovery of product from [P6,6,6,14][NTf2] by washing with water 
Sulfoxidation of sulfide 3 (30 mM, normalization based on aqueous volume) 
or 5 (40 mM, normalization based on aqueous volume) with resting cells of E. 
coli (P450pyrI83H-GDH) (10 g CDW/L, normalization based on aqueous 
volume) was carried out in KP buffer/[P6,6,6,14][NTf2] biphasic system 
containing 2% glucose (w/v, normalization based on aqueous volume) at 250 
rpm and 30°C in 100 mL flask for 24 h. KP buffer/[P6,6,6,14][NTf2] biphasic 
system consisted of 3.3 mL [P6,6,6,14][NTf2] and 10 mL KP buffer (100 mM 
and pH 8). For each sulfoxidation, multiple flasks were used. 
After 24 h reaction, [P6,6,6,14][NTf2] in the above KP buffer/[P6,6,6,14][NTf2] 
system was separated from aqueous phase by centrifugation at 1000 g for 3 
min. Then, [P6,6,6,14][NTf2] (5 mL) [either containing 3 and (R)-4, or 
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containing 5 and (R)-6] was extracted with 15 mL water. The mixture was 
centrifuged at 10000 g for 1 min to separate the aqueous phase from IL phase. 
After removal of the aqueous phase, the procedures of washing, extraction, 
and centrifugation were repeated as stated above for 2 times [to wash (R)-4] or 
4 times [to wash (R)-6]. At each step, 50 µL [P6,6,6,14][NTf2] was sampled and 
dissolved in 1 mL ethanol containing 1 mM internal standard benzylacetone 
by vortexing. The mixture was centrifuged at 13000 g for 5 min, and the 
supernatant was subjected to HPLC analysis.  
4.2.12 Preparation of (R)-2, 4, and 6 by asymmetric sulfoxidations of 1, 3, 
and 5 with resting cells of E. coli (P450pyrI83H-GDH).  
[P6,6,6,14][NTf2] (17 mL) containing 1 (353 µL), 3 (183 µL), or 5 (271 µL) was 
added to the freshly prepared 50 mL cell suspension (15 g CDW/L) in KP 
buffer (100 mM; pH 8) containing 2% (w/v) glucose to give an initial 
substrate concentration of 60, 30, or 40 mM (concentrations based on the 
volume of the aqueous phase), respectively. The asymmetric sulfoxidations 
were conducted at 30°C and 250 rpm for 24 h. The biotransformation solution 
was centrifuged at 1000 g for 1 min to separate aqueous phase of cell 
suspension from IL phase. The aqueous phase (50 mL) was then centrifuged at 
5000 g for 10 min to remove the cell pellets, and the supernatant was extracted 
with ethyl acetate (3 × 50 mL). [P6,6,6,14][NTf2] phase (17 mL) was first 
washed with water (3 × 50 mL) to extract the sulfoxide; the collected aqueous 
phase was extracted with ethyl acetate (2 × 150 mL). The separated ethyl 
acetate phase was combined and dried over Na2SO4, followed by evaporation 
at reduced pressure. The crude sulfoxides were purified by flash 
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chromatography on a silica gel with n-hexane/ethyl acetate (2: 1-2) as eluent 
(Rf ≈ 0.4). (R)-phenyl methyl sulfoxide 2: 89 mg, colorless liquid; 99% ee and 
21% isolated yield.  
1
H NMR (CDCl3) δ 2.72 (3H, s), 7.47-7.55 (3H, m), 7.63-
7.66 (2H, m). (R)-4-fluorophenyl methyl sulfoxide 4: 52 mg, colorless liquid; 
98% ee and 22% isolated yield. 
1
H NMR (CDCl3) δ 2.71 (3H, s), 7.19-7.25 
(2H, m), 7.62-7.67 (2H, m). (R)-ethyl phenyl sulfoxide 6: 59 mg, colorless 
liquid; 96% ee and 19% isolated yield. 
1
H NMR (CDCl3) δ 1.19 (3H, t, J=7.6), 
2.71-2.94 (2H, m), 7.48-7.53 (3H, m), 7.59-7.61 (2H, m). 
In another representative experiment, [P6,6,6,14][NTf2] (17 mL) containing 
sulfide 3 (61 µL) was added to the freshly prepared 50 mL cell suspension (15 
g CDW/L) in KP buffer (100 mM; pH 8) containing 2% (w/v) glucose to give 
an initial substrate concentration of 10 mM (concentrations based on the 
volume of the aqueous phase). The reaction was performed for 24 h and then 
subjected to purification, according to process described above. 53.7 mg (R)-
phenyl methyl sulfoxide 4 was obtained as colorless liquid in 98 % ee and 
68% isolated yield. 
4.3 Results and discussion 
4.3.1 Asymmetric sulfoxidation of thioanisole 1 with recombinant E. coli 
strains co-expressing P450pyr or its mutant and glucose dehydrogenase. 
Recently, a novel three-component P450pyr monooxygenase from 
Sphingomonas sp. HXN-200 was discovered and engineered in our laboratory 
for regio- and stereoselective biohydroxylations and asymmetric 
epoxidations.
[4, 39, 41 – 51, 232, 233]
 As some P450 enzymes are known to catalyze 
sulfoxidations,
[77, 186, 248 – 250]
 we decided to examine the possibility of using 
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P450pyr and several P450pyr mutants (P450pyrI83H, P450pyrM305Q, and 
P450pyrA77S) proven with hydroxylation activities by our previous work
[50, 
51]
 for asymmetric sulfoxidation. At first, the three-component monooxygenase 
of P450pyr and other P450pyr mutants
[50]
 (P450pyrI83H, P450pyrM305Q, and 
P450pyrA77S) was co-expressed, respectively, with a GDH in E. coli. As a 
representative example, E. coli (P450pyrI83H-GDH) was engineered by using 
double plasmids: pETDuet-1-PI83HR carrying P450pyrI83H and ferredoxin 
reductase genes and pRSFDuet1-GDH-Fdx
[51]
 carrying GDH and ferredoxin 
genes (Figure 4.1). Biotransformation with these E. coli cells could give the 
desired oxidation with the recycling of the necessary cofactor NAD(P)H via 
GDH-catalyzed oxidation of glucose.  
 
Figure 4.1 Engineering of E. coli (P450pyrI83H-GDH) with double plasmids. 
The four newly engineered strains and E. coli (P450pyrTM-GDH)
[51]
 were 
then used separately as resting cells (10 g CDW/L; CDW: cell dry weight) to 
catalyze the sulfoxidation of thioanisole 1 (10 mM) in potassium phosphate 
(KP) buffer at 30 °C and 250 rpm for 24 h. All these P450s are able to 
catalyze the asymmetric sulfoxidation with R-enantioselectivity. E. coli 
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(P450pyrI83H-GDH), E. coli (P450pyrM305Q-GDH), E. coli (P450pyrA77S-
GDH), E. coli (P450pyrTM-GDH),
[51]
 and E. coli (P450pyr-GDH) produced 
(R)-phenyl methyl sulfoxide 2 in 85%, 62%, 83%, 63%, and 82% ee, 
respectively (Figure 4.2).  
        
Figure 4.2 ee values of (R)-phenyl methyl sulfoxide 2 produced by asymmetric 
sulfoxidation of phenyl methyl sulfide 1 (10.0 mM) with resting cells of E. coli 
(P450pyrI83H-GDH), E. coli (P450pyrM305Q-GDH), E. coli (P450pyrA77S-GDH), 
E. coli (P450pyrTM-GDH), and E. coli (P450pyr-GDH) (cell densities of all resting 
cell suspensions were 10 g CDW/L) in 10 mL KP buffer (pH 8.0; 100 mM) 
containing 2% (w/v) glucose at 30°C and 250 rpm for 24 h, respectively. Data are the 
mean values with standard deviation of 3 replicates. 
Shown in Figure 4.2, these P450s demonstrated much higher R-
enantioselectivity for the sulfoxidation than other P450s,
[77, 186, 248 – 250]
 which 
could be valued for producing useful intermediates as drugs or other materials. 
E. coli (P450pyrI83H-GDH) gave the highest product ee value, thus being 













































































4.3.2 Asymmetric sulfoxidation of thioanisole 1, 4-fluorothioanisole 3, 
ethyl phenyl sulfide 5, methyl p-tolyl sulfide 7, and 4-methoxythioanisole 9 
with resting cells of E. coli (P450pyrI83H-GDH) in aqueous buffer.  
Cell growth curves and specific sulfoxidation activities of E. coli 
(P450pyrI83H-GDH) were given in Figure 4.3 (a). Cells were cultivated in 
Terrific Broth (TB) medium at 37°C and 250 rpm, following by induction at 2 
h with IPTG and ALA. The expression of the P450 enzyme was evidenced by 
the SDS-PAGE [Figure 4.3 (b)] of the cell-free extracts of the cells taken at 8 
h growth. At 8 − 12 h, the cells reached a density of 2.8 − 3.8 g CDW/L in the 
late exponential or early stationery growth phase and gave higher specific 
sulfoxidation activities [Figure 4.3 (a)]. The highest specific activities for the 
sulfoxidation of 1, 3, 5, 7, and 9 were 9.6, 4.0, 5.7, 11, and 16 U/g CDW, 
respectively.  
 
Figure 4.3 (a) Cell growth and specific activity curves for the asymmetric 
sulfoxidations with E. coli (P450pyrI83H-GDH). Cell density (■); activity for 
thioanisole 1 (●), 4-fluorothioanisole 3 (▲), phenylthioethane 5 (▼), p-
methylthioanisole 7 (◆), and 4-methoxythioanisole 9 (◄).  Data are the mean values 
with standard deviations of 3 replicates. (b) SDS-PAGE. Lane 1, cell free extract of 
E. coli (P450pyrI83H-GDH) before induction; lane 2, cell free extract of E. coli 























































The cells harvested after 8 − 10 h growth were used as resting cells (10 g 
CDW/L) for the sulfoxidation of 10 mM sulfides 3, 5, 7, and 9, respectively, 
in a mono-phasic KP buffer system for 24 h. Sulfoxides (R)-4, 6, 8, and 10 
were obtained in 80%, 88%, 35%, and 53% ee, respectively (Table 4.2).  
Accordingly, P450pyrI83H showed much higher R-enantioselectivity for the 
sulfoxidation of 3, 5, 7, and 9 than other P450s.
[77, 186, 248 – 250]
 The final 
concentrations of (R)-4, 6, 8, and 10 were 1.9, 5.4, 4.2, and 5.7 mM, 
respectively. These values were much lower than the expected product 
concentrations based on the specific activities, indicating inhibition during the 
biotransformations. The sulfoxidation of 1 was then performed with the 
resting cells under the same conditions at a substrate concentration of 10 mM, 
20 mM, and 30 mM, respectively. (R)-2 was formed in 9.4 mM, 4.4 mM, and 
4.2 mM, respectively (Table 4.2). The decrease of product concentration with 
the increase of substrate concentration clearly suggests the substrate inhibition.  
4.3.3 Toxicity to the E. coli (P450pyrI83H-GDH) cells and inhibition to 
the sulfoxidation with the sulfide substrates and sulfoxide products.  
The toxicity and inhibition were further investigated by adding 20 mM 
sulfides (1, 3, 5, 7, or 9) and sulfoxides (2, 4, 6, 8, or 10), respectively, to the 
cell suspension (10 g CDW/L) of E. coli (P450pyrI83H-GDH) in KP buffer 
and incubating at 30°C and 1000 rpm for 6 h. Only 3 − 5% of the cells were 
viable after the pretreatment with the sulfides 1, 3, 5, 7, or 9, while 40% − 75% 
of the cells could survive pretreatment with sulfoxides 2, 4, 6, 8, or 10 (Figure 
4.4). The E. coli cells pretreated by the sulfides 1, 3, 5, 7, or 9 showed 0.5 − 2%
  









































1 (R)-2 10.0 9.38 0.66 85.4 0.4 
 
50.0 0.19 0.01 7.42 0.37 12.1 1.1 11.4 0.7 99.2 0.0 
1 (R)-2 20.0 4.36 0.37 85.5 0.0 60.0 0.34 0.01 12.9 1.2 21.1 2.1 20.0 1.9 99.5 0.0 
1 (R)-2 30.0 4.24 0.36 85.9 0.2 70.0 0.34 0.02 7.93 0.51 13.4 0.8 12.4 0.7 99.5 0.0 
3 (R)-4 10.0 1.93 0.14 80.2 0.4 30.0 0.10 0.01 5.83 0.35 12.2 0.4 9.91 0.48 98.2 0.5 
5 (R)-6 10.0 5.44 0.19 88.3 0.6 40.0 0.04 0.00 6.41 0.23 28.4 1.4 15.8 0.6 96.0 1.6 
7 (R)-8 10.0 4.17 0.12 35.2 0.0 40.0 0.03 0.00 9.84 0.52 35.3 1.3 21.6 0.9 61.8 0.0 
9 (R)-10 10.0 5.67 0.23 52.8 0.1 40.0 0.04 0.00 15.5 0.5 26.8 1.0 24.4 0.8 66.9 0.0 
a
Biotransformation was conducted at 30°C and 250 rpm in 10 mL KP buffer (100 mM; pH 8.0) containing 2% (w/v) glucose at a cell density of 10 g CDW/L 
for 24 h; product formation was determined by HPLC. 
b
Biotransformation was conducted in KP buffer (10 mL; 100 mM; pH 8.0)/[P6,6,6,14][NTf2] (3.3 mL) at 
30°C and 250 rpm for 24 h; KP buffer (10 mL) contained 2% (w/v) glucose and the E. coli cells (10 g CDW/L); product formation was determined by HPLC. 
c
Concentrations at 24 h. 
d
ee was determined by chiral HPLC. 
e
Concentrations were normalized based on the volume of aqueous phase. 
f
Concentrations (at 24 
h) without normalization. 
g
Concentrations (at 24 h) were normalized based on the volume of aqueous phase. Data are the mean values with standard 






specific activity for the sulfoxidation of 1, 3, 5, 7, and 9, while the cells 
pretreated by the sulfoxides 2, 4, 6, 8, and 10 retained 42% − 91% specific 
activity for the sulfoxidation of 1, 3, 5, 7, and 9 (Figure 4.4). These results 
clearly demonstrated that both sulfides and sulfoxides were toxic to the cells 
and inhibitory to the sulfoxidation, and sulfides were much more toxic and 
inhibitory than the corresponding sulfoxides. 
 
Figure 4.4 Viability and residual activity of E. coli (P450pyrI83H-GDH) cells after 
pretreatment with the sulfides (1, 3, 5, 7, and 9) and the corresponding sulfoxides (2, 
4, 6, 8, and 10). (a) Cell viability. (b) Residual activity. Pretreated with 20 mM 
sulfide (white); pretreated with 20 mM sulfoxide (grey); control without pretreatment 
(black). Data are the mean values with standard deviation of 3 replicates. 
The loss of cell viability could be caused by the damages to membrane 
integrity with the high concentrations of substrate and product. To investigate 
the inhibition, the apparent kinetics of the whole cell-catalyzed asymmetric 
sulfoxidations was measured. Only 2 mM sulfoxides were used for 15 min to 
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determine the kinetics, thus the toxicity of sulfoxides to the cells could be 
negligible. Sulfoxides were found to show competitive inhibitions, with 
apparent Ki values of 2.0 mM for (R)-2, 1.2 mM for (R)-4, 1.5 mM for (R)-6, 
3.7 mM for (R)-8, and 7.3 mM for (R)-10, respectively (Table 4.3).  
Table 4.3. Kinetic data of the asymmetric sulfoxidations of 1, 3, 5, 7 and 9 with the 












(μmol min-1 g CDW-1 mM-1) 
1 to 2 1.50 0.58 0.02 27.0 0.7 1.95 0.07 46.5 0.4 
3 to 4 1.50 0.37 0.01 10.5 0.1 1.18 0.02 28.5 0.6 
5 to 6 1.50 0.75 0.00 15.4 0.1 1.52 0.01 20.6 0.7 
7 to 8 1.50 2.23 0.02 48.9 0.2 3.71 0.11 21.9 0.1 
9 to 10 1.50 0.95 0.01 41.5 1.0 7.26 0.38 43.5 0.8 
a
The reactions were carried out at 30°C with cell suspension (1.5 g CDW/L) in 0.5 
mL KP buffer (50 mM; pH 8.0) containing 2% (w/v) glucose for 15 min; product 
formation was determined by HPLC; data are the mean values with standard 
deviations of 3 replicates.
 b
Ki is for the sulfoxide product (R)-2, 4, 6, 8, or 10 as an 
inhibitor of the corresponding sulfoxidation. 
As shown in Table 4.3, apparent Vmax values for the sulfoxidations of 1, 3, 5, 
7, and 9 were 27, 11, 15, 49, and 41 μmol/min/g CDW, respectively, and 
apparent Km values for the sulfoxidations of 1, 3, 5, 7, and 9 were 0.6, 0.4, 0.7, 
2.2, and 1.0 mM, respectively.  
4.3.4 Selection of ionic liquid for establishing a KP buffer/IL biphasic 
system for efficient sulfoxidation.  
To select a suitable IL for establishing the efficient KP buffer/IL biphasic 
system, the biocompatibility of four hydrophobic ILs, [P6,6,6,14][NTf2], 
[BMIM][NTf2], [BMIM][Pf6], and [NMeOct3][NTf2] (Table 4.1), to the E. coli 
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cells were examined based on cell growth rate. ILs with better 
biocompatibility should have less toxic effects on the cell growth, thus giving 
higher growth rate, and vice versa.
6
 With this criterion, E. coli (P450pyrI83H-
GDH) cells were first cultivated in aqueous medium, followed by the addition 
of individual IL at 2 h to a phase ratio of 10:1 (v/v; aq./IL) [Figure 4.5(a)].  
 
Figure 4.5 Growth curves of E. coli (P450pyrI83H-GDH) in LB medium at 37°C and 
250 rpm with the addition of ILs at 2 h to a phase ratio of 10: 1 (aqueous to IL, v/v). 
(a) Without adding sulfide 1 at 2 h. (b) With the addition of 10 mM sulfide 1 at 2 h. 
●: Before adding ILs; ○: control (without adding IL); *: KP buffer/[P6,6,6,14][NTf2]; ■: 
KP buffer/[BMIM][NTf2]; ◆ : KP buffer/[BMIM][Pf6]; ▲: KP 
buffer/[NMeOct3][NTf2]. Data are the mean values with standard deviations of 3 
replicates.  
As shown in Figure 4.5(a), the biphasic system of KP buffer/[P6,6,6,14][NTf2] 
remained the highest growth rate of 1.02 h
-1
, similar to the cell cultivation 
































without adding IL. The cells ceased to grow in all other three biphasic 
systems. These results indicated that [P6,6,6,14][NTf2] is compatible with the E. 
coli cells while the other three ILs imposed toxic effects to the cells. Although 
[BMIM][Pf6] was reported as cosolvent for biohydroxylation
[215]
 and 
[NMeOct3][NTf2] was reported with biocompatibility to other E. coli cells 
deprived of plasmids,
[210]
 the hazardous effects brought by the two ILs to the 
cells of our E. coli strain containing dual plasmids carrying four different 
genes were observed in this work.  
To test the capability of ILs in alleviating the toxicity of substrate during cell 
growth, 10 mM sulfide 1 was also added, together with the IL, at 2 h. The 
results in Figure 4.5(b) indicated that sulfide 1 has no toxic effect on the cell 
growth in KP buffer/[P6,6,6,14][NTf2] biphasic system. This indicated that 
[P6,6,6,14][NTf2] could shield much of the substrate toxicity to the cells and 
hence protect the cells. Remarkably, cell grow in control (i.e., in mono-
aqueous system) was most severely inhibited by sulfide 1 [Figure 4.5(b)].  As 
for the other three KP buffer/IL biphasic systems, cell growths were inhibited 
but better than that from the control [Figure 4.5(b)]. 
Simple tests for the sulfoxidation of 1 (10 mM) with resting cells of E. coli 
(P450pyrI83H-GDH) in the four buffer/IL biphasic systems (phase ratio 10: 1, 
v/v) gave (R)-2 in 98% ee in KP buffer/[P6,6,6,14][NTf2] , much higher than the 
85% ee from the control, (R)-2 in 88% ee in KP buffer/[BMIM][Pf6], (R)-2 in 
87% ee in KP buffer/[BMIM][NTf2], and no product in KP 
buffer/[NMeOct3][NTf2] (Table 4.4), respectively.  
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Table 4.4 Ee values of (R)-2 produced by asymmetric sulfoxidation of phenyl methyl 
sulfide 1 (10 mM) with resting cells of E. coli (P450pyrI83H-GDH) in different KP 
















1 to 2 88.1 0.3 87.2 1.1 N. D.c 98.0 0.1 85.5 0.5 
a
Asymmetric sulfoxidations with the freshly prepared resting cells of E. coli (P450pyrI83H-
GDH) (10 g CDW/L) were carried out at 30°C and 250 rpm for 24 h at phase ratio of 10: 1 
(v/v); ee was determined by chiral HPLC; unless stated otherwise, 2% (w/v) glucose, substrate 
concentration, and cell density (10 g CDW/L) were based on the volume of the aqueous phase; 
KP buffer mentioned was 10 mL, 100 mM, and pH 8.0; data are the mean values with 
standard deviation of 3 replicates. 
b
Control: asymmetric sulfoxidation was conducted in mono-
phasic KP buffer without IL; 
 c
N. D.: not determined. 
Based on these results, [P6,6,6,14][NTf2] was chosen as the cosolvent in the KP 
buffer/IL biphasic system for efficient asymmetric sulfoxidations of sulfide 
thioanisole 1, 4-fluorothioanisole 3, phenylthioethane 5, p-methylthioanisole 
7, and 4-methoxythioanisole 9 with E. coli (P450pyrI83H-GDH). 
4.3.5 Enhancements of productivities of asymmetric sulfoxidations with E. 
coli (P450pyrI83H-GDH) cells in KP buffer/[P6,6,6,14][NTf2] biphasic 
system.  
To perform the asymmetric sulfoxidations in the biphasic system, the cells of 
E. coli (P450pyrI83H-GDH) that were harvested at exponential phase were 
first re-suspended in KP buffer containing 2% (w/v) glucose to a density of 10 
g CDW/L. [P6,6,6,14][NTf2] containing sulfides 1, 3, 5, 7, or 9, respectively, was 
then added to the cell suspension to form a biphasic system with a 3:1 ratio of 
aqueous phase to IL to start the biotransformation. In such a biphasic system, 
more than 99% of substrate 1, 3, 5, 7, and 9 remained in IL (Table 4.5), thus 
intensively reducing the substrate toxicities and inhibitions. The partition 
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Table 4.5 Distribution of sulfide and the corresponding sulfoxide in KP 
buffer/[P6,6,6,14][NTf2] biphasic system containing 2% (w/v) glucose for asymmetric 


















1 to 2 20: 1 40.0 0.32 0.02 20.8 0.4 33.5 1.0 22.5 0.4 96.5 0.5 
1 to 2 10: 1 40.0 0.19 0.01 14.3 0.7 26.4 1.4 16.9 0.8 98.5 0.9 
1 to 2 5: 1 40.0 0.17 0.00 5.89 0.18 9.93 0.80 7.88 0.21 99.4 0.0 
1 to 2 5: 1 50.0 0.37 0.01 6.62 0.36 11.7 1.1 8.97 0.52 99.6 0.1 
1 to 2 5: 1 70.0 0.39 0.01 8.46 0.52 14.7 0.8 11.4 0.6 99.7 0.1 
1 to 2 5: 1 90.0 0.51 0.01 8.36 0.58 14.8 0.8 11.3 0.7 99.7 0.1 
1 to 2 3: 1 50.0 0.19 0.01 7.42 0.37 12.1 1.1 11.4 0.7 99.2 0.0 
1 to 2 3: 1 60.0 0.34 0.01 12.9 1.2 21.1 2.1 20.0 1.9 99.5 0.0 
1 to 2 3: 1 70.0 0.34 0.02 7.93 0.51 13.4 0.8 12.4 0.7 99.5 0.0 
1 to 2 3: 1 100 0.34 0.01 7.47 0.36 13.1 1.1 11.8 0.7 99.8 0.1 
3 to 4 5: 1 20.0 0.06 0.01 3.13 0.16 7.20 0.22 4.57 0.20 96.6 0.8 
3 to 4 5: 1 30.0 0.13 0.01 3.45 0.12 8.60 0.36 5.17 0.19 96.4 0.6 
3 to 4 5: 1 40.0 0.24 0.02 3.63 0.16 9.54 0.48 5.54 0.25 96.3 0.0 
3 to 4 5: 1 50.0 0.71 0.02 3.94 0.11 10.1 0.3 5.97 0.16 96.4 0.8 
3 to 4 3: 1 20.0 0.05 0.00 5.71 0.30 11.6 0.3 9.58 0.38 99.3 0.5 
3 to 4 3: 1 30.0 0.10 0.01 5.83 0.35 12.2 0.4 9.91 0.48 98.2 0.5 
3 to 4 3: 1 40.0 0.13 0.01 5.58 0.20 11.9 0.6 9.54 0.37 97.8 0.0 
5 to 6 5: 1 20.0 0.04 0.00 3.45 0.13 18.2 0.9 7.08 0.29 94.5 0.0 
5 to 6 5: 1 30.0 0.04 0.00 5.07 0.28 29.3 1.0 10.9 0.5 94.3 0.7 
5 to 6 5: 1 40.0 0.05 0.01 4.58 0.30 24.9 1.0 9.56 0.51 93.6 0.0 
5 to 6 3: 1 20.0 0.03 0.00 4.64 0.28 20.1 0.4 11.3 0.4 95.7 0.2 
5 to 6 3: 1 30.0 0.03 0.00 6.35 0.38 26.8 0.9 15.3 0.7 94.5 0.1 
5 to 6 3: 1 40.0 0.04 0.00 6.41 0.23 28.4 1.4 15.8 0.6 96.0 1.6 
7 to 8 5: 1 20.0 0.02 0.00 6.41 0.26 28.4 0.7 12.1 0.4 51.8 0.2 
7 to 8 5: 1 30.0 0.03 0.00 8.49 0.40 37.7 1.3 16.0 0.7 44.7 0.0 
7 to 8 5: 1 40.0 0.03 0.01 10.9 0.4 50.2 2.3 20.9 0.9 44.0 0.0 
7 to 8 3: 1 40.0 0.03 0.00 9.84 0.52 35.3 1.3 21.6 0.9 61.8 0.0 
9 to 10 5: 1 20.0 0.05 0.00 9.56 0.39 18.1 0.4 13.2 0.5 67.3 0.1 
9 to 10 5: 1 30.0 0.05 0.00 13.4 0.6 32.0 1.1 19.8 0.8 56.9 0.0 
9 to 10 5: 1 40.0 0.10 0.01 16.3 0.6 34.2 1.6 23.2 0.9 54.4 0.0 
9 to 10 3: 1 40.0 0.04 0.00 15.5 0.5 26.8 1.0 24.4 0.8 66.9 0.0 
a
Asymmetric sulfoxidations (AS) with the freshly prepared resting cells of E. coli 
(P450pyrI83H-GDH) (10 g CDW/L) were carried out at 30°C and 250 rpm for 24 h; 
unless stated otherwise, 2% (w/v) glucose and cell density (10 g CDW/L) were based 
on the volume of the aqueous phase; KP buffer used was 10 mL, 100 mM, and pH 8.0; 
data are the mean values with standard deviation of 3 replicates. 
b
Phase ratio (PR) 
refers to the ratio of aqueous volume to IL volume. 
c
Initial substrate concentrations 
(ISC, in mM) at 0 h were normalized based on the volume of the aqueous phase. 
d
Substrate concentration in KP buffer (SK, in mM) at 24 h without normalization. 
e
Product concentration in KP buffer (PK, in mM) at 24 h without normalization. 
f
Product concentration in IL (PI, in mM) at 24 h without normalization. 
g
Total 
product concentration (TP, in mM) at 24 h was normalized based on the volume of 
the aqueous phase. 
h
Product ee (at 24 h) was measured by chiral HPLC.   
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coefficients ([Conc. in IL]/[Conc. in aq.]) for sulfide 1, 3, 5, 7, and 9 were 
determined to be 855, 670, 1144, 364, and 324, respectively. Due to the 
hydrophilicity of the sulfoxides, 40% − 65% of the products 2, 4, 6, 8, and 10 
existed in aqueous buffer, and the rest 60% − 35% remained in [P6,6,6,14][NTf2] 
(Table 4.2). Thus, the biphasic system can only partially reduce the product 
toxicity and inhibition. Nevertheless, since the product is less toxic and 
inhibitory than the substrate, biotransformation in such a system could still 
significantly enhance the product concentration and thus the productivity.  
As shown in Table 4.2, sulfoxidation of 1 in the biphasic system for 24 h gave 
(R)-2 in 20 mM, being two-fold higher than the 9.4 mM obtained from the 
mono-phasic control. Similarly, sulfoxidations of 3, 5, 7, and 9 in the biphasic 
system for 24 h enhanced the productivities and gave (R)-4 in 9.9 mM, (R)-6 
in 16 mM, (R)-8 in 22 mM, and (R)-10 in 24 mM, respectively. The product 
concentrations are 3-5 folds higher than those achieved in the mono-phasic 
control (1.9 − 5.7 mM) (Table 4.2). No further oxidation of the sulfoxides to 
the corresponding sulfones was found at 24 h.  
The reaction courses for the sulfoxidations in the biphasic system were 
demonstrated in Figure 4.6(a – c). The product concentrations in aqueous 
buffer, IL, and total were normalized based on the volume of aqueous phase 
and given at several selected time points. During biotransformations of sulfide 
1, 3, and 5, the corresponding products 2, 4, and 6 in aqueous phase amounted 
to 65% − 67%, 55% − 60%, and 37% − 41%, respectively, while over 99% of 




Figure 4.6 (a-c) Time courses of asymmetric sulfoxidations with resting cells of E. 
coli (P450pyrI83H-GDH) (10 g CDW/L) in KP buffer (100 mM, pH 
8.0)/[P6,6,6,14][NTf2] biphasic system (3: 1, v/v) containing 2% (w/v) glucose at 30°C 
and 250 rpm. All concentrations were normalized based on the volume of aqueous 
phase. (a) Sulfoxidation of 1 (60 mM). (b) Sulfoxidation of 3 (30 mM). (c) 
Sulfoxidation of 5 (40 mM). (d) Time courses of asymmetric sulfoxidations of 10 
mM 1, 3, and 5 with resting cells of E. coli (P450pyrI83H-GDH) (10 g CDW/L) in 
mono-phasic KP buffer (100 mM, pH 8.0) containing 2% (w/v) glucose at 30°C and 
250 rpm, respectively. Data are the mean values with standard deviations of 3 
replicates. 
faster in the first 9 h, 12 h, and 9 h, respectively, and became slower 
afterwards. The time courses of the sulfoxidations in the mono-phasic buffer 
were given in Figure 4.6(d). In comparison, the biphasic system demonstrated 
a much longer period for faster reaction and gave higher product concentration 
at late time points than the mono-phasic one. The enhancement was mainly 
caused by the reduction of the substrate inhibition via keeping a very low 
substrate concentration in aqueous buffer (initial concentration of 0.15 mM, 
0.10 mM, and 0.08 mM for sulfide 1, 3, and 5, respectively) of the biphasic 
system. Moreover, the product inhibition was also reduced by in situ partial 
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extraction of the product into IL during reaction. As the apparent Ki values for 
(R)-2, (R)-4, and (R)-6 were 2.0 mM, 1.2 mM, and 1.5 mM, respectively, 
biotransformation of 1 to (R)-2 showed better tolerance to higher product 
concentration in aqueous buffer of the biphasic system than other two 







) for the sulfoxidation of 1 contributed to the higher product 
concentration of (R)-2, in comparison with the sulfoxidation of 3 or 5. 
4.3.6 Enhancements of enantioselectivities of asymmetric sulfoxidations 
with E. coli (P450pyrI83H-GDH) cells in KP buffer/[P6,6,6,14][NTf2] 
biphasic system.  
The biphasic system was found to enhance the enantioselectivities for the 
asymmetric sulfoxidations. Shown in Table 4.2 & Figure 4.7, sulfoxidations 
 
Figure 4.7 Product ee from asymmetric sulfoxidations of 1, 3, 5, 7, and 9 with resting 
cells of E. coli (P450pyrI83H-GDH) in KP buffer/[P6,6,6,14][NTf2] (3: 1, v/v) biphasic 
system and KP buffer mono-phasic system, respectively. 
of 1, 3, and 5 in the biphasic system gave (R)-2 in 99% ee, (R)-4 in 98% ee, 
and (R)-6 in 96% ee, respectively. These values are much higher than the 
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corresponding product ee of 85%, 80%, and 88% from the mono-phasic 
control experiments (Table 4.2, 4.5, and 4.6).  
Table 4.6 Ee values of the sulfoxides produced in asymmetric sulfoxidation of 1, 3, 5, 
7, or 9 with resting cells of E. coli (P450pyrI83H-GDH) in KP buffer/[P6,6,6,14][NTf2] 
biphasic system at different phase ratios and mono-phasic KP buffer system 






Product ee (%) 
Phase ratio (v/v) of the biphasic system  
KP buffer 
20: 1 10: 1 5: 1 3: 1  
1 to 2 10.0      85.4 0.4 
1 to 2 20.0 97.6 0.9     85.5 0.0 
1 to 2 30.0 97.1 0.2     85.9 0.2 
1 to 2 40.0 96.5 0.5 98.5 0.9 99.4 0.0   86.0 0.1 
1 to 2 50.0 96.6 0.2 98.4 0.0 99.6 0.1 99.2 0.0  85.6 0.0 
1 to 2 60.0   99.6 0.0 99.5 0.0   
1 to 2 70.0 96.0 0.1 98.6 0.3 99.7 0.1 99.5 0.0   
1 to 2 90.0  97.5 0.4 99.7 0.1 99.6 0.2   
1 to 2 100   99.6 0.2 99.8 0.1   
1 to 2 120    99.6 0.0   
3 to 4 10.0      80.2 0.4 
3 to 4 20.0   96.6 0.8 99.3 0.5  79.0 0.5 
3 to 4 30.0   96.4 0.6 98.2 0.5   
3 to 4 40.0   96.3 0.0 97.8 0.0   
3 to 4 50.0   96.4 0.8    
5 to 6 10.0      88.3 0.6 
5 to 6 20.0   94.5 0.0 95.7 0.2  87.9 0.3 
5 to 6 30.0   94.3 0.7 94.5 0.1   
5 to 6 40.0   93.6 0.0 96.0 1.6   
5 to 6 50.0   93.3 0.2    
7 to 8 10.0      35.2 0.0 
7 to 8 20.0   51.8 0.2   35.6 0.2 
7 to 8 30.0   44.7 0.0    
7 to 8 40.0   44.0 0.0 61.8 0.0   
9 to 10 10.0      52.8 0.1 
9 to 10 20.0   67.3 0.1   52.3 0.4 
9 to 10 30.0   56.9 0.0    
9 to 10 40.0   54.4 0.0 66.9 0.0   
a
Asymmetric sulfoxidations (AS) with the freshly prepared resting cells of E. coli 
(P450pyrI83H-GDH) (10 g CDW/L) were carried out at 30°C and 250 rpm for 24 h; 
unless stated otherwise, 2% (w/v) glucose and cell density (10 g CDW/L) were based 
on the volume of the aqueous phase; KP buffer used was 10 mL, 100 mM, and pH 8.0; 
data are the mean values with standard deviation of 3 replicates. 
b
Initial substrate 
concentrations (ISC, in mM) at 0 h were normalized based on the volume of the 
aqueous phase.   
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Similar enhancement of chemoselectivity in biohydroxylation of camphor in 
aqueous-organic two-phase system was observed through the gradually supply 
of the substrate to aqueous phase from the organic phase.
[95]
 The 
enhancements in enantioselectivity in our cases are also possibly caused by the 
low substrate concentrations in the aqueous phase of the biphasic system. This 
was further evidenced by the sulfoxidation of 1 mM sulfide 1 with the resting 
cells of E. coli (P450pyrI83H-GDH) (10 g CDW/L) in mono-phasic KP buffer 
to give (R)-2 in 97% ee.  
Moreover, lower ratio of aqueous buffer to [P6,6,6,14][NTf2] (v/v) in the 
biphasic system tended to give higher product ee  in the asymmetric 
sulfoxidation (Table 4.5 & 4.6). For example, sulfoxidation of 40 mM sulfide 
1 in KP buffer/[P6,6,6,14][NTf2] gave (R)-2 in 96%, 98%, and 99% ee at phase 
ratios (aq. to IL, v/v) of 20:1, 10:1, and 5:1, respectively. Here again, the 
enhancements in enantioselectivity are possibly caused by the low substrate 
concentrations in the aqueous phase of the biphasic system, since the sulfide 
concentration in the aqueous phase at the three phase ratios was 0.32, 0.19, 
and 0.17 mM, respectively (Table 4.5 & 4.6). Similarly, sulfoxidation of 
sulfide 3 (30 mM), 5 (40 mM), 7 (40 mM), or 9 (40 mM) at a phase ratio (aq. 
to IL, v/v) of 5:1 and 3:1 gave product (R)-4 in 96% and 98% ee, (R)-6 in 94% 
and 96% ee, (R)-8 in 44% and 62% ee, or (R)-10 in 54% and 67% ee, 
respectively (Table 4.5 & 4.6). The change of enantioselectivity at different 
substrate concentration might be explained as followings: higher substrate 
concentrations might change the conformation of enzyme and hence alter the 
enzyme enantioselectivity.  
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4.3.7 Preparation of sulfoxides (R)-2, (R)-4, and (R)-6 by asymmetric 
sulfoxidations with resting cells of E. coli (P450pyrI83H-GDH) in KP 
buffer/[P6,6,6,14][NTf2] biphasic system.  
As can been seen in Table 4.5 and Figure 4.6, the IL can harbor quite an 
amount of sulfoxide products for product inhibition prevention. Therefore, the 
sulfoxides reside in IL should be considered when conducting preparation. 
One of the advantages of using KP buffer/[P6,6,6,14][NTf2] biphasic system is to 
provide a convenient separation of sulfoxide product from sulfide substrate. 
As demonstrated in Figure 4.8, after 3 − 5 rounds of eluting product out from 
IL [P6,6,6,14][NTf2], over 90% of the sulfoxide products could be washed out, 
while the sulfide substrate IL [P6,6,6,14][NTf2] was hardly washed out. 
 
Figure 4.8 Recovery of sulfoxide (R)-4 or (R)-6 from [P6,6,6,14][NTf2] by washing 
with water. (a) For (R)-4. (b) For (R)-6. Sulfide (black); sulfoxide (grey). Data are the 
mean values with standard deviation of 3 replicates. 
The potential of using the KP buffer/[P6,6,6,14][NTf2] biphasic system for 
asymmetric bio-sulfoxidations to prepare chiral sulfoxides in high ee was 
explored. Oxidations of sulfides 1 (60 mM), 3 (30 mM), and 5 (40 mM) were 


































































for 24 h, respectively. After separation of the two phases, the aqueous phase 
contains mainly the sulfoxides, and the IL phase contains both unreacted 
sulfides and the sulfoxides products. Water was added to IL to extract the 
sulfoxides, and the aqueous solutions were combined and then extracted with 
ethyl acetate. The organic phase was dried over Na2SO4, the solvent was 
removed by evaporation, and the crude sulfoxides were purified by flash 
chromatography on a silica gel column. As shown in Table 4.7, the useful and 
valuable sulfoxides (R)-2, (R)-4, and (R)-6 were obtained in 99%, 98%, and 96%  
Table 4.7 Ee values and specific optical rotations of the sulfoxides (R)-2, (R)-4, and 
(R)-6 prepared by asymmetric sulfoxidations of 1, 3, and 5 with resting cells of E. 
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26 = −134.5 [(S), 99% 
ee]} 
(R)-4 
   
98 (R) 
[𝛼]D




20 = −120.0 [(S), 91% 
ee]}  
(R)-6 
    
96 (R) 
[𝛼]D




25 = +154 [(R), 86% 
ee]} 
a
Products (R)-2, 4, and 6 were prepared from asymmetric sulfoxidation of 1 (60 mM), 
3 (30 mM), and 5 (40 mM) with freshly prepared resting cells of E. coli 
(P450pyrI83H-GDH) (15 g CDW/L) in KP buffer/[P6,6,6,14][NTf2] biphasic system at 
phase ratio of 3: 1 at 30°C and 250 rpm for 24 h, respectively. Unless stated 
otherwise, 2% (w/v) glucose, substrate concentration and cell density (15 g CDW/L) 
were based on the volume of the aqueous phase; KP buffer mentioned was 50 mL, 
100 mM and pH 8.0.   
ee, respectively, and in 89 mg, 52 mg, and 59 mg, respectively. Since high 
substrate concentration was used, the yields amounted to 21 − 19% for (R)-2, 
4, and 6. Nevertheless, 119 mg (R)-2, 69 mg (R)-4, and 79 mg (R)-6 were 
produced by using 1 gram of dry cells, respectively. In another preparative 
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experiment, (R)-phenyl methyl sulfoxide 4 was obtained in 98% ee and 68% 
isolated yield from the sulfoxidation of 4-fluorothioanisole 3 (10 mM). 
4.4 Conclusion 
Recombinant E. coli (P450pyrI83H-GDH) co-expressing three-component 
P450pyrI83H monooxygenase and glucose dehydrogenase (GDH) was 
engineered for biocatalytic asymmetric sulfoxidations of thioanisole 1, 4-
fluorothioanisole 3, phenylthioethane 5, p-methylthioanisole 7, and 4-
methoxythioanisole 9, respectively, with co-factor recycling, giving higher R-
enantioselectivity and higher specific activity than any other known P450 
monooxygenases for this type of reaction. While the substrates and the 
corresponding products demonstrated strong toxicity to the cells and inhibition 
to the sulfoxidations, these problems were solved by developing a suitable KP 
buffer/IL biphasic system for the biotransformations. [P6,6,6,14][NTf2] showed 
excellent biocompatibility for the growth of E. coli (P450pyrI83H-GDH) cells 
and ability to shield much of the substrate toxicity to the cells, being an ideal 
co-solvent in the KP buffer/IL biphasic system for efficient biooxidations. 
Sulfoxidations of 1, 3, 5, 7, and 9 with resting cells of E. coli (P450pyrI83H-
GDH) in KP buffer/[P6,6,6,14][NTf2] at a ratio of 3:1 (v/v) significantly 
enhanced both enantioselectivity and productivity. In comparison with the 
mono-phasic KP buffer system, the product concentration was increased from 
9.4 mM to 20 mM for (R)-phenyl methyl sulfoxide 2, from 1.9 mM to 9.9 mM 
for (R)-4-fluorophenyl methyl sulfoxide 4, from 5.4 mM to 16 mM for (R)-
ethyl phenyl sulfoxide 6, from 4.2 mM to 22 mM for (R)-methyl p-tolyl 
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sulfoxide 8, and from 5.7 mM to 24 mM for (R)-methyl p-methoxyphenyl 
sulfoxide 10, respectively; the product ee was enhanced from 85% to 99% for 
(R)-2, from 80% to 98% for (R)-4, from 88% to 96% for (R)-6, from 35% to 
62% for (R)-8, and from 53% to 67% for (R)-10, respectively. In such a 
biphasic system, >99% of the substrates and 35 − 60% of the products 
remained in IL, thus greatly reducing the substrate toxicity and inhibition and 
partially reducing the product toxicity and inhibition. Accordingly, 
biotransformation in such a biphasic system significantly enhanced the 
product concentration. The enhancements in enantioselectivity are possibly 
caused by the low substrate concentrations in the aqueous phase of the 
biphasic system, evidenced by the higher enantioselectivity observed in the 
sulfoxidation of 1 at a smaller substrate concentration in aqueous system and 
the sulfoxidations of 1, 3, 5, 7, and 9 in the biphasic system at a lower ratio of 
aqueous phase to IL (v/v). Preparative sulfoxidations of 1, 3, and 5 in the 
biphasic system gave a green method to produce the useful and valuable 
sulfoxides (R)-2, (R)-4, and (R)-6 in 99%, 98%, and 96% ee, respectively. To 
our knowledge, it is the first report on the engineering of a biphasic system 
with IL to enhance both the enantioselectivity and productivity for a 
biooxidation reaction. For the first time, IL is successfully used as cosolvent in 
a biphasic system for a P450 monooxygenase-catalyzed oxidation. Our 
experiments show that solvent engineering with IL as a cosolvent is a simple 
and useful way for improving the catalytic performances of a biooxidation. 
The biphasic system with IL provides with a green and potent reaction 






CHAPTER V.  
ENHANCING PRODUCTIVITY FOR OXIDATIVE 
CASCADE BIOTRANSFORMATION OF STYRENE 
TO (S)-VICINAL DIOL BY USING 
AQUEOUS/ORGANIC BIPHASIC SYSTEM IN 






Biotransformation is a useful and green tool to produce enantiopure 
compounds as important building blocks for pharmaceutical manufacture 
which forms the greatest share of life-science market.
[1 – 6, 39] Recent progress 
in biotechnology enables successful cascade biotransformation in one pot, 
where multiple enzymes complimentary with each other in functioning could 
be expressed at high level within the same cell envelop. This cascade 
biocatalysis emerges as an efficient and green tool in the sustainable 
production for both chemical and biochemical compounds, where it enables 
selectively biocatalytic conversion without the labor- and time-consuming, 
yield-decreasing, waste-producing, and costly purification of the 
intermediates,
[1, 18, 46, 58, 126]
 and cascade biocatalysis can convert the non-
natural substrates by using the special designed combination of tandem 
enzymes which can work cooperatively and innovatively.
[46, 58, 126, 254 – 256]
 In 
comparison with the traditional tandem chemical synthesis, cascade 
biocatalysis is featured with alike mild reaction conditions required for 
different enzymes, environmentally benign, and highly chemo-, regio-, and 
stereoselectivity attained.
[1, 18, 46, 58, 126]
  
Despite its great achievements, many cascade biocatalysis reactions suffer 
from the toxic and inhibitory effects inherent to the organic substrates and 
products, exhibiting unsatisfied productivities. For example, deracemization of 
the racemic mandelic acids for the production of enantiopure (R)-(–)-mandelic 
acid by using an oxidase and a reductase concurrently was hampered by 





 To tackle the inhibition and toxicity, using a solid-
liquid biphasic system with solid particle (e.g., resin) as adsorbent for 
adsorption and mild delivery is a good choice for enhancing productivities for 
many types of biotransformations,
[206, 208, 209, 226 – 230]
 whereas this approach 
was criticized for low sorption (i.e., adsorption and desorption) capacities and 
poor diffusion coefficient.
[198, 257]
 Another conventional approach to prevent 
the toxicity and inhibition is to use a TDPB system, where a secondary phase 
made of organic solvents or ionic liquids could be used as the cosolvent to 
harbor the majority of the toxic substrate and product for preventing toxicity 
and inhibition.
[39, 73, 91 – 93, 210]
 However, the cosolvents in TDPB system could 
potentially impair the membrane integrity,
[39, 69]
 causing hazardous effects to 
the biocatalyst. In addition, emulsion-promoting biosurfactant produced by the 
microbial biocatalyst could cause foaming and emulsification and thus incur 
extra burden in solvent reuse and product purification.
[198 – 200, 257]
 
We noticed that different biphasic systems with various organic solvents as the 
cosolvents were established in HFMB for better conducting different 
biooxidations.
[219 – 222]
 In these reported HFMB-based biphasic systems, all the 
problems associated with the TDPB system could be solved successfully, 
where the aqueous phase and the organic phase could be thoroughly separated 
by membranes and aqueous-organic phase interface could be immobilized in 
the membrane pores.
[198 – 200, 219 – 222, 257]
 HFMB-based biphasic system could 
provide with independent flow rate, compact design, well-controlled modular 
parameters, and high specific interfacial area,
[198, 199]
 where the non-dispersive 





 Furthermore, compact design of HFMB-based 
biphasic system enables easier modeling, optimization, scaling up, and 
continuous operation, where the extra mass transfer resistance owing to the 
membrane could be decreased by expanding the interfacial areas.
[198]
 Despite 
great achievements made as a green and efficient reaction platform, this 
promising HFMB-based biphasic setup has not hitherto been used for the 
cascade oxidative biotransformation, and the reported biooxidations in the 
HFMB-based biphasic system with organic cosolvent sometimes provided yet 
satisfactory production titers.
[219 – 222]
 For example, Dihydroxylation of toluene 
to 3-methylcatechol in HFMB-based aq./octane biphasic system can only give 
ca., 3.5 mM production titer.
[220]
 As shown in Figure 5.1, we reported the first 
 
Figure 5.1 Biocatalytic trans-dihydroxylation of styrene for producing (S)-1-phenyl-
1,2-ethanediol with E. coli (SSP1) coexpressing SMO for epoxidation and SpEH for 
epoxide hydrolysis via cascade reactions in HFMB-based aq./org. biphasic system. 
HFMB-based biphasic system to enhance the productivity for the model 
oxidative cascade biotransformation of styrene to give the corresponding (S)-
vicinal diol, as a trans-dihydroxylation via epoxidation and sequential 
hydrolysis, with recombinant whole cells of E. coli (SSP1) coexpressing SMO 
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for epoxidation and SpEH for hydrolysis as the tandem biocatalyst. The 
combination of biphasic system with HFMB can give higher production titer 
with prevention of both toxicity and the undesirable phenomenon in traditional 
TDPB systems. The success of this work signifies that bioprocess engineering 
via establishing HFMB-based biphasic system could be a suitable platform for 
conducting the biooxidations on industrial scale. 
5.2 Materials and methods 
5.2.1 Chemicals and organic solvents 
Kanamycin disulfate salt (>99%) and isopropyl β-D-1-thiogalactopyranoside 
(>99%) was purchased from Sigma. Medium components LB premix, tryptone, 
and yeast extract were purchased from Biomed Diagnostics, USA. Styrene 
(>99%) was purchased from Sigma. Unless stated otherwise, all the inorganic 
salts for the medium preparations were purchased from Sigma. 
Organic solvents including 1-octanol, 2-undecanone, ethyl acetate, 
cyclohexane, n-hexadecane were purchased from Sigma. n-Octane was 
purchased from Merck. 
5.2.2 Strain and medium compositions 
Genetic recombinant E. coli (SSP1) constructed previously
[58]
 were preserved 
the in − 80○C ultra freezer and were used as the whole cell biocatalyst.  




 contained yeast 
extract (24 g/L), trypton (12 g/L), glycerol (5 g/L), KH2PO4 (2.31 g/L), and 
K2HPO4 (12.54 g/L), MgSO4 (0.24 g/L), and trace element [1 mL stock trace 
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solution (1000 ×) per litter medium]. IM9 medium
[259]
 was composed of 
Na2HPO4·2H2O (8.5 g/L), KH2PO4 (3.0 g/L), NaCl (0.5 g/L), NH4Cl (1.0 g/L), 
MgSO4 (0.24 g/L), and trace element [1 mL stock trace solution (1000 ×) per 
litter medium]. Stock trace solution (1000 ×) is composed of FeSO4·7H2O 
(4.78 g/L), MnCl2·4H2O (1.50 g/L), ZnSO4 (1.05 g/L), CuCl2·2H2O (0.15 g/L), 
H2BO3 (0.30 g/L), Na2MoO4·2H2O (0.25 g/L), and disodium EDTA·2H2O 
(0.84 g/L). Media were sterilized in autoclave at 121
○
C for 20 min. 
5.2.3 Analytical methods 
For compounds in aqueous phase, the concentrations of the substrate styrene, 
the product (S)-1-phenyl-1,2-ethanediol and the intermediate styrene oxide 
were analyzed by using a Waters HPLC on an Agilent Poroshell 120 EC-C18 
column (150 mm × 4.6 mm; 2.7 µm). UV detection: 210 nm; flow rate: 0.4 
mL/min; eluent: acetonitrile/water (60: 40, v/v); retention time: 4.8 min for 
product (S)-1-phenyl-1,2-ethanediol; 14.8 min for substrate styrene; 8.2 min 
for styrene oxide. 
For compounds in organic phase, the concentrations of the substrate styrene, 
the product (S)-1-phenyl-1,2-ethanediol and the intermediate styrene oxide 
were analyzed by using a Perkin Elmer Clarus 600GC equipped with a flame 
ionization detector on Elite-5 capillary column (30 m × 320 µm × 0.25 µm). 
Helium was used as the carrier gas at a flow rate of 1.0 mL/min, and the 
detector temperature was 250°C. The temperature was programmed as 120°C 
(0 min)-30°C/min-300°C (2 min). Retention time: 3.08 min for substrate 




5.2.4 Cell growth and specific dihydroxylation activity of E. coli (SSP1)  
Cryogenic E. coli (SSP1) cells (preserved at − 80°C) were inoculated into 20 
mL LB medium containing 50 µg/mL kanamycin. Incubation was conducted 
at 37°C and 250 rpm for 12 h in a tribaffled flask to prepare the seed. The 
seeds (3 − 5%, v/v) were then introduced to 50 mL TB medium containing 50 
µg/mL kanamycin in a tribaffled flask. Incubation was carried out at 37°C and 
250 rpm for 2 h to reach an OD600 of 0.5 to 0.8. IPTG was added to a final 
concentration of 0.25 mM for induction, followed by incubation at 25°C. 
Samples at different time points were taken for the analysis of the cell density 
and the specific activity. For biotransformation with resting cells, the E. coli 
cells were harvested at late exponential phase at 10 h and used as the fresh 
biocatalyst.  
The specific activity for trans-dihydroxylation of styrene was tested with the 
cell density 1.0 g CDW/L in (10 mL KP buffer, 200 mM, pH 8.0) containing 5 
mM styrene and glucose (2%, w/v) at 30°C and 250 rpm for the initial 15 min. 
Product formed was analyzed by HPLC, and the analytical samples were 
prepared as follows: reaction solution (0.5 mL) was mixed with 0.5 mL 
ethanol containing 2 mM acetophenone as internal standard; the mixture was 
centrifuged at 13000 g for 5 min, and the supernatant was analyzed by HPLC. 
The specific activity was then calculated in U/g CDW. 1 U is defined as 1 
µmol product formed per minute. 
5.2.5 Toxicity of the substrate and product on E. coli (SSP1).  
Freshly prepared E. coli (SSP1) cells were re-suspended to a cell density of 10 
g CDW/L in 30 mL KP buffer (200 mM; pH 8.0). The cell suspension (30 mL) 
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was divided equally into three flasks, and each flask contains 10 mL cell 
suspension. Substrate styrene and product (S)-1-phenyl-1,2-ethanediol were 
added into two flasks to a final concentration of 50 mM, respectively. The 3
rd
 
flask served as the control without the addition of substrate or product. The 
mixtures in the three flasks were shaken at 30°C and 250 rpm for 10 h, 
followed by washing with KP buffer (200 mM; pH 8.0) for 10 times to totally 
remove styrene and (S)-1-phenyl-1,2-ethanediol.   
The cells pretreated with the substrate and the product were examined for 
specific activity of the styrene trans-dihydroxylation, by using the procedures 
described above. The control cells without pretreatment by the substrate and 
product were also tested of specific activity. The residual activity was defined 
as the ratio of the specific activity of pretreated cells to that of the control cells 
(i.e., without pretreatment).  
The viability of the pretreated cells was checked via inoculation of diluted 
cells onto the LB agar plate at 37°C for 12 h, followed by counting the number 
of the colonies. The cell viability was defined as the ratio of the colony 
number for cells pretreated by the substrate or product to the colony number 
for control cells (i.e., without pretreatment). 
5.2.6 Biodegradability of different organic solvents with E. coli (SSP1)  
Seed of E. coli (SSP1) was prepared as previously described. The seed (5%, 
v/v) were inoculated in 7 tribaffled flasks with each one containing IM9 
medium (20 mL), respectively. The cells in the IM9 medium were grown in 
tribaffled flask at 30°C and 250 rpm for 24 h. The organic solvent (i.e., 1-
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octanol, 2-undecanone, ethyl acetate, cyclohexane, n-octane, and n-
hexadecane) was added to the 6 tribaffled flasks at 0 h (0.02%, v/v), 6 h 
(0.03%, v/v), and 12 h (0.05%, v/v), respectively. The 7
th
 tribaffled flask 
without adding any organic solvent served as the control. OD600 of E. coli 
(SSP1) at 0 h, 12 h, and 24 h were recorded. 
5.2.7 Biocompatibility of different organic solvents with E. coli (SSP1)  
Seed of E. coli (SSP1) was prepared as previously described. The seed (3%, 
v/v) were inoculated in 7 tribaffled flasks with each one containing LB 
medium (20 mL). The cells in the LB medium were grown in tribaffled flask 
at 30°C and 250 rpm. When reaching the exponential phase (OD600 1.0), 6 
tribaffled flasks were added with the organic solvent of 1-octanol, 2-
undecanone, ethyl acetate, cyclohexane, n-octane, and n-hexadecane, 
respectively, at phase ratio of 10: 1 (aq./organic, v/v). The 7
th
 tribaffled flask 
without adding any organic solvent served as the control. Record the OD600 for 
E. coli (SSP1) after 1 h cell growth at the same conditions.  
5.2.8 Partitioning coefficient determination for substrate and product 
Substrate styrene (11.5 µL, i.e., 100 mM), intermediate styrene oxide (11.4 µL, 
i.e., 100 mM) and product (S)-1-phenyl-1,2-ethanediol (13.8 µg, i.e., 100 mM) 
were added to the KP buffer (1 mL, 200 mM, pH 8.0), respectively. Organic 
solvent (1 mL) of 1-octanol, 2-undecanone, ethyl acetate, cyclohexane, n-
octane, or n-hexadecane was added to the KP buffer (1 mL, 200 mM, pH 8.0) 
containing styrene (100 mM, concentration on the basis of the KP buffer), 
styrene oxide (100 mM, concentration on the basis of the KP buffer), or (S)-1-
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phenyl-1,2-ethanediol (100 mM, concentration on the basis of the KP buffer) 
to form different biphasic systems of aq./1-octanol, aq./2-undecanone, 
aq./ethyl acetate, aq./cyclohexane, aq./n-octane, or aq./n-hexadecane. The 
mixture was then shaken at 30°C and 250 rpm for 3 h, and the aqueous phase 
and the organic phase was analyzed by HPLC and GC, respectively. For 
HPLC analysis, the KP buffer was combined with ethanol containing 
acetophenone as internal standard; the mixture was centrifuged at 13000 g for 
1 min, and the supernatant was analyzed by HPLC. For GC analysis, organic 
solvent (i.e., 1-octanol, 2-undecanone, ethyl acetate, cyclohexane, n-octane, or 
n-hexadecane) was dissolved in dichloromethane for GC analysis. Partition 
coefficient was defined as the ratio of the solute concentration in organic 
phase to the solute concentration in aqueous phase. 
5.2.9 Trans-dihydroxylation of styrene with E. coli (SSP1) in monophase 
Freshly prepared E. coli (SSP1) were suspended to a density of 10 g CDW/L 
in KP buffer (10 mL, 200 mM; pH 8) containing 2% (w/v) glucose. Styrene 
was added into 10 mL cell suspension. The trans-dihydroxylation was carried 
out at 30°C and 250 rpm. During the biotransformation, samples were taken at 
different time points for monitoring the oxidative cascade biotransformation of 
trans-dihydroxylation. The product concentration was analyzed by HPLC, 
with sample prepared as given above. 
5.2.10 Trans-dihydroxylation with E. coli (SSP1) in TDPB system 
Freshly prepared cell pellets of E. coli (SSP1) were suspended to a density of 
10 g CDW/L in KP buffer (10 mL, 200 mM; pH 8) containing 2% (w/v) 
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glucose. Then, 10 mL organic solvent (i.e., 1-octanol, 2-undecanone, ethyl 
acetate, cyclohexane, n-octane, or n-hexadecane) containing styrene at 
different concentrations (on the basis of the KP buffer) was added into 10 mL 
cell suspension to form a TDPB system at phase ratio of 1: 1. The trans-
dihydroxylation was carried out at 30°C and 250 rpm. During the 
biotransformation, samples were taken at different time points for monitoring 
the oxidative cascade biotransformation of trans-dihydroxylation, and the 
substrate and product was analyzed by HPLC and GC. Analytical samples 
were prepared as previously described. 
5.2.11 Trans-dihydroxylation with E. coli (SSP1) in HFMB-based biphase 
Freshly prepared cell pellets of E. coli (SSP1) were first suspended to a 
density of 10 g CDW/L in KP buffer (200 mM; pH 8) containing 2% (w/v) 
glucose, by using the procedures as described previously.  
Polypropylene was used to fabricate HFMB (Figure 5.2) with inner fiber 
diameter 280 µm, average pore size 0.1 µm, fiber thickness 30 µm, and fiber 
length 50 cm.
[198 – 200]
 Before the biotransformation, deionized (DI) water was 
pumped through the lumen side within the fibers in HFMB at flow rate of 5 
mL/min for 12-18 h for wetting the membrane by using the peristaltic pump 
(Masterflex). After wetting, the deionized water was drained out of the lumen 
side and the organic solvent (i.e., cosolvent of the biphasic system) was 
pumped through the shell side of the HFMB at flow at flow rate of 5 mL/min 
for 12-18 h by using the peristaltic pump (Masterflex with PTFE tubing pump 
head). For conducting the trans-dihydroxylation of styrene, the aqueous phase 
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of the cell suspension (10 g CDW/L, freshly prepared by the procedures as 
described previously) and the organic solvent with substrate laden was 
pumped through the lumen side and shell side of the hollow fiber membrane 
 
Figure 5.2 Schematics of HFMB-based aq./org. biphasic system for biooxidation. 
bioreactor by the corresponding peristaltic pumps, respectively. The flow rates 
for aqueous phase in lumen side and organic phase in shell side were 15 
mL/min. During the trans-dihydroxylation of styrene, samples were taken 
with regular time interval for monitoring the reaction by measuring the 
product concentration. The concentration of product (S)-1-phenyl-1,2-
ethanediol in the aqueous phase was analyzed by HPLC, and samples were 
prepared as described previously. 
5.3 Results and discussion 
5.3.1 Trans-dihydroxylation with E. coli (SSP1) in aqueous monophase 
Oxidative cascade biocatalyst of E. coli (SSP1)
[58]
 contained the widely-





Organic solvent in 
shell side




of styrene and the sequential hydrolase of SpEH from Sphingomonas sp. 
HXN-200 for “β” opening of styrene oxide to give (S)-1-phenyl-1,2-ethanediol 
(Figure 5.1),  which can be used as crucial pharmaceutical precursor for (R)-
fluoxetine,
[260]
 chiral ligand of phosphoramidite,
[261]
 and an useful auxiliary for 
glycosylation.
[262]
 The cell growth and specific dihydroxylation activity of E. 
coli (SSP1) are given in Figure 5.3. Cells were cultured in TB at 37°C, and 
induction was triggered at 2 h by adding IPTG, followed by incubation at 
lower temperature of 25°C to reduce inclusion body formation and incorrect 
folding due to the fast cell growth at higher temperature. The specific trans-
dihydroxylation activity at 8 – 12 h reached 71.8 – 88.0 U/g CDW at the late 
exponential and the early stationary phases, and the E. coli (SSP1) cells could  
 
Figure 5.3 Cell growth and specific activity curves for trans-dihydroxylation of 
styrene with E. coli (SSP1). Arrow indicating induction by adding IPTG to the 
concentration of 0.25 mM at 2 h.  
then be harvested for the preparation of fresh resting cells as robust whole cell 
biocatalyst for the trans-dihydroxylation of styrene to give (S)-1-phenyl-1,2-
ethanediol. However, the trans-dihydroxylation production titer in the aqueous 
monophase (Figure 5.4) was much lower than the expected value on the basis 






















































prepared biocatalyst of E. coli (SSP1), which clearly showed the effects of 
toxicity and inhibition. Shown in Figure 5.4, as the substrate concentration  
                    
Figure 5.4 Trans-dihydroxylation of styrene with E. coli (SSP1) (10 g CDW/L) in 
KP buffer (10 mL; 200 mM; pH 8.0) containing glucose [glucose (1%, w/v) was 
added at 0 h and 6 h, respectively] at 30°C and 250 rpm for 24 h.   
increased, the product titer first increased and then reduced drastically, which 
might be caused by the deterioration of the membrane integrity owing to the 
substrate toxicity at high concentration, thus disrupting the electron 
transferring mechanism and then deactivating the enzyme in vivo. Therefore, a 
secondary phase immiscible with the aqueous phase was required to dissolve 
most of the toxic substrate for controlled and mild delivery of the substrate to 
aqueous phase for better biotransformation performance. 
5.3.2 Toxicity and inhibition of substrate and product on E. coli (SSP1) 
The toxicity and inhibition were studied by adding substrate styrene (50 mM) 
and product (S)-1-phenyl-1,2-ethanediol (50 mM), respectively, to the fresh 
cell suspension (10 g CDW/L) of E. coli (SSP1) in KP buffer (200 mM, pH 






























viable after the pretreatment with substrate styrene, while the survival ratio for 
cells pretreated with (S)-1-phenyl-1,2-ethanediol were up to 43% (Figure 5.5). 
Similar situation went to the residual activity, where the cells pretreated by  
 
Figure 5.5 Viability and residual activity of E. coli (SSP1) cells after pretreatment 
with the substrate or product. (a) Cell viability. (b) Residual activity.  
styrene and the product (S)-1-phenyl-1,2-ethanediol showed 0.5% and 66% of 
the activity obtained in the control without pretreatment (Figure 5.5), which 
demonstrated that substrate styrene was much more toxic and inhibitory than 
the product (S)-1-phenyl-1,2-ethanediol. Therefore, reducing the substrate 
toxicity and inhibition is the main task. 
5.3.3 Investigation on the biodegradability, biocompatibility, and 
partition coefficient during solvent selection for establishing aq./org. 
biphasic system  
For establishing the aq./org. biphasic system, 6 different organic solvents (i.e., 
1-octanol, 2-undecanone, ethyl acetate, cyclohexane, n-octane, and n-
hexadecane) were examined for the biodegradability, biocompatibility, and 


























































Biodegradability could show the capability of the microbial biocatalyst in 
metabolizing the organic cosolvent, which could complicate the 
biotransformation or even compete with the biotransformation substrate for 
accessing the biocatalyst. Therefore, in aq./org. biphasic system, the organic 
solvent should be recalcitrant to the biodegradation. To measure the 
biodegradability of these 6 organic solvents, E. coli (SSP1) were inoculated in 
IM9 medium (no carbon source) with organic solvent (i.e., 1-octanol, 2-
undecanone, ethyl acetate, cyclohexane, n-octane, or n-hexadecane) added as 
the sole carbon source, and OD600 was recorded to reflect the biodegradability. 
Shown in Figure 5.6, the control was without any organic solvent added, 
which should not show any further cell growth, however, there was an increase 
in the OD600 observed, which could be caused by the residual nutrient in the 
seed culture during the inoculation procedure. The rationale was that E. coli 
(SSP1) could show higher OD600 than the control if the cell could use the 
organic solvent (i.e., 1-octanol, 2-undecanone, ethyl acetate, cyclohexane, n-
octane, or n-hexadecane) as carbon source, and vice versa. Therefore, organic 
solvent could not be degraded by E. coli (SSP1) if OD600 did not exceed that 
of the control. As shown in Figure 5.6, after the inoculation and the 
introduction of the organic solvents (i.e., 1-octanol, 2-undecanone, ethyl 
acetate, cyclohexane, n-octane, and n-hexadecane), E. coli (SSP1) showed 
OD600 values of 0.09, 0.13, 0.13, 0.18, 0.23, and 0.24 at 12 h with 1-octanol, 
2-undecanone, ethyl acetate, cyclohexane, n-octane, and n-hexadecane added 
to the IM9 as the carbon sources, respectively, which did not exceed the OD600 
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value of 0.24 for the control. The similar situation was observed at 24 h, when 
E. coli (SSP1) showed OD600 of 0.07, 0.18, 0.09, 0.26, 0.34, and 0.39 with 1-
octanol, 2-undecanone, ethyl acetate, cyclohexane, n-octane, and n-
hexadecane added to the IM9, lower than the OD600 value of 0.40 for the 
control again. It was apparent that E. coli (SSP1) cell could not degrade the 
any of the 6 solvents as all the cell densities with the organic solvents added as 
carbon sources were lower than that of the control (no organic solvent added). 
                      
Figure 5.6 Cell growth of E. coli (SSP1) in IM9 minimum medium with different 
organic solvents as sole carbon sources at 30°C and 250 rpm.  
Biocompatibility demonstrates the adaptability of the cells to the organic 
solvent. Cells could be fragile, vulnerable, or deactivated in solvent with lower 
biocompatibility, and higher biocompatibility was more desired for choosing 
an organic solvent during establishing the aq./org. biphasic system, where the 
whole cell biocatalyst could be more protected for better enzymatic 
performance. In order the determine the biocompatibility, E. coli (SSP1) were 
first inoculated and cultivated in the natural rich medium of LB medium, 




















acetate, cyclohexane, n-octane, and n-hexadecane) to the cell culture broth, 
respectively, and OD600 was recorded for reflection of the biocompatibility. 
Shown in Figure 5.7, OD600 for E. coli (SSP1) after adding the 6 organic 
solvents were 0.68, 1.03, 0.63, 1.04, 1.97, and 2.14 with 1-octanol, 2-
undecanone, ethyl acetate, cyclohexane, n-octane, and n-hexadecane added as 
the cosolvent, respectively. The control without adding any solvent gave the 
highest OD600 value of 2.27. Shown in Figure 5.7, n-hexadecane presented the 
highest biocompatibility due to highest optical density observed among all 
tested organic solvents, demonstrating that E. coli (SSP1) was more adaptive 
in presence of n-hexadecane and thus showed higher activity. 
                 
Figure 5.7 Cell growth of E. coli (SSP1) with LB medium in different 
aqueous/organic biphasic systems (phase ratio of aq./org. was 10: 1) at 30°C and 150 
rpm for 1h. 
Partition coefficient ([Solute conc. in org.]/[Solute conc. in aq.]) could reflect 
the capability of the solvent in dissolving the toxic organic substrate. Higher 
partition coefficient could be able to shield more toxicity as more solute being 
harbored in the water-immiscible phase, thus separating the concentrated toxic 
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2-undecanone, ethyl acetate, cyclohexane, n-octane, and n-hexadecane were 
determined to be 416, 244, 1731, 173, 179, and 284, respectively (Table 5.1). 
These high values demonstrate that the majority (>99%) of the styrene were in 
the organic phase of biphasic system, thus protecting biocatalyst from damage. 
On the other hand, partition coefficients of product (S)-1-phenyl-1,2-
ethanediol were low, and especially for cyclohexane, n-octane, and n-
hexadecane, partition coefficients were all below 0.01, demonstrating that >99% 
of the product would be in the aqueous phase. 
Table 5.1 Partition coefficient of styrene, styrene oxide, and (S)-1-phenyl-1,2-
ethanediol in different aq./org. biphasic systems. 
 
     
Aq./1-Octanol 416 39 81 3 3.0 0.2 
Aq./2-Undecanone 244 15 267 12 0.7 0.0 
Aq./Ethyl acetate 1731 76 289 6 3.3 0.2 
Aq./Cyclohexane 173 6 87 1 < 0.01 
Aq./n-Octane 179 19 59 2 < 0.01 
Aq./n-Hexadecane 284 26 58 1 < 0.01 
5.3.4 Trans-dihydroxylation with E. coli (SSP1) in TDPB systems with 
various organic solvents as cosolvents 
The trans-dihydroxylation of styrene (50 mM, concentration was normalized 
on the basis of the KP buffer) was conducted to produce (S)-1-phenyl-1,2-
ethanediol with E. coli (SSP1) in the different TDPB systems of aq./1-octanol, 
aq./2-undecanone, aq./ethyl acetate, aq./cyclohexane, aq./n-octane, and aq./n-
hexadecane, and results indicated that product titer (45 mM) given by using 
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TDPB of aq./n-hexadecane was the highest (Figure 5.8), which was 18 folds 
higher than the 2.5 mM product titer presented by the control in aqueous phase. 
TDPB systems of aq./1-octanol and aq./ethyl acetate, although high 
partitioning coefficients for styrene (i.e., 416 and 1731) exhibited, gave very 
low product titers of 2.39 and 2.07 mM, respectively (Figure 5.8), and this 
could be probably caused by low biocompatibilities for 1-octanol and ethyl 
acetate (Figure 5.7). Similarly, although n-octane and 2-undecanone 
demonstrated similar partition coefficients, aq./n-octane gave higher 
production titer of 39.9 mM than 19.8 mM of aq./2-undecanone, which was 
due to the higher biocompatibility of n-octane (Figure 5.7). 
                  
Figure 5.8 Trans-dihydroxylation of styrene (50 mM) with E. coli (SSP1) (10 g 
CDW/L) in different TDPB systems (phase ratio 1: 1, v/v) containing glucose 
[glucose (1%, w/v) was added at 0 h and 6 h, respectively] at 30°C and 250 rpm for 
24 h; All concentrations and cell density were normalized on the basis of the KP 
buffer. 
On the basis of results and discussion above, n-hexadecane was chosen as the 
desired organic solvent to establish an aq./org. biphasic system for the trans-




























5.3.5 Trans-dihydroxylation with E. coli (SSP1) in TDPB systems of 
aq./cyclohexane and aq./n-hexadecane 
Whole cell biocatalysis represents an elegant and practical way of producing 
fine chemicals, where the enzymes within the same cell envelop can show 
high stability and activity.
[23, 54, 64, 65, 69, 192]
 For the trans-dihydroxylation of 
styrene to (S)-1-phenyl-1,2-ethanediol with E. coli (SSP1), the SMO and 
SpEH were confined in the cell enclosure for higher catalytic performance, 
where the relaying of the cascade reaction between the SMO and SpEH can be 
much more efficient in the in vivo micro-environment. During this oxidative 
cascade biotransformation of styrene, SMO-catalyzed epoxidation was the 
rate-limiting step, and therefore the protection for the electron transferring 
mechanism owing to using the whole cell form can benefit the overall reaction 
of trans-dihydroxylation. To better protect the whole cell biocatalyst from the 
substrate toxicity (Figure 5.5), aq./org. biphasic system was established by 
adding the organic solvent with substrate laden into the cell suspension to 
form biphasic system and start the reaction. 
Shown in Figure 5.9, E. coli (SSP1) cells were harvested and re-suspended in 
the KP buffer containing the glucose, followed by adding organic solvent of n-
hexadecane with substrate at different concentrations, and phase ratio was set 
to be 1: 1 (v/v). In such a biphasic system, over 99% of the styrene was in the 
organic phase, leaving only a trace amount of styrene in the aqueous phase. 
Because of the low concentration, the styrene in the aqueous phase could be 
quickly converted to product of (S)-1-phenyl-1,2-ethanediol by E. coli (SSP1). 
At the same time, the styrene in the cosolvent of n-hexadecane could be 
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stripped into the aqueous phase to reach the equilibrium between the aqueous 
and organic phases. In the TDPB system, the aqueous and organic phases 
could be mixed thoroughly when agitated vigorously to form emulsion, which 
could expand the interfacial area intensively for better mass transportation and 
the substrate could be transferred continuously and swiftly for the biocatalysis. 
The cosolvent of n-hexadecane served as the reservoir for harboring substrate, 
and thus protected the whole cell biocatalyst from being poisoned. As shown 
in Figure 5.9, the product concentration could then reach the highest value 
                  
Figure 5.9 Trans-dihydroxylation of styrene with E. coli (SSP1) (10 g CDW/L) at 
different substrate concentrations in TDPB-based biphasic system (phase ratio 1: 1, 
v/v) consisted of KP buffer (10 mL; 200 mM; pH 8.0) and organic solvent of n-
hexadecane (white) or cyclohexane (grey) at 30°C and 250 rpm for 24 h. All 
concentrations and cell density were normalized on the basis of the KP buffer. 
of 124 mM for aq./n-hexadecane TDPB system at substrate concentration 500 
mM, which was over 14 folds higher than the highest product titer (8.8 mM) 
achieved in the aqueous phase (Figure 5.4). The high substrate concentration 
could impair the cell membrane integrity and thus disrupt the electron 
transferring mechanism, which could decrease the SMO-catalyzed epoxidation 
































biotransformation of trans-dihydroxylation. Shown in Figure 5.9, production 
titer were 94, 118, 124, and 93 mM for the trans-dihydroxylation in aq./n-
hexadecane TDPB system when converting 0.1, 0.2, 0.5, and 1.0 M styrene, 
respectively. Apparently, as the styrene concentration exceeded 500 mM, the 
final product titer for TDPB-based trans-dihydroxylation dropped with 
substrate concentration (Figure 5.9), which apparently showed the limited 
capacity of this TDPB in reducing substrate toxicity.  
In the TDPB system, the toxicity from the organic cosolvent itself could also 
be an issue of concern, because most of the organic solvent was toxic and 
explosive. This was the reason why biocompatibility was an important 
criterion for choosing the desired organic cosolvent in establishing biphasic 
system. For confirmation, we used the less biocompatible cyclohexane (Figure 
5.7) as the organic cosolvent for establishing the aq./cyclohexane TDPB 
system. Shown in Figure 5.9, trans-dihydroxylation of styrene with E. coli 
(SSP1) in aq./cyclohexane TDPB system exhibited much lower product titers 
than those achieved when using the aq./n-hexadecane TDPB system: 
production titer were 30.4, 44.1, 26.1, and 18.5 mM for the trans-
dihydroxylation in aq./cyclohexane TDPB system when oxidizing 0.1, 0.2, 0.5, 
and 1.0 M styrene, respectively. As the partition coefficiency of styrene for 
cyclohexane and n-hexadecane were 179 and 284, respectively, most of the 
styrene (>99%) were in organic phases of cyclohexane and n-hexadecane, 
which obviously signified that the less desired enzymatic performances for 




5.3.6 Trans-dihydroxylation with E. coli (SSP1) in HFMB-based biphasic 
systems of aq./cyclohexane and aq./n-hexadecane 
Although the TDPB system with organic solvent as cosolvent had effectively 
enhanced the productivity of the trans-dihydroxylation with E. coli (SSP1), 
this TDPB system has inherent problems such as the limited capacity for 
preventing the substrate toxicity (shown in Figure 5.9), cell membrane 
integrity deterioration owing to the hazardous effects from organic solvent,
[39, 
69]
 difficulties in the solvent reuse and the product purification caused by 
emulsification and foaming, etc.
[198 – 200, 257]
 So far, different biphasic systems 
with organic solvents as cosolvents were established in HFMB for different 
biotransformations,
[219 – 222]
 where most of the problems associated with TDPB 
systems could be solved successfully. Therefore, biphasic system with n-
hexadecane as the cosolvent was used in the HFMB as the first try for an 
oxidative cascade biotransformation. 
To establish the HFMB-based biphasic system, DI (Deionized) water and pure 
n-hexadecane were used for wetting the membrane prior to the 
biotransformation, which was to create more interfacial area within the highly 
porous membrane between the aqueous and organic phases for the liquid-
liquid mass transportation. When wetting procedure was done, the aqueous 
phase of cell suspension and the organic phase of n-hexadecane containing the 
substrate styrene at a preset concentration were pumped through the lumen 
side and shell side of the HFMB, respectively (Figure 5.2). Similar to the 
biotransformation TDPB system, the n-hexadecane cosolvent in the HFMB-
based aq./n-hexadecane biphasic system played the role as the substrate 
146 
 
reservoir for the controlled and mild releasing, which mitigated the substrate 
toxicity effectively and thus allowed biotransformation being carried out with 
better catalytic performance (Figure 5.1). Shown in Figure 5.10, the trans-
dihydroxylation with E. coli (SSP1) in the HFMB-based aq./n-hexadecane 
biphasic system gave product in 23.5, 35.8, 75.5, and 129 mM with substrate 
concentrations at 0.1, 0.2, 0.5, and 1.0 M, respectively. The similar situation 
was observed for HFMB-based aq./cyclohexane system, where product titers 
of 20.2, 44.3, 65.7, and 88.4 mM were achieved with 0.1, 0.2, 0.5, and 1.0 M 
substrate, respectively. In comparison with the aq./cyclohexane TDPB system 
in Figure 5.9, it clearly showed that the presence of the membrane could 
prevent the toxicity of cosolvent cyclohexane. Furthermore, membrane could 
strengthen the capacity of the biphasic system in reducing the substrate 
toxicity. Shown in Figure 5.10, product titer still increased even after the 
substrate concentration exceeding 500 mM. Comparatively, the production 
titer in TDPB-based system first increased and then decreased when substrate 
exceeding 500 mM (Figure 5.9).  
                   
Figure 5.10 Trans-dihydroxylation of styrene with E. coli (SSP1) (10 g CDW/L) at 
different substrate concentrations in HFMB-based biphasic system (phase ratio 1: 1, 
v/v) consisted of KP buffer (50 mL; 200 mM; pH 8.0) and organic solvent of n-
hexadecane (white) or cyclohexane (grey) at 30°C and 250 rpm for 24 h. All 



































5.3.7 Time course for trans-dihydroxylation with E. coli (SSP1) in TDPB- 
and HFMB-based aq./n-hexadecane biphasic systems  
Figure 5.11 compares the HFMB-based trans-dihydroxylation to the same 
reaction being carried out in TDPB system, where the HFMB-based reaction 
show higher product titer 143 mM, 1.6 folds higher than the 89.1 mM product 
titer achieved in TDPB system. Shown in Figure 5.11, the TDPB system gave 
the product at higher rate at the beginning; however, the reaction barely 
proceeded any more after 10 h. On the other hand, the HFMB-based system 
appeared to exhibit a little slower reaction rate at the beginning, while, a 
comparatively high reaction rate was maintained in a bigger time range, giving 
higher product concentration of 143 mM at 35 h (Figure 5.11). This signified 
that the whole cell biocatalyst cold be better protected from the toxicity due to 
the presence of membrane, thus showing higher product titer in a long run.  
                          
Figure 5.11 Time course for trans-dihydroxylation of styrene (1 M) with E. coli 
(SSP1) (10 g CDW/L) in TDPB- and HFMB-based KP buffer (100 mM; pH 8.0)/n-
hexadecane biphasic system at 30°C and 250 rpm, respectively. All concentrations 
and cell density were normalized on the basis of the KP buffer. 
As shown in Figure 5.1, the only difference between the TDPB and HFMB 
biphasic systems were the physical membrane, which actually formed a solid 
barrier for the mass transportation. In the TDPB system, one phase could be 





































formed, which could give high interfacial area for diffusion. On the other hand, 
this foaming and emulsification in the TDPB system could generate much 
more difficulty in downstream purification and solvent reuse. Comparatively, 
the HFMB-based biphasic system could quench the turbulence and provide a 
complete separation between aqueous and organic phases to reduce the burden 
in purification.  
5.3.8 Time course for trans-dihydroxylation with E. coli (SSP1) in HFMB-
based aq./n-hexadecane system with different interfacial areas and cell 
densities 
As for mass transport barrier, it could be overcome by enlarging interfacial 
area. Shown in Figure 5.12a, the final product concentration was only 87.8 
mM if the apparent interfacial area was 0.15 m
2
/g CDW, while the final 
production titer was 144 mM given 0.3 m
2
/g CDW apparent interfacial area 
used. To bring down the mass transportation barrier, membrane with higher 
porosity was desired, and this explained why a sufficient wetting procedure on 
both the lumen and the shell sides was required. Besides porosity which 
influenced the interfacial area, cell density also played a role in the trans-
dihydroxylation of styrene with E. coli (SSP1). Shown in Figure 5.12b, the 
product titer (155 mM) when using the cell density of 15 g CDW/L as 
biocatalyst was almost 1.9 folds higher than 83.6 mM achieved for 5 g 
CDW/L cell used. Given that the cells were freshly harvested with the highest 
specific cell activity, this could be explained as positively proportionality 
between the reaction rate and the absolute amount of the whole cell biocatalyst 
engaged in the trans-dihydroxylation. 
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Figure 5.12 Time course for trans-dihydroxylation of styrene (1 M) with E. coli 
(SSP1) (10 g CDW/L) in HFMB-based KP buffer (100 mM; pH 8.0)/n-hexadecane 
system (phase ratio 1: 1, v/v) at 30°C and 250 rpm. a: different interfacial areas (cell 
density was 10 g CDW/L). b: different cell densities (apparent interfacial area was 0.3 
square meter/g CDW). All concentrations and cell densities were normalized on the 
basis of KP buffer. 
5.4 Conclusion 
E. coli (SSP1) as the oxidative cascade biocatalyst coexpressing 
monooxygenase of SMO and hydrolase of SpEH used for trans-
dihydroxylation of styrene to (S)-vicinal diol of (S)-1-phenyl-1,2-ethanediol, 
as an complementary and alternative approach to the Sharpless 
dihydroxylation, was used in the HFMB-based aq./org. biphasic system for the 
first time. In aqueous monophase, E. coli (SSP1) exhibited a high specific cell 
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showed low productivity, because of the substrate toxicity and inhibition. To 
tackle this problem, aq./organic biphasic systems were built in HFMB with 
organic solvent as cosolvent. Different organic solvents (i.e., 1-octanol, 2-
undecanone, ethyl acetate, cyclohexane, n-octane, and n-hexadecane) were 
tested by partitioning coefficient, biodegradability, and biocompatibility for 
establishing the biphasic system, n-hexadecane was chosen as the desired 
organic solvent for engineering the HFMB-based aq./organic system, where 
the cosolvent n-hexadecane was in the shell side and aqueous cell suspension 
in the lumen side of HFMB. The established HFMB-based aq./n-hexadecane 
system enhanced the trans-dihydroxylation production titer to 143 mM, which 
was 16 folds higher than 8.75 mM achieved in the aqueous phase and 1.6 folds 
higher than the 89.1 mM in TDPB-based aq./n-hexadecane system. The results 
of this work demonstrated that bioprocess engineering via building biphasic 
system was a useful tool for enhancing the enzymatic performance of cascade 
oxidative biotransformation, and it also demonstrated that using the biphasic 
system in HFMB could exhibit higher production titer, possibly because the 
membrane in HFMB could further protect whole cell biocatalyst from being 
exposed to the substrate and cosolvent toxicity and hence maintained the cell 
membrane integrity. The combination of biphasic system with HFMB also 
prevented foaming and emulsification, thus reducing the burden in 
downstream purification, which showed that HFMB-based biphasic system 
could serve as a more suitable platform for conducting the biooxidations in an 













Oxidation reactions are of great use in industrial and academic practices, 
enabling producing many useful chemical compounds with applications in 
various areas ranging from daily commodity to pharmaceutical manufacture. 
The performances of oxidation reactions via traditional chemical routes are yet 
satisfactory owing to many factors including less desired selectivities, lack of 
predictability of the product structures, soaring prices of the noble metals for 
preparing the chemical catalysts, etc.
[39, 254]
 Oxidative transformation via 
biological process, featured by high selectivity, environmentally benign 
operations, and convenient biocatalyst preparation, appears to attract more 
attention under the mushrooming burden of environmental and energy crisis.  
Although highlighted intensively, biooxidation has yet made great 
achievement especially in the industrial applications, and one of the reasons 
for such a predicament is caused by the inhibition and toxicity inherent to 
many of the substrates and products involved in the biooxidations. Genetic 
approaches for overcoming this problem, although proven as useful, are 
usually time-consuming and labor-intensive, which is so far mainly a work of 
chance.
[39]
 Alternatively, the bioprocess engineering via building multiphasic 
system as a useful and convenient reaction platform can prevent the inhibition 
and toxicity significantly, where the hazardous effects could be eliminated or 
decreased through adsorption and preferential solvation of the substrate and 
the product in non-aqueous phase and biooxidation being carried out in 
aqueous phase simultaneously, hence enhancing the productivity and 
sometimes selectivity. This multiphasic system can also provide a preliminary 
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separation of the product from substrate on the basis of the different 
hydrophobic properties between the substrate and product. In this thesis, we 
demonstrate three different platforms to prevent inhibition and toxicity via 
bioprocess engineering for three different intensively-studied biooxidations of 
hydroxylation, sulfoxidation, and epoxidation, respectively, hence giving 
enhanced productivity and sometimes improved enantioselectivity. It kindles 
the interest in bioprocess engineering as complementary approach to genetic 
method for conducting biooxidations with efficiency and selectivity, and it 
further highlights the significance of downstream engineering for biological 
manufacture and biotransformation in both academic and the industrial areas. 
As the first exemplary biooxidation, biohydroxylation of BP with Escherichia 
coli (P450pyrTM-GDH) coexpressing three-component P450pyrTM 
monooxygenase and cofactor-regenerator GDH was conducted in 
aq./Amberlite
®
 XAD4 solid-liuquid biphase, which allowed simultaneous 
biotransformation and in-situ adsorption of substrate and product in one-pot, 
enhancing the productivity by preventing the substrate and product inhibitions. 
This system gave the product of (S)-BPOH as a drug intermediate with the 
highest production titer among all the best known P450 monooxygenases for 
biohydroxylation. In aq./Amberlite
®
 XAD4 biphasic system, resin Amberlite
®
 
XAD4 showed high adsorption capacity to the adsorbates of both substrate 
and product in comparison with all the other tested resins, hence exhibiting 
strong capability in preventing inhibition effects of substrate and product. E. 
coli (P450pyrTM-GDH) demonstrated good specific activity (13.5 U/g CDW) 





the solid phase of adsorbent resin Amberlite
®
 XAD4 successfully adsorbed the 
majority of both the substrate (79.9% – 89.5%) and product (55.3% – 67.3%) 
from the aqueous phase via in situ adsorption, hence giving the final 
production titer of ca., 50 mM, over 2 folds higher than the control in aqueous 
monophase. The hydrophobic resin Amberlite
®
 XAD4 in the established 
aq./Amberlite
®
 XAD4 system demonstrated green procedures of pretreatment 
and regeneration. Preparative biohydroxylation of BP in our biphasic system 
produced useful and valuable (S)-BPOH as the intermediate for synthesizing 
drugs of carbapenem antibiotic CS-834 and nootropic drug (S)-Oxiracetame. 
To our best knowledge, so far, this is the first report of using non-charged 
hydrophobic resin to build a solid-liquid biphasic system for P450 
monooxygenase-catalyzed biohydroxylation, as an exemplary procedure of 
simultaneous biohydroxylation and in situ adsorption in one pot. We believe 
that our work exhibits good maneuverability and practicability and could 
hence be useful for the biooxidations on a large scale.  
In the second experimental part of the thesis, asymmetric sulfoxidations of 
thioanisole 1, 4-fluorothioanisole 3, phenylthioethane 5, p-methylthioanisole 7, and 
4-methoxythioanisole 9 with recombinant E. coli (P450pyrI83H-GDH) co-
expressing the three-component P450pyrI83H monooxygenase and the GDH 
for cofactor regenerating were conducted in an aq./IL system for 
simultaneously enhancing enantioselectivity and productivity of the target 
sulfoxidation reactions. IL [P6,6,6,14][NTf2] exhibited outstanding 
biocompatibility for the growth of E. coli (P450pyrI83H-GDH) cells and 
capability to fend off substrate toxicity to the cells, being the desired cosolvent 
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for building the KP buffer/IL biphasic system. In the established biphasic 
system, >99% of the substrates and 35-60% of the products remained in IL, 
thus greatly reducing the substrate toxicity and inhibition and partially 
reducing the product toxicity and inhibition. Therefore, using our KP 
buffer/[P6,6,6,14][NTf2] system, the final product titers and enantioselectivities 
for asymmetric sulfoxidations of thioanisole 1, 4-fluorothioanisole 3, 
phenylthioethane 5, p-methylthioanisole 7, and 4-methoxythioanisole 9 were 
enhanced from 9.4 mM and 85% ee to 20 mM and 99% ee, from 1.9 mM and 
80% ee to 9.9 mM and 98% ee, from 5.4 mM and 88% ee to 16 mM and 96% 
ee, from 4.2 mM and 35% ee to 22 mM and 62% ee, and from 5.7 mM and 53% 
ee to 24 mM and 67% ee, respectively. So far, it is the first try in the 
establishing a biphasic system with IL to enhance both enantioselectivity and 
productivity for biooxidation reaction, and IL for the first time is successfully 
used as cosolvent in a biphasic system for a P450 monooxygenase-catalyzed 
oxidation. It also demonstrates that the biphasic system with IL provides a 
green and potent platform for efficient biooxidation. 
The third exemplary biooxidation of asymmetric epoxidation catalyzed by 
SMO together with hydrolysis catalyzed by SpEH hydrolase form cascade 
oxidative biotransformation of styrene to (S)-vicinal diol of (S)-1-phenyl-1,2-
ethanediol, an alternative and complementary approach to the Sharpless 
dihydroxylation method for performing dihydroxylation. SMO and SpEH 
were coexpressed in the recombinant E. coli to first fabricate the cascade 
whole cell biocatalyst of E. coli (SSP1),
[58]
 which exhibited the high specific 
cell activity (up to 88 U/g CDW) for the target trans-dihydroxylation of 
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styrene to (S)-vicinal diol of (S)-1-phenyl-1,2-ethanediol. The toxicity of 
substrate styrene to whole cell biocatalyst E. coli (SSP1) was proven by the 
vanishing of the specific dihydroxylation activity and the cell aggregation with 
addition of styrene to the cell suspension. This severe substrate toxicity was 
tackled by carrying out the target oxidative cascade biotransformation in the 
aq./organic solvent biphasic system, which was built in a HFMB bioreactor 
and dissolved the toxic substrate in organic cosolvent. n-Hexadecane gave the 
most desired performance regarding partitioning coefficient, biodegradability, 
and biocompatibility among various organic solvents tested, and was chosen 
as the cosolvent for establishing the aq./organic biphasic system in the HFMB. 
In the established biphasic system, organic cosolvent of n-hexadecane was in 
the shell side and cell suspension in the lumen side of HFMB, which gave a 
thorough separation of organic phase to aqueous phase, hence preventing the 
foaming and emulsification. Using the HFMB-based aq./n-hexadecane 
biphasic system, trans-dihydroxylation of styrene with E. coli (SSP1) 
produced 143 mM product of (S)-1-phenyl-1,2-ethanediol, which was over 16 
folds to the production titer observed in control in the aqueous mono-phase 
and also much higher than 89.1 mM production titer achieved by TDPB-based 
aq./n-hexadecane system. The results confirmed bioprocess engineering via 
engineering aq./organic solvent biphasic system as an important approach for 
enhancing the productivity of biooxidation, and it also demonstrated that 
HFMB could further improve the performance of aq./organic biphasic system. 
The possible reason could be that the membrane in HFMB could provide a 
better environment for maintaining the integrity of the whole cell biocatalyst 
to better perform in a longer run. The combination of biphasic system with 
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HFMB not only showed high production titer but also prevented foaming and 
emulsification due to the non-dispersive operation, thus lowering down the 
downstream processing burden, which signifies that multi-phasic system 
together with HFMB could be as a more suitable platform for conducting the 
biooxidations on a large scale. 
6.2 Recommendation 
6.2.1  Developing selective adsorption carrier for the hydroxylated 
product 
As the biooxidation products are more hydrophilic, either the solid adsorbent 
of hydrophobic resin or water-immiscible non-aqueous cosolvent is less 
effective in harboring the products, which is proven in the lower adsorption 
capacity in chapter III and partitioning coefficient in chapter IV. Therefore, 
there is a need to develop more potent carrier for adsorbing more product from 
the aqueous phase. The proposal is to immobilize hydroxo complexes such as 
aluminium glycinate, cis-[Cu(CO3)2(OH)2]
4−
 or cis-tetraaquadihydroxoiron(III) 
onto PS-MNPs coated with GMA, which contains an epoxide group to provide 
a lonely pair of electrons. The hydroxo complex such as aluminium glycinate, 
by coordinating with the oxygen atoms from the epoxide group of GMA 
through the pair of lonely electrons, could be immobilized onto the PS-MNPs 
coated with GMA. This PS-MNPs coated with hydroxo complex could hence 
in-situ adsorb more hydroxyl products via coordinating between the hydroxo 
complex and the oxygen atom from the hydroxyl product itself through 
another pair of lonely electrons, and the PS-MNPs could be separated by an 
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external magnet for the product recover and the PS-MNPs reuse after the 
biotransformation (Figure 6.1).  
 
Figure 6.1 PS-MNPs coated with the aluminium glycinate for selective in-situ 
product recovery. 
6.2.2  Biooxidation with continuous mode by using growing cells in 
HFMB-based biphasic system 
Using growing cells for the biooxidation in a HFMB-based biphasic system 
could be a reasonable choice: cells are first grown in the medium. When cells 
enter into the late exponential phase, fresh medium is fed into the cell culture 
broth by a peristaltic pump at a certain dilution rate in order to maintain the 
highest specific hydroxylation activity at a predetermined specific growth rate 
(Figure 6.2). At the same time, an equal amount of the stale medium 
containing aged cells will be withdrawn out of the system by a second 
peristaltic pump (Figure 6.2). This will give a continuous mode operation 






pump organic phase from the corresponding flask to the HFMB (Figure 6.2). 
Medium containing the growing cell biocatalysts is circulated through the 
lumen side of the HFMB, whereas the organic solvent containing the substrate 
and/or product is circulated through the shell side (Figure 6.2). Aqueous-
organic interface can be immobilized in the membrane pores, and the cells can 
catalyze the reaction in a sub-inhibitory level. The rationale is to maintain the 
highest specific biooxidation activity at a predetermined specific growth rate 
by controlling the dilution rate, which could be a novel platform worth further 
investigation. 
 
Figure 6.2 Continuous schematics for biooxidation in HFMB-based aq./org. biphase. 
6.2.3 Coexpressing SrpABC and monooxygenase genes in E. coli for 
engineering toxicity-recalcitrant whole cell biocatalyst in biphasic system 
In the whole cell-based biotransformations, substrate and product molecules 
are transported in and out of the cell envelope across cell membrane with the 






























aid of a group of transporter proteins functioning as the pumps for moving the 
target molecules, where influx transporters are reponsible to uptake substrates 
for further biotransformation in vivo, and the efflux transporters contribute to 
the accumulation of products extracellularly.
[263]
 The significance of these 
pumping proteins reaches well beyond unveiling the intrinsic transportation 
mechanism for many molecules across the cell membrane. Strategic steps have 
been taken in modern areas of biocatalysis, directed evolution, and synthetic 
biology for improving the extracellular product formation with manipulating 
the transporter proteins.
[263]
 An example could be found that E. coli expressing 
cytochrome P450 could give significant 7.1 folds higher production titer for 
hydroxylating compactin into pravastatin with the mutation of arcAB-tolC 
efflux pumping system, where mutation on tolC gene was proven to increase 
the cells’ ability in uptaking substrate molecules.[264] It is also reported that 
arcAB-tolC is related to the fabrication of the solvent recalcitrant cells, where 
arcAB-tolC efflux pumping system decrase the solvent concentration in vivo 
given cells being exposed in the organic solvent.
[264, 265]
  
It has not escaped from our vision that efflux pumping SrpABC gene in 
Pseudomonas endows its host cells with admirable capability in surviving in 
toxic solvents, substrates and products,
[266]
 and so far, to our best knowledge, 
SrpABC efflux pumping system has not yet been grafted into the E. coli 
recombinant host cells for engineering potent oxidative biocatalysts with 
recalcitrance to many solvents and ILs. We therefore propose here to 
coexpress this SrpABC gene together with the P450 monooxygenase for 
fabricating solvent-tolerant whole-cell biocatalyst for biooxidations in various 
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